<SEC-DOCUMENT>0001731122-20-000447.txt : 20200507
<SEC-HEADER>0001731122-20-000447.hdr.sgml : 20200507
<ACCEPTANCE-DATETIME>20200507163206
ACCESSION NUMBER:		0001731122-20-000447
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		39
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200507
DATE AS OF CHANGE:		20200507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		20856984

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e1894_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
<B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&nbsp;ACT&nbsp;OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the quarterly period ended: <B><U>March 31, 2020</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
<B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&nbsp;ACT&nbsp;OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from _____to _____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <U>001-37606</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ANAVEX
LIFE SCIENCES CORP.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>98-0608404</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>51
West 52nd Street, 7th Floor, New York, NY USA 10019</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>1-844-689-3939</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&rsquo;s
telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>N/A</U><BR>
</B>(Former name, former address and former fiscal year, if changed since last report)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
Registered Pursuant to Section&nbsp;12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of Each Class</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Symbol</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of Each Exchange on Which Registered</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock Par Value $0.001</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AVXL</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ
    Stock Market LLC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;<B>&#9746;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;No</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files).&nbsp;&nbsp;&#9746;&nbsp;&nbsp;<B>Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;No</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 27%; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 3%; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 41%; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 26%; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 3%; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&#9744;&nbsp;&nbsp;<B>Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;No</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of shares outstanding of each of the issuer&rsquo;s classes of common stock, as of the latest practicable date: 58,664,946
shares of common stock outstanding as of May 7, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001"><B>PART
    I - FINANCIAL INFORMATION</B></A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Item
    1.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt; width: 83%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">FINANCIAL
    STATEMENTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Item
    2.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Item
    3.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Quantitative
    and Qualitative Disclosures about Market Risks.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Item
    4.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Controls
    and Procedures.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006"><B>PART
    II &ndash; OTHER INFORMATION</B></A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Item
    1.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Legal
    Proceedings.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Item
    1A.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Risk
    Factors.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Item
    2.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Unregistered
    Sales of Equity Securities and Use of Proceeds.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Item
    3.</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Defaults
    Upon Senior Securities.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Item
    4</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Mine
    Safety Disclosures</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Item
    5</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Other
    Information.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Item
    4</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Exhibits.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-align: left; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-transform: uppercase; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">SIGNATURES</A></FONT></P>
                    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
</TABLE>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_001"></A>PART
I - FINANCIAL INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_002"></A>Item
1. FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERIM
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERIM
CONDENSED CONSOLIDATED BALANCE SHEETS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020 and September 30, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30,</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</FONT></TD><TD STYLE="width: 4%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,563,071</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,185,630</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
    and tax receivables</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,151,947</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,642,745</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and deposits</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">305,559</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,998</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Assets</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,020,577</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,329,373</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities and Stockholders'
    Equity</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Liabilities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,649,734</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,523,332</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    liabilities</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,579,097</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,516,342</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Liabilities</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,228,831</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,039,674</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and Contingencies
    - Note 5</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital stock</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000 preferred
    stock, par value $0.001 per share<BR> 100,000,000 common stock, par value $0.001 per share</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
    and outstanding:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,664,946 common
    shares<BR> (September 30, 2019 - 52,650,251)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,666</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,652</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in
    capital</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171,958,462</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">153,633,807</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(147,225,382</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(133,396,760</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders' Equity</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,791,746</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,289,699</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Liabilities and Stockholders' Equity</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,020,577</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,329,373</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERIM
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three and six months ended March 31, 2020 and 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    months ended<BR> March 31,</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
    months ended<BR> March 31,</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,720,142</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,061,251</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,072,176</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,822,559</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,053,047</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,078,786</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,401,715</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,790,996</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expenses</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,773,189</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,140,037</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,473,891</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,613,555</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income (expenses)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant income</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74,944</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74,527</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">149,888</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">149,055</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    incentive income</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">717,328</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">760,990</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,660,543</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,174,672</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest income, net</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,180</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,465</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,900</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">130,265</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange (loss) gain, net</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(325,960</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,199</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(272,848</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,693</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other income, net</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">536,492</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">941,181</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,654,483</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,503,685</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss before provision
    for income taxes</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,236,697</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,198,856</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,819,408</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,109,870</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax expense, current</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(48,048</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,214</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(56,765</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss and comprehensive loss</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,236,697</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,246,904</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,828,622</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,166,635</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Loss per share</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.12</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.15</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.24</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.30</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average number of shares outstanding</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,353,954</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,134,686</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,554,037</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,726,649</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTERIM
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended March 31, 2020 and 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Flows used in
    Operating Activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD><TD STYLE="width: 4%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,828,622</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,166,635</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments to reconcile
    net loss to net cash used in operations:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,965,177</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,960,139</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in non-cash
    working capital balances related to operations:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
    and tax receivables</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,509,202</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,210,661</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and deposits</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">195,439</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">439,552</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">126,402</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,434,633</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    liabilities</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,062,755</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,345</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in operating
    activities</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,988,051</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,491,627</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Flows provided
    by Financing Activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common shares</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,365,492</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,068,834</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    financing charges</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(50,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash provided by
    financing activities</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,365,492</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,018,834</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase (decrease)
    in cash and cash equivalents during the period</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,377,441</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,472,793</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents, beginning of period</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,185,630</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,930,638</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents, end of period</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,563,071</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,457,845</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERIM
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2020 and 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid-in</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    to be</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par
    Value</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, January 1, 2020</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,080,356</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,082</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,891,753</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(139,988,685</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,960,150</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued under 2019 Purchase Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,570,424</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,571</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,365,969</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,367,540</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitment shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,166</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,700,753</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,700,753</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,236,697</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,236,697</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, March 31, 2020</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,664,946</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,666</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171,958,462</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(147,225,382</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,791,746</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, January 1, 2019</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,887,056</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,888</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,438,276</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(114,021,512</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,463,652</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued under 2015 Purchase Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,279,592</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,279</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,365,555</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(292,700</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,074,134</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitment shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,047</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued pursuant to cashless exercise
    of warrants</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">546</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,893,152</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,893,152</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,246,904</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,246,904</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, March 31, 2019</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,173,241</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,175</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">138,696,975</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(292,700</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(121,268,416</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,184,034</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTERIM
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended March 31, 2020 and 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid-in</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    to be</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par
    Value</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, October 1, 2019</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,650,521</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,652</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">153,633,807</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(133,396,760</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,289,699</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued under 2019 Purchase Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,964,584</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,965</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,359,527</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,365,492</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitment shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,841</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(49</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,965,177</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,965,177</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,828,622</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,828,622</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, March 31, 2020</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,664,946</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,666</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171,958,462</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(147,225,382</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,791,746</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, October 1, 2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,933,472</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,935</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">129,377,542</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(107,101,781</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,321,696</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued under 2015 Purchase Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,229,592</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,229</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,359,305</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(292,700</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,068,834</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitment shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,631</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares issued pursuant to cashless exercise
    of warrants</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">546</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,960,139</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,960,139</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,166,635</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,166,635</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, March 31, 2019</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,173,241</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,175</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">138,696,975</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(292,700</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(121,268,416</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,184,034</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Business
                                         Description and Basis of Presentation</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp. (the &ldquo;Company&rdquo;) is a clinical stage biopharmaceutical company engaged in the development of differentiated
therapeutics by applying precision medicine to central nervous system (&ldquo;CNS&rdquo;) diseases with high unmet need. Anavex
analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic
benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&rsquo;s lead compound ANAVEX&reg;2-73
is being developed to treat Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease and potentially other central nervous system
diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in
the X-linked gene, methyl-CpG-binding protein 2 (&ldquo;MECP2&rdquo;).</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
of Presentation</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission (&ldquo;SEC&rdquo;) and accounting principles generally accepted in the United States of America
(&ldquo;U.S. GAAP&rdquo;) for interim reporting. Accordingly, certain information and note disclosures normally included in the
annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
In the opinion of management, the disclosures are adequate to make the information presented not misleading.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring
adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated
balance sheet as of September 30, 2019 was derived from the audited annual financial statements but does not include all disclosures
required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and notes thereto included in the Company&rsquo;s annual report on Form 10-K
for the year ended September 30, 2019 filed with the SEC on December 16, 2019. The Company follows the same accounting policies
in the preparation of interim reports.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
results for the six months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year
ending September 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&rsquo;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Business
                                         Description and Basis of Presentation &ndash; (continued)</U></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least the next two years after the date that these interim condensed consolidated
financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
is uncertain.&nbsp;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to
change.&nbsp;The actual amount of the Company&rsquo;s expenditures will vary depending upon a number of factors including but
not limited to the design, timing and duration of future clinical trials, the progress of the Company&rsquo;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels
based on the timing of future clinical trials.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our rights related to the Sales Agreement and the 2019 Purchase Agreement (each as defined below), there can be no assurance
that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable
terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to
delay or scale down some or all of our research and development activities.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World
Health Organization (&ldquo;WHO&rdquo;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus
beyond its point of origin.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global outbreak of COVID-19 continues to rapidly evolve as of the date these interim condensed consolidated financial statements
are issued. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&rsquo;s financial condition
and future results of operations. Management is actively monitoring the global situation on its business, including on its clinical
trials and operations and financial condition. Given the daily evolution of the COVID-19 situation, and the global responses to
curb its spread, the Company is not able to estimate the effects of COVID-19 on its results of operations or financial condition
for the year ending September 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the President of the United States signed into law the &ldquo;Coronavirus Aid, Relief, and Economic Security (CARES)
Act.&rdquo; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer
side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to
the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections
to tax depreciation methods for qualified improvement property. The enactment of the CARES Act did not have any impact on the
Company&rsquo;s interim condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Business
                                         Description and Basis of Presentation </U>&ndash; (continued)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Use
of Estimates</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors
that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company&rsquo;s estimates. To the extent
there are material differences between the estimate s and the actual results, future results of operations will be affected.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment
of Prior Period Financial Statements</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed in Note 1 to the Company&rsquo;s consolidated financial statements included in the Company&rsquo;s annual
report on Form 10-K for the year ended September 30, 2019, the Company adjusted amounts to previously reported consolidated financial
statements which were immaterial. These adjustments were identified in connection with the preparation of the consolidated financial
statements for the year ended September 30, 2019 and related to the timing of recognition of research and development incentive
income. Previously the Company accounted for research and development incentive income when received in cash. During the year
ended September 30, 2019, based on a continuing assessment regarding the Company&rsquo;s eligibility for the incentive programs
under which it was receiving such income, the Company determined that the income should have been accrued and recorded in the
period in which the qualifying research and development expenditures were incurred.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
interim condensed consolidated financial statements for the three and six months ended March 31, 2019 have been similarly adjusted
to reflect the adjusted research and development incentive income for the three and six months accordingly in the amount of $510,990
and $924,672, respectively and should be read in conjunction with Note 1 to the Company&rsquo;s consolidated financial statements
for the year ended September 30, 2019.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Principles
of Consolidation</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the
laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Business
                                         Description and Basis of Presentation </U>&ndash; (continued)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Fair
Value Measurements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quoted
    prices (unadjusted) in active markets for identical assets or liabilities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">observable
    inputs other than Level 1, quoted prices for similar assets or liabilities in active &nbsp;markets, quoted prices for identical
    or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or
    whose significant value drivers are observable; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assets
    and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
    to the fair value of the assets or liabilities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2020 and September 30, 2019, the Company did not have any Level 3 assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Basic
and Diluted Loss per Share</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except
that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into
shares of common stock that were outstanding during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2020, loss per share excludes 10,486,266 (September 30, 2019 &ndash; 8,812,933) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Recent
                                         Accounting Pronouncements</U></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recently
Adopted Accounting Pronouncements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected to the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
results of operations, financial condition, cash flows, and financial statement disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results
of operations, financial condition, cash flows, and financial statement disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recent
Accounting Pronouncements Not Yet Adopted</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, &quot;Simplifying the Accounting for Income Taxes (ASC 740)&quot;, which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
                                         Income</U></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
Income</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant was being received
in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for
a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant income has been deferred when received and amortized to other income as the related research and development expenditures
are incurred. During the three and six months ended March 31, 2020, the Company recognized $74,944 and $149,888, respectively
(2019:$74,527 and $149,055, respectively) of this grant on its statement of operations within grant income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development incentive income</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit
(&ldquo;NYC Biotech credit&rdquo;), and the Australian research and development tax incentive credit (the &ldquo;Australia R&amp;D
credit&rdquo;) through a program administered through the Australian Tax Office (the &ldquo;ATO&rdquo;), which provides for a
cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company&rsquo;s
wholly owned subsidiary, Anavex Australia Pty Ltd. (&ldquo;Anavex Australia&rdquo;).&nbsp;Research and development incentive income
during the three and six months ended March 31, 2020 and 2019 represents the receipt by the Company&rsquo;s Australian subsidiary,
of the Australian research and development incentive credit, (the &ldquo;ATO R&amp;D Credit&rdquo;), as well as receipt by the
Company of the New York City Biotechnology Credit (&ldquo;NYC Biotech credit&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">During the
three and six months ended March 31, 2020, the Company recorded research and development incentive income of $717,328 (AUD 1,203,000)
and $1,660,543 (AUD 2,548,000), respectively (2019: $510,990 and $924,672, respectively) in respect of the ATO R&amp;D Credit for
eligible research and development expenses incurred during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">During the
three and six months ended March 31, 2019, the Company recorded research and development incentive income of $250,000 and $250,000
respectively, in respect of the NYC Biotech credit.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equity
                                         Offering Agreements</U></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company has entered into a Sales
Agreement dated July 6, 2018, as amended May 1, 2020 (the &ldquo;Sales Agreement&rdquo;) with Cantor Fitzgerald&nbsp;&amp; Co.,
(&ldquo;Cantor Fitzgerald&rdquo;) and SVB Leerink LLC (&ldquo;Leerink&rdquo;), and together with Cantor Fitzgerald as Sales Agents,
pursuant to which the Company may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $50,000,000
from time to time through the Sales Agents (the &ldquo;Offering&rdquo;).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Upon delivery of a placement notice
based on the Company&rsquo;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may
sell the Shares by methods deemed to be an &ldquo;at the market offering&rdquo; offering, in negotiated transactions at market
prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by
law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make
any sales of Shares under the Sales Agreement. The Company or the Sales Agents may suspend or terminate the offering of Shares
upon notice to the other party, subject to certain conditions.&nbsp; The Sales Agents will act as sales agent on a commercially
reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules&nbsp;and
regulations and the rules&nbsp;of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company has agreed to pay the
Sales Agents commissions for their services of acting as agents of 3.0% of the gross proceeds from the sale of the Shares pursuant
to the Sales Agreement.&nbsp; The Company also agreed to provide the Sales Agents with customary indemnification and contribution
rights. As of March 31, 2020, no shares had been sold pursuant to the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">2015 Purchase Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On October 21, 2015, the Company
entered into a $50,000,000 purchase agreement (the &ldquo;2015 Purchase Agreement&rdquo;) with Lincoln Park Capital Fund, LLC (&ldquo;Lincoln
Park&rdquo;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up
to $50,000,000 in value of its shares of common stock from time to time over a 36-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">During the six months ended March
31, 2019, the Company issued an aggregate of 2,239,223 shares of common stock under the 2015 Purchase Agreement, including 2,229,592
shares of common stock for an aggregate purchase price of $5,361,534 and 9,631 commitment shares. At March 31, 2020 and September
30, 2019, all remaining purchase amounts available for issuance under the 2015 Purchase Agreement had been utilized and the 2015
Purchase Agreement has expired pursuant to its terms. As such, no further shares will be sold under the 2015 Purchase Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equity
                                         Offering Agreements </U>&ndash; (continued)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019
Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2019, the Company entered into a $50,000,000 purchase agreement (the &ldquo;2019 Purchase Agreement&rdquo;) with Lincoln
Park, pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $50,000,000
in value of its shares of common stock from time to time from June 12, 2019, the date a prospectus supplement under which shares
of common stock issuable under the 2019 Purchase Agreement was filed with the SEC, until July 1, 2022, which is the first day
of the next month following the 36-month anniversary of June 12, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &ldquo;Regular Purchase&rdquo;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&rsquo;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase
price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares
at the time of sales as described in the 2019 Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2019 Purchase Agreement limits the Company&rsquo;s sale of shares of Common Stock to Lincoln Park to 10,076,680 shares of Common
Stock, representing 19.99% of the shares of the Common Stock outstanding on the date of the 2019 Purchase Agreement unless (i)
shareholder approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock
to Lincoln Park under the 2019 Purchase Agreement equals or exceeds the lower of (A) the closing price of the Common Stock on
the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average of the closing prices of the Common Stock
on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date, and it also limits the Company&rsquo;s
sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of the Company&rsquo;s
outstanding shares of Common Stock at any given time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock
as a commitment fee and agreed to issue up to 162,191 shares pro rata, when and if, Lincoln Park purchases at the Company&rsquo;s
discretion the $50,000,000 aggregate commitment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">During the six months ended March
31, 2020, the Company issued to Lincoln Park an aggregate of 6,014,425 (2019: Nil) shares of common stock under the 2019 Purchase
Agreement, including 5,964,584 (2019: Nil) shares of common stock for an aggregate purchase price of $15,365,492 (2019: $Nil) and
49,841 (2019: Nil) commitment shares. At March 31, 2020, an amount of $30,000,000 remained available under the 2019 Purchase Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Commitments
                                         and Contingencies</U></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Leases
                                         </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">During
the three and six months ended March 31, 2020, the Company incurred office lease expense of $60,861 and $110,915, respectively
(2019: $40,507 and $78,261, respectively).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Litigation</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Share
                                         Purchase Warrants</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of the Company&rsquo;s outstanding share purchase warrants is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price ($)</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Balance, September 30, 2018</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">678,379</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.87</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Exercised</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,750</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Expired</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(319,629</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Balance, September 30, 2019</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Granted</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Balance, March 31, 2020</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.88</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2020, the Company had share purchase warrants outstanding as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiry
    Date</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 25%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 25%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 44%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30,
    2021</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6, 2024</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.8pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
5</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Commitments
                                         and Contingencies</U> &ndash; (continued)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Stock&ndash;based
                                         Compensation Plan</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015
Stock Option Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 18, 2015, the Company&rsquo;s board of directors (the &ldquo;Board&rdquo;) approved a 2015 Omnibus Incentive Plan (the
&ldquo;2015 Plan&rdquo;), which provides for the grant of stock options and restricted stock awards to directors, officers, employees
and consultants of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of our common shares reserved for issue under the plan is 6,050,553 shares, subject to adjustment in the event
of a change of the Company&rsquo;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards were
granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing
stock option plans remain outstanding in accordance with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2015 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date.
If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value
of the Company&rsquo;s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise
period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject
to earlier termination in accordance with the terms of the 2015 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019
Stock Option Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &ldquo;2019 Plan&rdquo;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, 6,000,000 additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&rsquo;s 2007 Stock Option
Plan (the &ldquo;2007 Plan&rdquo;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&rsquo;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the Board, subject to earlier termination in accordance with the terms of the 2019 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2020</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
5</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Commitments
                                         and Contingencies</U> &ndash; (continued)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Stock-based
                                         Compensation Plan &ndash; (continued)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of Company&rsquo;s outstanding stock purchase options is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price ($)</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Grant Date Fair Value ($)</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
    <BR> intrinsic value ($)</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    September 30, 2018</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,506,917</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.83</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,353,088</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,265,399</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.79</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.27</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(309,383</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.25</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    September 30, 2019</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,462,933</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.58</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,115,032</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,525,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.86</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.17</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,667</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.64</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    March 31, 2020</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,986,266</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.47</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,517,080</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable,
    March 31, 2020</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,925,642</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.70</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,815,680</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&rsquo;s stock for the options that were in-the-money at March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended March 31, 2020, the Company recognized stock-based compensation expense of $1,700,753 and $2,965,177,
respectively (2019: $1,893,152 and $3,960,139, respectively) in connection with the issuance and vesting &#9;of stock options
and warrants in exchange for services. These amounts have been included in general and &#9;administrative expenses and research
and development expenses on the Company&rsquo;s interim condensed consolidated statements of &#9;operations as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    months ended<BR>
    March 31,</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
    months ended<BR>
    March 31,</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">810,309</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">950,999</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,291,410</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,006,587</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">890,444</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">942,153</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,673,767</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,953,552</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total share based compensation</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,700,753</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,893,152</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,965,177</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,960,139</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
amount of approximately $5,708,800 in stock-based compensation is expected to be recorded over the remaining vesting period &#9;of
such options through fiscal 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest
    rate</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.68</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.91</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of options
    (years)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.44</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.59</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annualized volatility</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.61</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105.96</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend rate</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_003"></A>Item
2. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-Looking
Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Quarterly Report on Form 10-Q includes forward-looking statements. All statements other than statements of historical facts contained
in this Quarterly Report on Form 10-Q, including statements regarding our anticipated future clinical and regulatory milestone
events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking
statements. The words &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;expect&rdquo; &ldquo;should,&rdquo; &ldquo;forecast,&rdquo; &ldquo;could,&rdquo; &ldquo;suggest,&rdquo;
&ldquo;plan&rdquo; and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking
statements include, without limitation, statements regarding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to generate any revenue or to continue as a going concern;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully conduct clinical and preclinical trials for our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to raise additional capital on favorable terms and the impact of such activities on our stockholders and stock price;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the COVID-19 outbreak and its effect on us;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to execute our research and development plan on time and on budget;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    products ability to demonstrate efficacy or an acceptable safety profile of our product candidates;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain the support of qualified scientific collaborators;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability, whether alone or with commercial partners, to successfully commercialize any of our product candidates that may be
    approved for sale;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify and obtain additional product candidates;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third parties in non-clinical and clinical studies;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to defend against product liability claims;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to safeguard against security breaches;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain sufficient intellectual property protection for our product candidates;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to comply with our intellectual property licensing agreements;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to defend against claims of intellectual property infringement;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to comply with the maintenance requirements of the government patent agencies;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our intellectual property rights throughout the world;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    anticipated start dates, durations and completion dates of our ongoing and future clinical studies;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    anticipated designs of our future clinical studies;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    anticipated future regulatory submissions and our ability to receive regulatory approvals to develop and market our product
    candidates; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 28px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    anticipated future cash position.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based these forward-looking statements largely on our current expectations and projections about future events, including
the responses we expect from the U.S. Food and Drug Administration, (&ldquo;FDA&rdquo;), and other regulatory authorities and
financial trends that we believe may affect our financial condition, results of operations, business strategy, preclinical and
clinical trials, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions
including without limitation the risks described in &ldquo;Risk Factors&rdquo; in Part I, Item 1A of our Annual Report on Form
10-K filed with the Securities and Exchange Commission on December 16, 2019. These risks are not exhaustive. Other sections of
this Quarterly Report on Form 10-Q include additional factors which could adversely impact our business and financial performance.
Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it
is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or
the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained
in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot
assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual
results could differ materially from those projected in the forward-looking statements. Except as required by applicable laws
including the securities laws of the United States, we assume no obligation to update or supplement forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Quarterly Report on Form 10-Q, the terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and &ldquo;Anavex&rdquo;
mean Anavex Life Sciences Corp., unless the context clearly requires otherwise.</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Current Business</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&ldquo;CNS&rdquo;) diseases with high unmet need. We analyze genomic data
from clinical studies to identify biomarkers, which we use to select patients that will receive the therapeutic benefit for the
treatment of neurodegenerative and neurodevelopmental diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead compound, ANAVEX&reg;2-73, is being developed to treat Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease and potentially
other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder
caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&ldquo;MECP2&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
total portfolio currently consists of five programs. To prioritize the allocation of our resources, we designate certain programs
as core programs and others as seed programs. We currently have two core programs and three seed programs. Our core programs are
at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes key information about our programs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
has a portfolio of compounds varying in sigma-1 receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which
is an intracellular chaperone protein with important roles in cellular communication. S1R is also involved in transcriptional
regulation at the nuclear envelope and restores homeostasis and stimulates recovery of cell function when activated. In order
to validate the ability of our compounds to activate quantitatively the S1R, we performed, in collaboration with Stanford University,
a quantitative Positron Emission Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX&reg;2-73 target
engagement or receptor occupancy (RO) with S1R in the brain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cellular
Homeostasis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
diseases are possibly directly caused by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases
like Rett syndrome or infantile spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation.
In neurodegenerative diseases, such as Alzheimer&rsquo;s and Parkinson&rsquo;s diseases, chronic cellular stress is possibly caused
by age-correlated buildup of cellular insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein
or ribonucleic acid (&ldquo;RNA&rdquo;) lead to the death of neurons and dysfunction of the nervous system. The spreading of protein
aggregates resulting in a proteinopathy, a characteristic finding in Alzheimer&rsquo;s and Parkinson&rsquo;s diseases that results
from disorders of protein synthesis, trafficking, folding, processing or degradation in cells. The clearance of macromolecules
in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in nerve cells. For example,
Alzheimer&rsquo;s disease pathology is characterized by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates
of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation of microglia.
With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX&reg;2-73, our approach is to restore cellular balance, i.e. homeostasis.
Therapies that correct defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental and neurodegenerative
disease progression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ANAVEX</I></B>&reg;<B><I>2-73-specific
Biomarkers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
full genomic analysis of Alzheimer&rsquo;s disease (AD) patients treated with ANAVEX&reg;2-73 resulted in the identification of
actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX&reg;2-73 and
COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX&reg;2-73-specific
biomarker hypothesis. It is expected that <I>excluding</I> patients with these two identified biomarker variants (approximately
10%-20% of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically
significant improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX&reg;2-73,
which are considered independent of AD pathology, as well as multiple endpoints and time-points, provides support for precision
medicine clinical development of ANAVEX&reg;2-73 by using genetic biomarkers identified within the study population itself to
target patients who are most likely to respond to ANAVEX&reg;2-73 treatment in AD as well as indications like Parkinson&rsquo;s
disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX&reg;2-73 is currently studied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
Studies Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alzheimer&rsquo;s
Disease</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, we completed a Phase 2a clinical trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for
ANAVEX&reg;2-73 in mild-to-moderate Alzheimer&rsquo;s patients. This open-label randomized trial met both primary and secondary
endpoints and was designed to assess the safety and exploratory efficacy of ANAVEX&reg;2-73 in 32 patients. ANAVEX&reg;2-73 targets
sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed to
restore cellular homeostasis and to reverse the pathological hallmarks observed in Alzheimer&rsquo;s disease. In October 2017,
we presented positive pharmacokinetic (PK) and pharmacodynamic (PD) data from the Phase 2a study, which established a concentration-effect
relationship between ANAVEX&reg;2-73 and study measurements. These measures obtained from all patients who participated in the
entire 57 weeks include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally,
the study appears to show that ANAVEX&reg;2-73 activity is enhanced by its active metabolite (ANAVEX19-144), which also targets
the sigma-1 receptor and has a half-life approximately twice as long as the parent molecule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2016, we received approval from the Ethics Committee in Australia to extend the Phase 2a clinical trial by an additional
108 weeks, which had been requested by patients and their caregivers. Subsequently, in May 2018, we received approval from the
Ethics Committee in Australia to further extend the Phase 2a extension trial for an additional two years. The two consecutive
trial extensions have allowed participants who completed the 52-week PART B of the study to continue taking ANAVEX&reg;2-73, providing
an opportunity to gather extended safety data for a cumulative time period of five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2018, we presented new long-term clinical data for ANAVEX&reg;2-73 in a presentation at the 2018 Clinical Trials on Alzheimer&rsquo;s
Disease (CTAD) Meeting. At 148 weeks into the five-year extended Phase 2a clinical study, data confirmed a significant association
between ANAVEX&reg;2-73 concentration and both exploratory functional and cognitive endpoints as measured by the Alzheimer&rsquo;s
Disease Cooperative Study-Activities of Daily Living&nbsp;(ADCS-ADL)&nbsp;evaluation and the Mini Mental State Examination (MMSE),
respectively. The cohort of patients treated with higher ANAVEX&reg;2-73 concentration maintained ADCS-ADL performance compared
to the lower concentration cohort (p&lt;0.0001). As well, the patient cohort with the higher ANAVEX&reg;2-73 concentration performed
better at MMSE compared to the lower concentration cohort (p&lt;0.0008). A significant impact on the drug response levels of both
the SIGMAR1 (p&lt;0.0080) and COMT (p&lt;0.0014) genomic biomarkers, identified and specified at week 57, was also confirmed over
the 148-week period. Further, ANAVEX&reg;2-73 demonstrated continued favorable safety and tolerability through 148 weeks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
larger Phase 2b/3 double-blind, placebo-controlled study of ANAVEX&reg;2-73 in Alzheimer&rsquo;s disease commenced in August 2018,
which is independent of the ongoing Phase 2a extension study. The Phase 2b/3 study will enroll approximately 450 patients for
48 weeks, randomized 1:1:1 to two different ANAVEX&reg;2-73 doses or placebo. The trial is currently taking place in Australia;
however, additional regions are being added. The ANAVEX&reg;2-73 Phase 2b/3 study design incorporates genomic precision medicine
biomarkers identified in the ANAVEX&reg;2-73 Phase 2a study. Primary and secondary endpoints will assess safety and both cognitive
and functional efficacy, measured through Alzheimer&rsquo;s Disease Assessment Scale &ndash; Cognition (ADAS-Cog), ADCS-ADL and
Clinical Dementia Rating &ndash; Sum of Boxes for cognition and function (CDR-SB).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, we initiated a long-term open label extension study of ANAVEX&reg;2-73, entitled the ATTENTION-AD study, for patients
who have completed the 48-week Phase 2b/3 placebo-controlled trial referenced above. This study is expected to last two years
and will give patients the opportunity to continue their treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rett
Syndrome </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, we presented positive preclinical data for ANAVEX&reg;2-73 in Rett syndrome, a rare neurodevelopmental disease.
The study was funded by the International Rett Syndrome Foundation (&ldquo;Rettsyndrome.org&rdquo;). In January 2017, we were
awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter Phase
2 clinical trial of ANAVEX&reg;2-73 for the treatment of Rett syndrome. This award is being received in quarterly instalments
which commenced during fiscal 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2019, we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX&reg;2-73 for the treatment
of Rett syndrome. The studies will be conducted in a range of patient age demographics and geographic regions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first Phase 2 study, which commenced in March 2019, is taking place in the United States and is a randomized double-blind, placebo-controlled
safety, tolerability, pharmacokinetic and efficacy study of oral liquid ANAVEX&reg;2-73 formulation to treat Rett syndrome. Pharmacokinetic
and dose findings will be investigated in a total of 21 patients over a 7-week treatment period including ANAVEX&reg;2-73-specific
genomic precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX&reg;2-73 under
a voluntary open label extension protocol. Primary and secondary endpoints include safety as well as Rett syndrome conditions
such as cognitive impairment, motor impairment, behavioral symptoms and seizure activity. The ANAVEX&reg;2-73 Phase 2 Rett syndrome
study designs incorporate genomic precision medicine biomarkers identified in the ANAVEX&reg;2-73 Phase 2a Alzheimer&rsquo;s disease
study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2019, we commenced the second Phase 2 study of ANAVEX&reg;2-73 for the treatment of Rett syndrome, called the AVATAR study.
This study is taking place in Australia using a convenient once-daily oral liquid ANAVEX&reg;2-73 formulation. Similar to the
United States-based Phase 2 study for Rett syndrome, the study will evaluate the safety and efficacy of ANAVEX&reg;2-73 in approximately
33 patients over a 7-week treatment period including ANAVEX&reg;2-73 specific precision medicine biomarkers. All patients who
participate in the study will be eligible to receive ANAVEX&reg;2-73 under a voluntary open label extension protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2019, we announced approval from the Australian Human Research Ethics Committee to commence the third study of ANAVEX&reg;2-73
for the treatment of Rett syndrome, called the EXCELLENCE study. Similar to the AVATAR study, this study is taking place in Australia
and is using a convenient once-daily oral liquid ANAVEX&reg;2-73 formulation. The study will evaluate the safety and efficacy
of ANAVEX&reg;2-73 in at least 69 pediatric patients, aged 5 to 18, over a 12-week treatment period incorporating ANAVEX&reg;2-73
specific precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX&reg;2-73
under a voluntary open label extension protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Parkinson&rsquo;s
Disease</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2016, we presented positive preclinical data for ANAVEX&reg;2-73 in Parkinson&rsquo;s disease, which demonstrated significant
improvements on all measures: behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael
J. Fox Foundation. Additional data was announced in October 2017 from the model for experimental parkinsonism. The data presented
indicates that ANAVEX&reg;2-73 induces robust neurorestoration in experimental parkinsonism. The encouraging results we have gathered
in this model, coupled with the favorable profile of this compound in the Alzheimer&rsquo;s disease trial, support the notion
that ANAVEX&reg;2-73 is a promising clinical candidate drug for Parkinson&rsquo;s disease dementia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2018, we initiated a double-blind, randomized, placebo-controlled Phase 2 trial with ANAVEX&reg;2-73 in Parkinson&rsquo;s
Disease Dementia (PDD), which will study the effect of the compound on both the cognitive and motor impairment of Parkinson&rsquo;s
disease. The Phase 2 study has enrolled approximately 120 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX&reg;2-73
doses or placebo. The ANAVEX&reg;2-73 Phase 2 PDD study design incorporates genomic precision medicine biomarkers identified in
the ANAVEX&reg;2-73 Phase 2a study. The study has completed enrollment and topline results are expected by mid-2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Pipeline</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development pipeline includes ANAVEX&reg;2-73 currently in three different clinical studies, and several other compounds
in different stages of pre-clinical study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary SIGMACEPTOR&trade; Discovery Platform produced small molecule drug candidates with unique modes of action, based on
our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative
nature, including Alzheimer&rsquo;s disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate
ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin
or development) of disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compounds
that have been subjects of our research include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX&reg;2-73</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX&reg;2-73
may offer a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Rett syndrome, administration of ANAVEX&reg;2-73 resulted in both significant and dose related improvements in an array of behavioral
paradigms in the MECP2 HET Rett syndrome disease model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX&reg;2-73
was evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident.
Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice. Treatment with ANAVEX&reg;2-73 for
four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome disease mouse. Additionally, chronic
oral dosing daily for 6.5 weeks of ANAVEX&reg;2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome
disease mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths, some
of the core deficits observed in Rett syndrome. Administration of ANAVEX&reg;2-73 resulted in both significant and dose related
improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2019, we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX&reg;2-73 for the treatment
of Rett syndrome. The studies will be conducted in a range of patient age demographics and geographic regions, as more fully described
above under <I>Clinical Studies Overview &ndash; Rett Syndrome</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2016 and June 2016, the FDA granted Orphan Drug Designation to ANAVEX&reg;2-73 for the treatment of Rett syndrome and infantile
spasms, respectively. In November 2019, the FDA granted to ANAVEX&reg;2-73 the Rare Pediatric Disease (RPD) designation for the
treatment of Rett syndrome. The RPD designation provides priority review by the FDA to encourage the development of treatments
for rare pediatric diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
in February 2020, the FDA granted Fast Track designation for the ANAVEX&reg;2-73 clinical development program for the treatment
of Rett syndrome. The FDA Fast Track program is designed to facilitate and expedite the development and review of new drugs to
address unmet medical needs in the treatment of serious and life-threatening conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Parkinson&rsquo;s disease, data demonstrates significant improvements and restoration of function in a disease modifying animal
model of Parkinson&rsquo;s disease. Significant improvements were seen on all measures tested: behavioral, histopathological,
and neuroinflammatory endpoints. In July 2018 the Company received approval from the Spanish Agency for Medicinal Products and
Medical Devices (AEMPS), to initiate its Phase 2, double-blind, placebo-controlled 14-week trial of the safety and efficacy of
ANAVEX&reg;2-73 for the treatment of Parkinson&rsquo;s disease dementia. The Phase 2 study commenced in October 2018 and has enrolled
120 patients, randomized 1:1:1 to two different ANAVEX&reg;2-73 doses or placebo, in approximately 24 clinical study sites across
Spain and Australia. The study has completed enrollment and topline results are expected by mid-2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Alzheimer&rsquo;s disease (AD) animal models, ANAVEX&reg;2-73 has shown pharmacological, histological and behavioral evidence
as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity
to sigma-1 receptors and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX&reg;2-73 has shown a potential
dual mechanism which may impact both amyloid and tau pathology. In a transgenic AD animal model Tg2576, ANAVEX&reg;2-73 induced
a statistically significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as
significantly increased the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent.
It also statistically alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both
in terms of spatial working memory and long-term spatial reference memory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX&reg;2-73.
In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent
dose shown to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram
(ECG) parameters. ANAVEX&reg;2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed
adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity
and reversible. These side effects are often seen with drugs that target CNS conditions, including AD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ANAVEX&reg;2-73 Phase 1 SAD trial was conducted as a randomized, placebo-controlled study. Healthy male volunteers between the
ages of 18 and 55 received single, ascending oral doses over the course of the trial. Study endpoints included safety and tolerability
together with pharmacokinetic parameters. Pharmacokinetics includes the absorption and distribution of a drug, the rate at which
a drug enters the blood and the duration of its effect, as well as chemical changes of the substance in the body. This study was
conducted in Germany in collaboration with ABX-CRO, a clinical research organization that has conducted several Alzheimer&rsquo;s
disease studies, and the Technical University of Dresden.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2014, a Phase 2a clinical trial was initiated for ANAVEX&reg;2-73, for the treatment of Alzheimer&rsquo;s disease. The
open-label randomized trial was designed to assess the safety and exploratory efficacy of ANAVEX&reg;2-73 in 32 patients with
mild-to-moderate Alzheimer&rsquo;s disease. ANAVEX&reg;2-73 targets sigma-1 and muscarinic receptors, which have been shown in
preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse the pathological
hallmarks observed in Alzheimer&rsquo;s disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 2a study met both primary and secondary objectives of the study.&nbsp;The 31-week&nbsp;preliminary exploratory&nbsp;safety
and&nbsp;efficacy data from the&nbsp;Phase 2a study of ANAVEX&reg;2-73 in Alzheimer&rsquo;s&nbsp;patients, with most receiving
also donepezil, the current standard of care, demonstrated&nbsp;favorable&nbsp;safety, maximum tolerated&nbsp;dose, positive dose
response, sustained efficacy response through 31 weeks for both cognitive and functional measures, as well as&nbsp;positive unexpected
therapeutic response events. ANAVEX&reg;2-73 continued to demonstrate a favorable adverse event (AE) profile&nbsp;through 31 weeks
in a patient population of elderly Alzheimer&rsquo;s patients with varying degrees of physical fragility. The most common&nbsp;side
effects across all AE categories tended to be of mild severity grade 1 and were resolved with dose reductions that were&nbsp;anticipated
within the adaptive design of the study protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
57 weeks, Alzheimer&rsquo;s patients taking a daily oral dose between 10mg and 50mg of ANAVEX&reg;2-73 was well tolerated. There
were no clinically significant treatment-related adverse events and no serious adverse events. Despite non-optimized dosing of
ANAVEX&reg;2-73 throughout the 57-week study, continued significant improvements from baseline of cognitive, functional and behavioral
scores in a group of patients were observed, respectively. This data was analyzed using refined mathematical modeling methods
in conjunction with the detailed pharmacokinetic (PK) information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2017, we presented positive PK and PD data from the Phase 2a study, which established a concentration-effect relationship
between ANAVEX&reg;2-73 and study measurements. These measures, obtained from all patients who participated in the entire 57 weeks,
include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally, the study appears
to show that ANAVEX&reg;2-73 activity is enhanced by its active metabolite (ANAVEX19-144), which also targets the sigma-1 receptor
and has a half-life approximately twice as long as the parent molecule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-specified
exploratory analyses included the cognitive (MMSE) and the functional (ADCS-ADL) changes from baseline. A continued stabilization
of both cognitive and functional measures in patients treated with ANAVEX&reg;2-73 was observed. This correlation was positive
within all measured scores (MMSE, ADCS-ADL, Cogstate, HAM-D and EEG/ERP).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2018, we presented the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000
genes were analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp;
RNA data in patients exposed to ANAVEX&reg;2-73. The analysis identified genetic variants that impacted response to ANAVEX&reg;2-73,
among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX&reg;2-73. Results showed that study participants
without the SIGMAR1 (rs1800866) variants, which is about 80 percent of the population worldwide, demonstrated improved cognitive
(MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation may enable a precision medicine approach, since
these signatures can now be applied to neurological indications tested in clinical studies with ANAVEX&reg;2-73 including Alzheimer&rsquo;s
disease, Parkinson&rsquo;s disease dementia and Rett syndrome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX&reg;2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018,
the Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled
48-week safety and efficacy trial of ANAVEX&reg;2-73 for the treatment of early Alzheimer&rsquo;s disease. This Phase 2b/3 study
design incorporates inclusion of genomic precision medicine biomarkers identified in the ANAVEX&reg;2-73 Phase 2a study. The Phase
2b/3 study, which is expected to enroll approximately 450 patients, randomized 1:1:1 to either two different ANAVEX&reg;2-73 doses
or placebo, commenced in October 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data also validates ANAVEX&reg;2-73 as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer&rsquo;s
disease, Parkinson&rsquo;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman
syndrome, multiple sclerosis and, more recently, tuberous sclerosis complex (TSC). ANAVEX&reg;2-73 demonstrated significant improvements
in all of these indications in the respective preclinical animal models.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a study sponsored by the Foundation for Angelman Syndrome, ANAVEX&reg;2-73 was assessed in a mouse model for the development of
audiogenic seizures. &nbsp;The results indicated that ANAVEX&reg;2-73 administration significantly reduced audiogenic-induced
seizures. In a study sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX&reg;2-73
restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed
in many neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory
synapses. ANAVEX&reg;2-73 normalization of BDNF expression could be a contributing factor for the positive data observed in both
neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data presented also indicates that ANAVEX&reg;2-73 demonstrates protective effects of mitochondrial enzyme complexes during pathological
conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data on ANAVEX&reg;2-73 related to multiple sclerosis indicates that ANAVEX&reg;2-73 may promote remyelination in multiple sclerosis
disease. Further, data also demonstrates that ANAVEX&reg;2-73 provides protection for oligodendrocytes (&ldquo;OL&rsquo;s&rdquo;)
and oligodendrocyte precursor cells (&ldquo;OPC&rsquo;s&rdquo;), as well as central nervous system neurons in addition to helping
repair by increasing OPC proliferation and maturation in tissue culture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, we presented preclinical data of ANAVEX&reg;2-73 in a genetic mouse model of tuberous sclerosis complex (&ldquo;TSC&rdquo;).
TSC is a rare genetic disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence
of seizures. The new preclinical data demonstrates that treatment with ANAVEX&reg;2-73 significantly increases survival and reduces
seizures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX&reg;3-71</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX&reg;3-71
is a preclinical drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric
modulation, which has been shown to enhance neuroprotection and cognition in Alzheimer&rsquo;s disease models. ANAVEX&reg;3-71
is a CNS-penetrable mono-therapy that bridges treatment of both cognitive impairments with disease modifications. It is highly
effective in very small doses against the major Alzheimer&rsquo;s hallmarks in transgenic (3xTg-AD) mice, including cognitive
deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation and mitochondrial dysfunctions. ANAVEX&reg;3-71
indicates extensive therapeutic advantages in Alzheimer&rsquo;s and other protein-aggregation-related diseases given its ability
to enhance neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
preclinical study examined the response of ANAVEX&reg;3-71 in aged transgenic animal models and showed a significant reduction
in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In April 2016,
the FDA granted Orphan Drug Designation to ANAVEX&reg;3-71 for the treatment of Frontotemporal dementia (FTD).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
pathological conditions ANAVEX&reg;3-71 demonstrated the formation of new synapses between neurons (synaptogenesis) without causing
an abnormal increase in the number of astrocytes. In neurodegenerative diseases such as Alzheimer&rsquo;s and Parkinson&rsquo;s
disease, synaptogenesis is believed to be impaired. Additional preclinical data presented also indicates that in addition to reducing
oxidative stress, ANAVEX&reg;3-71 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions,
which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX&reg;1-41</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX&reg;1-41
is a sigma-1 agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration
or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell
viability. In addition, in animal models, ANAVEX&reg;1-41 prevented the expression of caspase-3, an enzyme that plays a key role
in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion
and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data presented also indicates that ANAVEX&reg;1-41 demonstrates protective effects of mitochondrial enzyme complexes during pathological
conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX&reg;1066</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX&reg;1066,
a mixed sigma-1/sigma-2 ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX&reg;1066 was tested
in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction
injury model of neuropathic pain, a single oral administration of ANAVEX&reg;1066 dose-dependently restored the nociceptive threshold
in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant
for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent
directly into the colon and a single oral administration of ANAVEX&reg;1066 returned the nociceptive threshold to control levels
in a dose-dependent manner. Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit
with ANAVEX&reg;1066 and a favorable safety profile in a battery of behavioral measures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX&reg;1037
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX&reg;1037
is designed for the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high
affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar
levels. In advanced pre-clinical studies, this compound revealed antitumor potential. It has also been shown to selectively kill
human cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient
mice models. Scientific publications highlight the possibility that these ligands may stop tumor growth and induce selective cell
death in various tumor cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate
sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions
with ion channels, our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer
cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compounds are in the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated
in pre-clinical models will be shown in human testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to identify and initiate discussions with potential strategic and commercial partners to most effectively advance our
programs and realize maximum shareholder value. Further, we may acquire or develop new intellectual property and assign, license,
or otherwise transfer our intellectual property to further our goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Target Indications</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed compounds with potential application to two broad categories and several specific indications. including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Central
Nervous System Diseases</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alzheimer&rsquo;s
    disease &ndash; In 2019, an estimated 5.8 million Americans were suffering from Alzheimer&rsquo;s disease. The Alzheimer&rsquo;s
    Association&reg; reports that by 2025, 7.2 million Americans will be afflicted by the disease, about a 24 percent increase
    from currently affected patients. Medications on the market today treat only the symptoms of Alzheimer&rsquo;s disease and
    do not have the ability to stop its onset or its progression. There is an urgent and unmet need for both a disease modifying
    cure for Alzheimer&rsquo;s disease as well as for better symptomatic treatments.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parkinson&rsquo;s
    disease &ndash; Parkinson&rsquo;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity,
    and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the
    neurotransmitter dopamine. Parkinson&rsquo;s disease afflicts more than 10 million people worldwide, typically middle-aged
    and elderly people. The Parkinson&rsquo;s disease market is expected to expand to $3.2 billion by 2021, according to business
    intelligence provider GBI Research.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rett
    syndrome - Rett syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way the brain
    develops, including protein transcription, which is altered and as a result leads to severe disruptions in neuronal homeostasis.
    It is considered a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the MECP2 gene. Because
    males have a different chromosome combination from females, boys who have the genetic MECP2 mutation are affected in devastating
    ways. Most of them die before birth or in early infancy. For females who survive infancy, Rett syndrome leads to severe impairments,
    affecting nearly every aspect of the child&rsquo;s life; severe mental retardation, their ability to speak, walk and eat,
    sleeping problems, seizures and even the ability to breathe easily. Rett syndrome affects approximately 1 in every 10,000-15,000
    females.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depression
    - Depression is a major cause of morbidity worldwide according to the World Health Organization. Pharmaceutical treatment
    for depression is dominated by blockbuster brands, with the leading nine brands historically accounting for approximately
    75% of total sales. However, the dominance of the leading brands is waning, largely due to the effects of patent expiration
    and generic competition.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epilepsy
    - Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient
    signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease
    Control and Prevention, in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled, but not cured,
    with medication that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs.
    Because epilepsy afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional
    anti-epileptic drugs and second generation anti-epileptic drugs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic
    Pain &ndash; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in
    any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well
    to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category
    of membrane stabilizing drugs or antidepressants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malignant
    Melanoma - Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant
    melanoma accounts for 75% of all deaths associated with skin cancer. The treatment includes surgical removal of the tumor,
    adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to IMS Health the worldwide malignant melanoma
    market is expected to grow to $4.4 billion by 2022.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding: 0; width: 24px; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate
    Cancer &ndash; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive
    system. The cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes.
    Drug therapeutics for prostate cancer are expected to increase to nearly $13.5 billion in 2024 according to Datamonitor Healthcare.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding: 0; text-indent: 0; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic
    Cancer - Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 55,000 new cases of
    pancreatic cancer will be diagnosed this year and approximately 44,000 patients will die as a result of their cancer, according
    to the American Cancer Society. Sales predictions by GBI Research forecast that the market for the pharmaceutical treatment
    of pancreatic cancer in the United States and five largest European countries will increase to $2.9 billion by 2021.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Patents,
Trademarks and Intellectual Property </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold ownership or exclusive rights to nine U.S. patents, ten U.S. patent applications, and various PCT or ex-U.S. patent applications
relating to our drug candidates, methods associated therewith, and to our research programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own one issued U.S. patent entitled &ldquo;ANAVEX&reg;2-73 and certain anticholinesterase inhibitors composition and method for
neuroprotection&rdquo; claims a composition of matter of ANAVEX&reg;2-73 directed to a novel and synergistic neuroprotective compound
combined with donepezil and other cholinesterase inhibitors.&nbsp; This patent is expected to expire in June 2034, absent any
patent term extension for regulatory delays. We own two issued U.S. patents each with claims directed to crystalline forms of
ANAVEX&reg;2-73. The first of these two patents claims crystalline forms of ANAVEX&reg;2-73, dosage forms and compositions containing
crystalline ANAVEX&reg;2-73, and methods of treatment for Alzheimer&rsquo;s disease using them. This patent is expected to expire
in July 2036, absent any patent term extension for regulatory delays. The second of these two patents claims pharmaceutical compositions
containing a crystalline form of ANAVEX&reg;2-73, and methods of treatment for Alzheimer&rsquo;s disease using the compositions.
This patent is expected to expire in June 2037, absent any patent term extension for regulatory delays. We also own an issued
U.S. patent that claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug
combined with either: (i) ANAVEX&reg;2-73 and its active metabolite ANAVEX&reg;19-144; or (ii) ANAVEX&reg;19-144. This patent
is expected to expire in October 2035, absent any patent term extension for regulatory delays. We also own an issued U.S. patent
that claims methods for treating a neurodevelopmental disorder or multiple sclerosis by administering ANAVEX&reg;2-73, ANAVEX&reg;19-144,
and/or ANAVEX&reg;1-41, another sigma receptor ligand similar to ANAVEX&reg;2-73. This patent is expected to expire in January
2037, absent any patent term extension for regulatory delays. In addition, we own one issued U.S. Patent with claims directed
to methods of treating melanoma with a compound related to ANAVEX&reg;2-73. This patent is expected to expire in February 2030,
absent any patent term extension for regulatory delays.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also own one issued patent with claims directed to methods for treating or preventing pain with ANAVEX&reg;1066. This patent is
expected to expire in November 2036, absent any patent term extension for regulatory delays.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
regard to ANAVEX&reg;3-71, we own exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX&reg;3-71
compound and methods of treating various diseases including Alzheimer&rsquo;s with the same. These patents are expected to expire
in April 2030, and January 2030, respectively, absent any patent term extension for regulatory delays. We also own exclusive rights
to related patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand,
Russia, and South Africa, and are expected to expire in January 2030.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also own other patent applications directed to enantiomers, formulations and uses that may provide additional protection for one
or more of our product candidates.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
regard patents and other intellectual property rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual
property in developing our business strategy including the selective development, protection, and exploitation of our intellectual
property rights. In addition to filings made with intellectual property authorities, we protect our intellectual property and
confidential information by means of carefully considered processes of communication and the sharing of information, and by the
use of confidentiality and non-disclosure agreements and provisions for the same in contractor&rsquo;s agreements. While no agreement
offers absolute protection, such agreements provide some form of recourse in the event of disclosure, or anticipated disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical
questions for which important legal principles are unresolved. For more information regarding challenges to our existing or future
patents, see &ldquo;Risk Factors&rdquo; &rdquo; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities
and Exchange Commission on December 16, 2019.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Highlights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
expenses for the second quarter of fiscal 2020 were $7.8 million, compared to $8.1 million for the comparable quarter in fiscal
2019. The operating expenses include an aggregate of $1.7 million, as compared to $1.9 million in the second quarter of fiscal
2019, in non-cash charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss for the second quarter of fiscal 2020 was $7.2 million, or $0.12 per share, as compared to $7.2 million, or $0.15 per share
in the comparative quarter of fiscal 2019.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of Operations</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">We
are in the development stage and have not earned any revenues since our inception and we do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Three
and six months ended March 31, 2020 compared to three and six months ended March 31, 2019</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
operating expenses for the second quarter of fiscal 2020 were $7.8 million, compared to $8.1 million for the second quarter of
fiscal 2019. Total operating expenses for the first half of fiscal 2020 were $15.5 million compared to $15.6 million for the same
period in fiscal 2019. This represents a decrease of $0.3 million for the three-month period and $0.1 million for the six-month
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses have decreased by $0.4 million to $1.7 million for the three months ended March 31, 2020, as compared
to $2.1 million for the second quarter of fiscal 2019. General and administrative expenses decreased by $0.7 million to $3.1 million
for the six-month period ended March 31, 2020, as compared to $3.8 million for the applicable prior year period. The decrease
in general and administrative expenses was primarily related to a decrease in stock option compensation charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses have remained consistent at $6.1 million for the three months ended March 31, 2020 and increased by $0.6
million to $12.4 million for the six-month period ended March 31, 2020, as compared to $11.8 million for the applicable prior
year period. &nbsp;The increase is related to an increase in clinical trial activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
income (net)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net amount of other income was $0.5 million as compared to $0.9 million for the three-month ended March 31, 2020 and $1.7 million
for the six-month period as compared to $1.5 million for the comparable six-month period in fiscal 2019. The decrease in other
income in the second quarter of fiscal 2020 is due to an increase in foreign exchange loss, which is the impact of the fluctuation
in the value of the Australian Dollar on the Company&rsquo;s incentive and tax receivables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
and Capital Resources</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working
Capital</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2020</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30,
    2019</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Assets</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,020,577</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,329,373</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Liabilities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,228,831</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,039,674</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working
    Capital</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,791,746</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,289,699</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2020, we had $26.6 million in
cash and cash equivalents, an increase of $4.4 million from September 30, 2019. The principal reason for this increase is due to
cash received from financing activities of $15.4 million from the issuance of shares of common stock under the 2019 Purchase Agreement
(as defined below), offset by cash used in operations of $11.0 million.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
Flows</FONT></P>

<P STYLE="text-indent: 20pt; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
    months ended <BR>
    March 31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash flows used in operating activities</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,988,051</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,491,627</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash flows from
    financing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,365,492</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,018,834</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase (decrease)
    in cash and cash equivalents</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,377,441</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,472,793</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flow used in operating activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the first six months in fiscal 2020 was $11.0 million, compared to $8.5 million during the
comparable period of fiscal 2019. The principal reason for this increase in net cash used from operating activities in the current
period is due to an increase in operating expenses, net of non-cash charges, and an increase in research and development incentive
income receivables, as compared to the comparable period.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flow provided by financing activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the first six months in fiscal 2020 was $15.4 million, attributable to cash received from
the issuance of common shares at various market prices under the 2019 Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash provided by financing activities for the
first six months in fiscal 2019 was $5.0 million, primarily attributable to cash received from the issuance of common shares at
various market prices under the 2015 Purchase Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
Financing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purchase
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2019, we entered into the 2019 Purchase Agreement (the &ldquo;2019 Purchase Agreement&rdquo;) with Lincoln Park Capital
Fund, LLC (&ldquo;Lincoln Park&rdquo;), pursuant to which Lincoln Park committed to purchase up to $50,000,000 of our common stock.
Concurrently with the execution of the 2019 Purchase Agreement, we issued 324,383 shares of our common stock to Lincoln Park as
a fee for its commitment to purchase shares of our common stock under the 2019 Purchase Agreement and shall issue up to 162,191
shares pro rata, when and if Lincoln Park purchases, at our discretion, the $50,000,000 aggregate commitment. The purchase shares
that may be sold pursuant to the 2019 Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time
until July 1, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may direct Lincoln Park, at our sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common
stock on any business day (a &ldquo;Regular Purchase&rdquo;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares provided that Lincoln Park&rsquo;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the even we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional purchases. The purchase price
of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the
time of sales as described in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2020, approximately $30.0 million in shares of our common stock remained available for purchase by Lincoln Park under
the 2019 Purchase Agreement.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Sales Agreement </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1 2020, we entered into an Amended and
Restated&nbsp;Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with Cantor Fitzgerald&nbsp;&amp; Co. (&ldquo;Cantor Fitzgerald&rdquo;)
and SVB Leerink LLC (&ldquo;Leerink&rdquo;) and together with Cantor Fitzgerald as Sales Agents, pursuant to which we may offer
and sell shares of common stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through the Sales Agents
(the &ldquo;At-the-Market Offering&rdquo;).&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
delivery of a placement notice based on our instructions and subject to the terms and conditions of the Sales Agreement, the Sales
Agents may sell shares of common stock by methods deemed to be an &ldquo;at the market offering&rdquo; offering, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any
other method permitted by law, including negotiated transactions, subject to our prior written consent. We are not obligated to
make any sales of shares under the Sales Agreement. We or the Sales Agents may suspend or terminate the At-the-Market Offering
upon notice to the other party, subject to certain conditions.&nbsp; The Sales Agents will act as sales agent on a commercially
reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules&nbsp;and
regulations and the rules&nbsp;of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay the Sales Agents commissions for their services of acting as agent of 3.0% of the gross proceeds from the sale
of the Shares pursuant to the Sales Agreement.&nbsp; We have also agreed to provide the Sales Agents with customary indemnification
and contribution rights. To date, no shares of common stock have been sold pursuant to the Sales Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that we will be able to continue to fund our operations through existing cash on hand and through equity and debt financing
in the future. If we raise additional financing by issuing equity securities, our existing stockholders&rsquo; ownership will
be diluted. Obtaining commercial loans, assuming these loans would be available, would increase our liabilities and future cash
commitments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our rights related to the Lincoln Park financing and the At-the-Market Offering, there can be no assurance that additional
financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we
are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to delay or scale
down some or all of our research and development activities or perhaps even cease the operation of our business.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Off-Balance
Sheet Arrangements</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that are material to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CRITICAL
ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
prepare our interim condensed consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America, and make estimates and assumptions that affect our reported amounts of assets, liabilities, revenue
and expenses, and the related disclosures of contingent liabilities. We base our estimates on historical experience and other
assumptions that we believe are reasonable in the circumstances. Actual results may differ from these estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described in Note 2 &ldquo;Recent Accounting Pronouncements&rdquo; to our Consolidated Financial Statements included herein,
there have been no significant changes in the critical accounting policies and estimates described in our Annual Report on Form
10-K for the year ended September 30, 2019 as filed with the SEC on December 16, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECENT
ACCOUNTING PRONOUNCEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
refer to Note 2 &ldquo;Recent Accounting Pronouncements&rdquo; in notes to our Interim Condensed Consolidated Financial Statements
included in this Form 10-Q.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_004"></A>Item
3. Quantitative and Qualitative Disclosures about Market Risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_005"></A>Item
4. Controls and Procedures.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Disclosure
Controls and Procedures </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required
to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the
time periods specified in the SEC&rsquo;s rules and forms and to provide reasonable assurance that such information is accumulated
and communicated to our management, our chief executive officer and our principal financial officer, to allow timely decisions
regarding required disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
carried out an evaluation, under the supervision and with the participation of our management, including our principal executive
officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures,
as defined in Rule 13a 15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.
Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls
and procedures were effective as of March 31, 2020.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Changes
in Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the quarter ended March 31, 2020, there were no changes in our internal control over financial reporting identified in management&rsquo;s
evaluation pursuant to Rules 13a 15(d) or 15d 15(d) of the Exchange Act during the period covered by this Form 10-Q that materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_006"></A>PART
II &ndash; OTHER INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_007"></A>Item
1. Legal Proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our
Company or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse
party or has a material interest adverse to our or our subsidiary&rsquo;s interest.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_008"></A>Item
1A. Risk Factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no material changes to the risk factors discussed in &ldquo;Risk Factors&rdquo; in Part I, Item 1A of our Annual Report
on Form 10-K for the fiscal year ended September 30, 2019 filed with the SEC on December 16, 2019 except for the following new
risk:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
COVID-19 coronavirus could adversely impact our business, including our clinical trials, and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, the COVID-19
coronavirus has spread to multiple countries, including the United States, Australia and European and Asia-Pacific countries,
including countries in which we have planned or active clinical trial sites. As the COVID-19 coronavirus continues to spread around
the globe, we may experience disruptions that could potentially impact our business and clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the spread of COVID-19 coronavirus has had and may continue to severely impact the trading price of shares of our common
stock and could further severely impact our ability to raise additional capital on a timely basis or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global outbreak of the COVID-19 coronavirus continues to rapidly evolve. The extent to which the COVID-19 coronavirus may impact
our business, including our clinical trials, and financial condition will depend on future developments, which are highly uncertain
and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak,
travel restrictions and social distancing in the United States and other countries, business closures or business disruptions
and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the information set forth in this Form 10-Q, you should carefully review and consider the risk factors discussed in
&ldquo;Risk Factors&rdquo; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2019 filed
with the SEC on December 16, 2019. These risks could materially and adversely affect our business, financial condition, and results
of operations. The risks described in herein and in our Form 10-K are not the only risks we face. Our operations could also be
affected by additional factors that are not presently known to us or by factors that we currently consider immaterial to our business.
There have been no material changes in the significant factors that may affect our business and operations as described in &ldquo;Risk
Factors&rdquo; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_009"></A>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period covered by this Quarterly Report on Form 10-Q, we have not sold any equity securities that were not registered under
the Securities Act of 1933 that were not previously reported in a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_010"></A>Item
3. Defaults Upon Senior Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_011"></A>Item
4. Mine Safety Disclosures</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_012"></A>Item
5. Other Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">None</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_013"></A>Item
6. Exhibits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; text-align: left; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    <BR> Number</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 9%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%; font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles
    of Incorporation and Bylaws</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex3-1.htm">Articles
    of Incorporation (incorporated by reference to Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended March
    31, 2019 filed on May 9, 2019)</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm">Bylaws
    (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm">Articles
    of Merger filed with the Secretary of State of Nevada on January 10, 2007 and which is effective January 25, 2007 (incorporated
    by reference to our Current Report on Form 8-K filed on January 25, 2007)</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(31)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
    13a-14(a)/15(d)-14(a)Certifications</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="e1894_31-1.htm">Certification
    of Christopher Missling, PhD.</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="e1894_31-2.htm">Certification
    of Sandra Boenisch</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1350 Certifications</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="e1894_32-1.htm">Certification
    of Christopher Missling, PhD and Sandra Boenisch.</A></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(101)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    INSTANCE DOCUMENT</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION SCHEMA</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION CALCULATION LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION DEFINITION LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION LABEL LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION PRESENTATION LINKBASE</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
                                         herewith.</FONT></TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_014"></A>SIGNATURES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
LIFE SCIENCES CORP. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Christopher Missling, PhD</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
Missling, PhD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Executive Officer)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 7, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Sandra Boenisch</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra
Boenisch, CPA, CGA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Financial Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Financial and Accounting Officer)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 7, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>e1894_31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Christopher Missling, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
I have reviewed this Quarterly Report on Form 10-Q for the three months ended March 31, 2020 of Anavex Life Sciences Corp. (the
&ldquo;registrant&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)
disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
May 7, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Christopher
Missling, PhD </FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 40%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><BR>
Christopher Missling, PhD<BR>
Chief Executive Officer, President and Secretary<BR>
(Principal Executive Officer)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>e1894_31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Sandra Boenisch, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
I have reviewed this Quarterly Report on Form 10-Q for the three months ended March 31, 2020 of Anavex Life Sciences Corp. (the
&ldquo;registrant&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)
disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
May 7, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Sandra
Boenisch</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 40%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra
Boenisch, CPA, CGA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal
Financial Officer, Treasurer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
Financial and Accounting Officer)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>e1894_32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTIFICATION
PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the Quarterly Report of Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months
ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned,
in the capacities and on the date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0; width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    May 7, 2020</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; width: 40%; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Christopher
    Missling, PhD </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Christopher
    Missling, PhD</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Chief
    Executive Officer, President, Secretary</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
        Executive Officer)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Sandra
    Boenisch</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra
    Boenisch, CPA, CGA</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal
    Financial Officer, Treasurer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference
into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language
in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging,
or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required
by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &G G # 2(  A$! Q$!_\0
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MV_\ BZ /4J*\M_X7=\(O^BB^$_\ P;VW_P 71_PN[X1?]%%\)_\ @WMO_BZ
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M 'J5%>6_\+N^$7_11?"?_@WMO_BZ/^%W?"+_ **+X3_\&]M_\70!ZE17EO\
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MEW<1-\Q:[^S7^S!J.H:WJ>@?&S2?!%[XBUSQQ_:-[X7N;6SNK/P#X]\*>'/
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MXL75YHNNZ)<Q6MQ93>,M9^)'AVYNXGEUGPMJUHT>GP@'WS17EO\ PN[X1?\
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M_"+^&?\ H7="_P#!1I__ ,CT?ZM_2B_Z.WX,?^*4XH_^FH']J>$W_1'<<_\
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M).\I_P"B[S7_ ,,66?\ S<?TI_\ "ROAU_T/W@K_ ,*K0O\ Y/H_X65\.O\
MH?O!7_A5:%_\GU_-9]KN_P#GYN/^_P!)_P#%4?:[O_GYN/\ O])_\51_Q5/X
MN_Z,QPI_XFG$_P#\Y _XD[RG_HN\U_\ #%EG_P W']*?_"ROAU_T/W@K_P *
MK0O_ )/H_P"%E?#K_H?O!7_A5:%_\GU_-9]KN_\ GYN/^_TG_P 51]KN_P#G
MYN/^_P!)_P#%4?\ %4_B[_HS'"G_ (FG$_\ \Y _XD[RG_HN\U_\,66?_-Q_
M2G_PLKX=?]#]X*_\*K0O_D^C_A97PZ_Z'[P5_P"%5H7_ ,GU_-9]KN_^?FX_
M[_2?_%4?:[O_ )^;C_O])_\ %4?\53^+O^C,<*?^)IQ/_P#.0/\ B3O*?^B[
MS7_PQ99_\W']*?\ PLKX=?\ 0_>"O_"JT+_Y/H_X65\.O^A^\%?^%5H7_P G
MU_-9]KN_^?FX_P"_TG_Q5'VN[_Y^;C_O])_\51_Q5/XN_P"C,<*?^)IQ/_\
M.0/^).\I_P"B[S7_ ,,66?\ S<?TI_\ "ROAU_T/W@K_ ,*K0O\ Y/H_X65\
M.O\ H?O!7_A5:%_\GU_-9]KN_P#GYN/^_P!)_P#%4?:[O_GYN/\ O])_\51_
MQ5/XN_Z,QPI_XFG$_P#\Y _XD[RG_HN\U_\ #%EG_P W']*?_"ROAU_T/W@K
M_P *K0O_ )/H_P"%E?#K_H?O!7_A5:%_\GU_-9]KN_\ GYN/^_TG_P 51]KN
M_P#GYN/^_P!)_P#%4?\ %4_B[_HS'"G_ (FG$_\ \Y _XD[RG_HN\U_\,66?
M_-Q_2G_PLKX=?]#]X*_\*K0O_D^C_A97PZ_Z'[P5_P"%5H7_ ,GU_-9]KN_^
M?FX_[_2?_%4?:[O_ )^;C_O])_\ %4?\53^+O^C,<*?^)IQ/_P#.0/\ B3O*
M?^B[S7_PQ99_\W']*?\ PLKX=?\ 0_>"O_"JT+_Y/H_X65\.O^A^\%?^%5H7
M_P GU_-9]KN_^?FX_P"_TG_Q5'VN[_Y^;C_O])_\51_Q5/XN_P"C,<*?^)IQ
M/_\ .0/^).\I_P"B[S7_ ,,66?\ S<?TI_\ "ROAU_T/W@K_ ,*K0O\ Y/H_
MX65\.O\ H?O!7_A5:%_\GU_-9]KN_P#GYN/^_P!)_P#%4?:[O_GYN/\ O])_
M\51_Q5/XN_Z,QPI_XFG$_P#\Y _XD[RG_HN\U_\ #%EG_P W']*?_"ROAU_T
M/W@K_P *K0O_ )/H_P"%E?#K_H?O!7_A5:%_\GU_-9]KN_\ GYN/^_TG_P 5
M1]KN_P#GYN/^_P!)_P#%4?\ %4_B[_HS'"G_ (FG$_\ \Y _XD[RG_HN\U_\
M,66?_-Q_2G_PLKX=?]#]X*_\*K0O_D^C_A97PZ_Z'[P5_P"%5H7_ ,GU_-9]
MKN_^?FX_[_2?_%4?:[O_ )^;C_O])_\ %4?\53^+O^C,<*?^)IQ/_P#.0/\
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M^#EUI7A3PGXNO_"%S\?]=\0Z)\//#OCN]@T6ST62'7;JWURTNK(LOR[\:_\
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M ,%&B?\ S2TJ_A_X)XO#8_#8WZ?'!F-CFU#$8;-J^)X)X=EC,TI8C#8C"?\
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ME/\ \^#\'O\ A"/&'_0M:S_X 3__ !%'_"$>,/\ H6M9_P# "?\ ^(K]XO\
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M_P  )_\ XBOV,_X;[^!O_/KXW_\ !1HG_P TM'_#??P-_P"?7QO_ ."C1/\
MYI:/^)7?HI?])O<(_P#B.Y=_\UA_Q&#QG_Z,#G'_ (<<5_\ ('XY_P#"$>,/
M^A:UG_P G_\ B*/^$(\8?]"UK/\ X 3_ /Q%?L9_PWW\#?\ GU\;_P#@HT3_
M .:6C_AOOX&_\^OC?_P4:)_\TM'_ !*[]%+_ *3>X1_\1W+O_FL/^(P>,_\
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M ) _'/\ X0CQA_T+6L_^ $__ ,11_P (1XP_Z%K6?_ "?_XBOV,_X;[^!O\
MSZ^-_P#P4:)_\TM'_#??P-_Y]?&__@HT3_YI:/\ B5WZ*7_2;W"/_B.Y=_\
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MPO./X-?\(1XP_P"A:UG_ , )_P#XBC_A"/&'_0M:S_X 3_\ Q%?TST5^T?\
M%*W*/^CVYQ_X@64?_1.?"?\ $XF8_P#1!9?_ .)!C?\ YV'\S'_"$>,/^A:U
MG_P G_\ B*/^$(\8?]"UK/\ X 3_ /Q%?TST4?\ %*W*/^CVYQ_X@64?_1.'
M_$XF8_\ 1!9?_P")!C?_ )V'\S'_  A'C#_H6M9_\ )__B*/^$(\8?\ 0M:S
M_P" $_\ \17],]%'_%*W*/\ H]N<?^(%E'_T3A_Q.)F/_1!9?_XD&-_^=A_,
MQ_PA'C#_ *%K6?\ P G_ /B*/^$(\8?]"UK/_@!/_P#$5_3/11_Q2MRC_H]N
M<?\ B!91_P#1.'_$XF8_]$%E_P#XD&-_^=A^*7[+_P"R7K/Q*U=/%'CVQOM%
M\"Z3<KNMITEM+[Q)=Q;7-A8E@DD5BA*C4-2CXC&;.Q<W[37&E?M!INFZ?H^G
MV>E:596VG:;IUM#9V-A9PI;VMI:VZ".&WMX(E6.**-%"HBJ  *NT5_<WT>?H
MX\#_ $=N%JN2\-J>;\09K*%;B?C/,,+AZ&<9[5I3J2PV&C3HRK0RS)L!&=L!
MD^$Q$Z$*TJ^.Q=7'9AB98FA_/7B;XI<0^)^<0S#-G'!Y=A$X93D>&JU9X'+H
M3455J7GR2Q6-Q#5\1C:U-5)05/#T8T,-35.H4445_01^:!1110!\7>-O^3V_
MA!_V3C5O_2/XCU]HU\7>-O\ D]OX0?\ 9.-6_P#2/XCU]HU^ >!W_)0?2-_[
M2)XH_P#6$\)C]'X__P"1;X8_]FTRG_U?\7G*KX&\&IXSO?B,OA;01X]U'PKI
M_@:_\8_V7:'Q'=^#=*U75-=T[PM/JYB-[)H-GK.MZMJD&EF;[(E_J%U=>499
M"U>9Z9^R_P#LY:-X/F^'VE_ WX5V7@:?7/ /B:7PC#X(\/CP\WB+X51^%HOA
MGK@THV)LTU7X?Q^!_!R>#;](EN?#B^%]"_LF2T_LNS\KW:BOW\_.#S+3?@O\
M)-&T3X=>&])^&_@O3- ^$6MCQ)\+M'L?#VFVNG_#_P 0#2/$&@G6O"5M#;I%
MH>J2:)XL\3Z5-?6"PW$]AXAUFVFD>+4KM9?-_$/[&O[)_BOX:^"/@YXC_9S^
M#>K_  I^&=W=W_P[^'MW\/\ PXWA'P/>W\.IV]]=>%-#2P2QT&>^@UK5XKR3
M38;9KJ/4[Y9S(+F8/]*T4 >*Z)^SA\ O#6FZ!I'A_P"#OPYT;3O"WQ"A^+/A
MRUT[PGH]HFB?$ZWT67PU#X_TYH;59+7Q='X:GF\.+KT;C41X?D;1/M']F'[+
M4OQE_9V^!/[0]AX=TOXZ_"/X?_%K3_"&L7'B#PK:^/O#&E>)8O#FNW6F7FBW
M.L:&-3MYVTO4I]'U"_TN:]LS#<26%Y=6C2&">5&]EHH \UNO@W\*+[X9V'P9
MOOAUX/O?A-I>F>'M%T_X<7F@Z?=>#;72/"=WIU_X;TN/P_<02::;#1;S2-,N
M-/M'MV@@DL;9E3]VHKF?%O[,_P"SSX^^*'A;XV>-O@E\+_%GQ<\$KIR>%/B/
MX@\%:!JWC#0AHMU>7^A-8:Y>V,U]')X?U#4+_4/#TK2O+H&H7MW?Z.]E=W,T
MS^X44 %%%% 'Q9^VC_R!O@__ -E;T3_T@U"OM.OBS]M'_D#?!_\ [*WHG_I!
MJ'^!K[3K^>_#S_E(/Z2?_8#X"?\ KO\ BT_2N)?^3;^%W_7_ ,0__6DR@***
M*_H0_-0K\;_V^8(KKX^>$+6=6:"Z\'^$;:=5)5FAN/%7B6&559?F5FC=E!'(
M)!'(K]D*_.G]K#]FKXH_%[XFZ1XM\$Q:8+#3O"NC::MS=:K;65S%J>G:QKM^
MS)%,RL!$M]:212C<&<.."G/\=?3IX1XHXW\!:V1\(\,9SQ?FZX]X S&>29%@
M)9EF%?+LMS?,<1F-6.%C4I<U"EAY*->4IJ$(XB'/[LY6_<_H[YYD_#WB/3S'
M/,VP.2X'_5SB3"K'YAB%AL-3Q6+P6%I86#JN,[5)U5>FE'F;I2<=8J_S*OPC
M^%VH^.-7LX=(TIM.\)ZAXIT;Q+H_A/QA?7FGVT&K>(K/PM\/=1OM8\0WT4=M
MXGTN.3Q'XG\1:'8:I<P2V7AB!)+6VENI[<\"OPM\,Z1\,O$W_"1:=IS>-_#U
ME\4WN);;5=>3Q;+J?@KQ'I.AZ;=:3I*D^&;OPK9?:YKCQ+)=!=133':_L@_D
M"0>DWW[%'[2&IV^IVNHW.E7MMK6M'Q)J\%QXBLI(]2U\QW<7]KWBF3]]?"._
MO565ONB[N"H!D8G3N?V0OVJ;RY@O+O7+:XN[6WU6T@N)?$]DTL=KKMBFF:U;
M[B_SQ:KI\:6E^LF_[3"H$A)RQ_S6Q7ASQOBYYA7_ .).?$'"8K%TN)</2GA^
M"\MGA84N(YXG#T*TL'*.'C#%\.X+!</8G+:E%X>C6S"6?4Z,<EPV*IXG&_UC
M1XNX:H+#4WXW\.5Z-&>559QJYWBXUG+*XTJM2G&NG5;H9GB,1FE+%QJ*M4IX
M59;.<L?6HSI8?S'XB?#+P1X5\1ZKH6EZ%+=64_@KXC^,K/Q VHWLEC:ZAH/A
M2YEL?".F*MVY:X\):G%'?>()-5WW]W?WEK$L$6BK;/J%_P 2_"OX9Z5+XF\4
M1:;J[^"= G^'NB^(;&QO;FYUCPYKIUWPPOBR*Q,LQ>ZB\4^%=2FUC0C=&01S
M/JMG;M')IBNG?R_LA?M43QZG%-KEM-%K4][=:K'+XHLY%O[G4=(;0=0N)PSG
M]]?:*YTN\DCV-<V:QQ3%Q%$4?!^R-^U9:W>HW]KX@CMKW6+O1[_5;F#Q9;PR
MZA>^'Y%ET.[NC'*HDN-)D16L92 \/S*"5=U98GPTXSK8S-:U+Z(?B-2PN/QN
M,QF78=^'F23_ + M1QG]F86A&.88>.;9?2Q5;GS+!X^M0J9C@\95POUS"5\I
MR?&1*/&/#M.A@X3\:N&9UL-AZ%#%55Q'F$?[2]_#K&5JC>%JO!8J=&G;"5\-
M3J1PF(H0K?5Z]+&X^A+Q+Q)X6\*>&]"UOXD+X.\)^(=!F?PM9>#;30]>\9/X
M-U'3=;N_%L5UXMU)+W4+?Q997UM+X8;PU+H5YJ%E!::V;BY87*FW23KO^%.>
M!-3A.EZ7IFH6/BC7?%_A&^\+Z5=ZK=SNFFWW@3POXT\2_#2Z:4PM+J/V/6]3
MDT+49(HM5FGTNTTZ:0W%]D^G)^RS^UW'K,_B!/$\:ZQ<Z?#I4]X/$VGE9=+M
MI?/MM.:S.;#[%;7'^E6]N+41071:ZB5+AFE.,?V.OVHFN8[UM:@>^A\1_P#"
M7QWS^+(7O4\5;84_X2$7;3FX_M8);P*+LR[PL48'"BLUX7\;0Q5>I4^BAXHY
MC@<4W2J9=B?#KAS"SPTJ^+53-LXP&:X:M#'PQV:82O*AEN6XRG6R_A=Y%DKH
M/,)X_/Z^/M\:<-RI4XQ\8^$\-B*/OQQ-+B/-:T:JIT>7 X'$X.M"6&EA\)7I
M*KB\50E#$YO_ &CF"J+"QP^6TL-XS96OPLE\:Z[X/?PUI%I=Z)=Z[X;\,3^*
MM1\0VWAWQ!XHN/']ZL5KXCU?P]<QZGIL,7AH0Z#X2O;B0VT%[ ]YKKN)A);\
M7H.E:+X?T?XI:GXK\%6NN:IX1\1>&/#\/A_4=8UJTCTR;4=7\166L6B7FA:A
M:SW-] =*BL[6YDDNHPZ-.(9BY5OJ31_V1?VJO#^HZKJ^B:Y:Z9JFN2O<:Q?6
MOB:R6XU*YDN9+TW5TSLZO=I>32W4-T%6XM[B1Y;>6)V),.@_L??M2^%YM0N/
M#NM6NCW&K-$^J3V7BBT2;4)8)I;B":ZE>21Y;B&XFFGBN"1/'-+)(D@=B:^<
MEX1>+F)Q&4XK$_1O\2<+B,%F'',IRR_PIX9>%P^5YW@,9@^%(SRS%8BI@L^S
M'A^<LMJ*>92PN"IT,-6HQP>+Q\J><UO37'G U*GBZ-+Q0X6K4JV&X?2CB>+L
MW5:KBLOQ%"MG%L71I1KY=A<SBL5%QPJK8B56K"HZU##J6 I^8:IX"^%O@S51
M!KMNB6TNM>/=+TJY\5W>N'2+/58M*^'NI^&-)\>3>&7@U*WLM#;7];TB_P!0
MTJ&"4ZL+:XU& VL4UO'C>,/ FB>&?!]CI\OAKPEIOQ$UWQ#XRT1-%NM9\::I
MX@CO+'Q?;:/H]IX/FL)Y?#-[9VEK<1QK>:](UQ?PG[0/M$SIN]QTC]DO]J_0
M7672/$$-C()]3NF9/%%E-YMSK4ME/JUQ<"Y><74VH7&FV%Q<R7(E9KBSM[@%
M9HP]7+/]EK]KW3X?(M/%?E1?VC=:N%;Q593L-5O;Q=1O-166Y::9;RYOT6]G
MG60/)=*)B=X!KZ&KX5\;8K!YCAE]%;Q3RAX[#9AA,)++?#?(*]3)J.8RRWV]
M>GB,3CYULRS&G1PV*P^58N<\OI932Q%6E4PV.IU:./PWFT^-N&Z-?"U7XO<(
MXWZO5PU:NL5Q-F=...J86.*]E3E2I8:-/"X6=2M1JXV@HXJ>-G2A.%7#2C4P
M]7R;Q;\,?A[X"\0^&[S7;*.U\,RZ'XD\(7%UJVIZAJ7AR?XH^%4M8(/$7B:;
MPK>SZUI_A/Q,+Z/4$L]/D@N;(IN:V-G!<1-RWC3P?X:\'>";MM6\/^"M%\97
MWB+QQ8+I]UKOC;5M0@M]-N?#XTA?!-UI]Q+X?O[.VL]5>ZBO/$LQEO()86?S
MW!6O</#W[(7[4_A)+J/PUK-EHT5]=+?7T-GXCL/(O;M898!<7=O,98+B0PS2
M(QFC<-E68%XXF2Q)^R;^UC-I^IZ3<>(HKG3=9N-1N]5L[OQ197<=_=:N8SJM
MQ<-<M+*9M0,41NI%D5I3&F3\BXSS#PLXZQ> SJ. ^BEXGY)C,TP>;PR^A1\/
MLEQV%R+&9CEN68'VD,=4KT\;F,(RR?#2R^K'#Y34R99EG\I87,ZV8PS"E6&X
MUX8HXC /$>,/"F/H8.O@I8BI4XBS##ULPH87%8O$<LL/"G/#X64OKU98J#J8
MV./^J98E6P<,++#5/ ?!OA/P9K.D?"S0-2\,"?5/B/#X_-]XPM=6U>#5O#LF
M@:A>6^FZG#8BZ;0IM(TN&U6YUB"]TXFXLENF%[:2K',G0VOA?X7Q>+?AAX?O
M]&\,WMA>Z!H/B'QA8Z3JWCB/QO<6\OPQF\5:G_:$UY,OAJUMKV_9;FQ70V:Y
MCV64,@CA:YC;U2V_9!_:HL_#\GA2SUV"U\-RI>12:+;>*K6"Q:'4)%EU" I'
M*K_9[^10][;"0073#]_&X)%6W_9/_:SDM=-LI/$5N]KH\20:5"_B33C]@ABT
MRXT:*&VD/[U(H])N[G3HXS(42TF:)0!MQCE?A9XCX'+\KH5_HM>(^+QN"P_"
M*KXFOX8</U*==9%6R6KF^45(1QD9YA@\YQ&6X[&XC-LT?]IXJ.<8K)\6_P"S
MHP<;QG&O"6(Q.*J4_%SABCAZ\\ZY*5/BO-(2@\QACX8+&QDZ$EAJ^ I8O#X>
ME@L&EA*3P-''4?\ :I23\AT_X->&M$TKQ/%XDCGU?5KSQ1X/D\"W4-Y-;13?
M#J[\=>%M#G\2^5 Z1W'_  E]EXF2STUY=RVQTS4Y8-LJHZRKX,^%&L>(_B=H
M\R>%M+TW0-&32M#USPCJ7C1[+PWXFU7Q_;^&M&U+Q0/%L@EO/L7FV]MK262-
MI::;=7%Y;LUU K)Z3_PQU^U%LAC_ +8M2EMI.CZ#;!O%%JWV;1?#VHQ:OH6E
MP%I28K+2-4@AO["%"%@N8UD7IBK6M?LD?M6>(TO8]>URTU5-1M%L-06[\1Z<
MPO;-=1BU=;>Z\OR_/C75((;\>9N;[3&LF[(.>A>%_&^&P>'PV ^B+XC*E@IR
M<<)F7 N"Q[S6A/+^+(RPN:YNLPAF5H9IQ/2J4L90G#&4L!D'#JP__"CE-.I7
MR?&G#=6O5JXGQHX9<ZZBG7PN?8G#?4ZD<3DS5;!X)X:6%][!Y3.,Z%1.A/$Y
MEFGM;X3'3C3\AU3POX2\%2^/]$USX9:/?:UX'^&7@?Q5-_:VL>+(KE?$FK#P
M+IVN6-VFF:]8VTE@MWK6JW< ACCD$\D6R<VB1PUM>'O@CH'B+5_$L46C216-
M_P"%OA_H/A/;K M8-*\?>,O %CXKGUV5]1OXIM2LM/O4BLY]-1KK:/$]LRV^
M((<=O??L;?M/:G-J=QJ.JVE]<:UI-AH6KSW?BBUGFU/1M*_L_P#LW3+V625G
MGL['^RM-^SQNQV?8;?D[.6ZA^QI^TWJR:4FI:E87J:'/%<Z.)_$MFW]F7,%I
MIFGP7%F1(#%-#8Z+I-K%("7C@TZUC4A8A44_#'Q 6.<L9]$WQ.S+)\#B<5/*
M,KEP)PUEV*J82MF6:T:%#-LUP&#A5Q%:APWFO)*NZ>-C//,MR[%T88>E0H8B
MA4N,^%OJZC1\9.%,+CL12HQQN,CGV;8JE&M3PF#G4J8+!XFNX4H5,UP?.J?-
M0:R_%8JC4E5G5J4JG@G[//C"]^''Q U/Q6_A;6_$D?A_PKK7_"0:)H<22:];
M:5]OTRSU>^L[28QK<S:*'^UW-J[Q%K>"X)DC*9'ZR:5\1]8U98_^$5\"QQ*;
M,WTNL>/_ !MX3\,Z5:VH0/)=-;:#J'B_6KNUC1E9IEL+6U 89N5.*^5?A3^S
M=^TK\*_B#=?$>#1?"7BC7+^RUFUODUOQ)%#'=SZY/#<WU_/-92+*US)-$SMP
M$D::0L <&OHZ2P_:+F54F^ _P.DC6X%V\']O.MM/=+S'<W-LJB"[FB;YX9+J
M.9H9,R1%)/FK^P/HDRX^\(/"FOPCQ'PKXT9#6GQAQ1FM+)*7@SG&9UHX+'XO
M+_J&81XARNKF$,/6S'!86DLPRZ&$Q/U+%8.<\#B5'%)1_&?&.OP;QMQ;1SC
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MBJBOM7_A@KX[_P#/IX>_\'MC_P#':/\ A@KX[_\ /IX>_P#![8__ !VOGO\
MB6/Z17_1D/$[_P 13&?_ #6>G_Q%[PN_Z+_A7_P[4O\ Y2?%5%?:O_#!7QW_
M .?3P]_X/;'_ ..T?\,%?'?_ )]/#W_@]L?_ ([1_P 2Q_2*_P"C(>)W_B*8
MS_YK#_B+WA=_T7_"O_AVI?\ RD^*J*^U?^&"OCO_ ,^GA[_P>V/_ ,=H_P"&
M"OCO_P ^GA[_ ,'MC_\ ':/^)8_I%?\ 1D/$[_Q%,9_\UA_Q%[PN_P"B_P"%
M?_#M2_\ E)\545]J_P##!7QW_P"?3P]_X/;'_P".T?\ #!7QW_Y]/#W_ (/;
M'_X[1_Q+'](K_HR'B=_XBF,_^:P_XB]X7?\ 1?\ "O\ X=J7_P I/BJBOM7_
M (8*^.__ #Z>'O\ P>V/_P =H_X8*^.__/IX>_\ ![8__':/^)8_I%?]&0\3
MO_$4QG_S6'_$7O"[_HO^%?\ P[4O_E)\545]J_\ #!7QW_Y]/#W_ (/;'_X[
M1_PP5\=_^?3P]_X/;'_X[1_Q+'](K_HR'B=_XBF,_P#FL/\ B+WA=_T7_"O_
M (=J7_RD^*J*^U?^&"OCO_SZ>'O_  >V/_QVC_A@KX[_ //IX>_\'MC_ /':
M/^)8_I%?]&0\3O\ Q%,9_P#-8?\ $7O"[_HO^%?_  [4O_E)\55JZ'K>K>'-
M6L-;T.^N=-U;3;F*ZL;VTEDAN+>XAD62*2*2-E=65U5@58$$ @@@&OL#_A@K
MX[_\^GA[_P 'MC_\=KVKX'?L'ZS8>*TUKXPC39-"TEH;BTT#3[V.\_MV\#,R
MQ:A+ 2MOID&U6N8P_GWI86ZB*'S9&^CX1^B7])'/^)\CRC#>%O&W"]?&9EA8
MPXDS_+,9D&3Y#[*K3Q#S?'9NL9[;!PRY4/K=.>#C/,*F(H8:AET'CJV&E2\K
M//&OPIR[*,QQE7BW(LXIT<)6<LJR[$TLQQN9<\)4E@J&#=#V=:6)=3V,E6<<
M/"E4JU,3)4*=12^V/V<?B/XM^*/PQTCQ/XR\.SZ)JCYM5OG6.&U\2PP(BC7;
M*T 62UBN'WQ2J(UM)KB*6>P*VLB6]O[S44$$-M##;6T,5O;V\4<$$$$:10P0
MQ((XH88HPJ1Q1HJI'&BJB(H50  *EK_HTX+R7..'.$>&\AX@XEQO&.>9/DN7
MY=FO%68X;#8/&Y_CL+AX4L1F6)PV$C&C3J8B<;?:KU(4J5;&5:V/KXZO6_RW
MSW'8+,\ZS3,<MRJADF7XW'XG$X/*,-5JUZ&78>M5E.EA:56LW.<:<7Y4XRG.
M%&,,/3P].!1117TYY(4444 %%%% !1110 4444 %%%% 'S1\8/V=I/BAXUT+
MQYI/Q#\0> M?T+11H<%UH<,QF^SBXU2<RP7=GJVCWEK+*FKW=O<@3S1S6^R,
M)&#-YW"?\,L?$3_HY[XH?^!/B'_YMZ^TJ*_$,\^CGX0\0Y]G?$N8\/9Q#.>(
M\QEFV=XC*>/O$KAVAF&9SPN"P53'5LNX;X_R'*XXJIA<NP-&K6I9=3G4CAJ7
M/*3B?>X#Q-XTRW+\!E6&S+!2P.5X98/ 4L9P]POF53#82-6O7CAX8G,^'LPQ
M;I0JXFO.$)XF48NK/E2N?%O_  RQ\1/^CGOBA_X$^(?_ )MZ/^&6/B)_T<]\
M4/\ P)\0_P#S;U]I45YG_$KW@Q_T).+?_%M^-'_TV#J_XBQQQ_T'Y/\ ^(=P
M/_\ 0@?%O_#+'Q$_Z.>^*'_@3XA_^;>C_AECXB?]'/?%#_P)\0__ #;U]I44
M?\2O>#'_ $).+?\ Q;?C1_\ 38#_ (BQQQ_T'Y/_ .(=P/\ _0@?%O\ PRQ\
M1/\ HY[XH?\ @3XA_P#FWH_X98^(G_1SWQ0_\"?$/_S;U]I44?\ $KW@Q_T)
M.+?_ !;?C1_]-@/^(L<<?]!^3_\ B'<#_P#T('Q;_P ,L?$3_HY[XH?^!/B'
M_P";>C_AECXB?]'/?%#_ ,"?$/\ \V]?:5%'_$KW@Q_T).+?_%M^-'_TV _X
MBQQQ_P!!^3_^(=P/_P#0@?%O_#+'Q$_Z.>^*'_@3XA_^;>C_ (98^(G_ $<]
M\4/_  )\0_\ S;U]I44?\2O>#'_0DXM_\6WXT?\ TV _XBQQQ_T'Y/\ ^(=P
M/_\ 0@?$C?L?ZUJ>IZ!=^+?CMXY\76&@ZU9ZU!I6LQZC>0FXM7Y: ZCXIU&&
MUGDA,D(N5M)7C61OD=<H?MNBBOON ?"G@/PQ>=SX+R?$Y;7XCK9=7SO%X[/^
M)^),=F,\IPM?!9:JV8<5<0\1X]4L%A<5B*.'H4\93H4XUI\M)-Z?/<1<8<0\
M5K 1SS&TL53RR&)IX"CA\NRK+,/AHXRM3KXKV>&RG+LLP[G7K4J<ZE25&523
MA&\W8****_1#YD*^'/VN_P!HKQY\#M3\&VG@Z#0IH=?L-3N;W^V-/GO'66SN
M+>*+R6BO;4(I25MP*N2><CM]QU^4/_!2#_D._#'_ +!.O?\ I99U_*?TUN+^
M*>!/HZ<9<3<&Y_F?#/$.!S3@VC@\YR?$+"YAAJ6.XIP>$QE.C7EA\2HQQ.%J
M3H55[&7-3DXWC?F/V/P$R3*.(O%#(<ISW+<)FV68C"YW.O@<;3=7#598?*:]
M:C*=-5*3;I58QJ0]]6DD]=CS0?\ !0#XY%'D%AX,,<31)+*- OS%$\^_R4ED
M&K%(WF\N3R4=E:7RWV!MC8C_ .'@_P ;""1:^!^,9_XDEYQGIQ_:^>>WK7SG
MH/Q<U+PY\+?&/PQ@T#0[VR\67"W,NM7<4K:K8!D"3I;2*PP0J1?9#&T21,]W
M]ICNTN=D?US?:]HNK^.M+DTJ[EOI_"_B?XDZ1=RW.J>%+;6=.N-2^$5TWA73
MO =\;6*QM_#%_>V5\VF'5!J#Z=XJMXB[I]IB$_\ E3P?XJ^-W&N7X2OE?TL?
M$6GF2PW#T<XRK%47AZF SC.,VS'#8S*\OK8BE3_MN&5Y+A,+G,\PP=*GAY+%
MSH5J"CAY*?\ 9F=\$^'V18BO#%^#7#$L*JN9/!8NC/VL<3@<%@\+4P^,Q,*4
MY++Y8O'UZV!CA:\YU5["-2%2]5<O)_\ #P;XVYQ]D\$9]/[#O<],]/[7].?I
M0/\ @H+\;6Z6G@@_30[WZ\_\3?TK@_\ A/\ Q]H>D?&BUG\2^*-)OK#3_!%Y
MH=GX@UW1-4\06<FH>)-(@OI4U'2[>&TNKNYTPLER=.A0QZ>PBN(U\N1SP7Q(
M\;>)_$?@WX7:=JGB6YU2'4/#=]J&KVUQ=6S1S:S;^-O$]E97>J",1E;F#3O(
M@C:Y9"EB(B,0[6KQ\Z\;?'+*<KS#%1^DGXR5<SP.4U,Q66XBEDN%A*O#C?$\
M#QP->O\ 6%C*$WBL++,YS_LJ-6.7U:/^Q0JRE*/=@?#SP\QF,PU%^%G T<+7
MQD,,\52GCZTE3ED%+/WB*=/V;H5(^QJK"1C]<E!XF$_]HE!)2]Y'_!07XVGI
M:>"#GIC0[SH20#_R%^A((!Z$@@=#1_P\%^-O/^B>". "?^)'>\ ]#_R%^A[4
MM_>0:KXF\(V/Q 06.A^/HM?\.>(/AK<:]X6O;'PW9:)9Z3KVC^)/ ?B#1VD_
MLOPK?ZQI5O9Z/8ZIB2V":K;65SJ5K>/=4_P)XK\/>.&^$S>*I/#6D:]=:[\1
M_B!IFHN+"TMK6\MM;O8;[P1J&_;';:7J?AH6O_"-QWH18M0T*PMX2R:@^/N:
M'%OTA<5FJRF'TL>.L)BJV+H8/!4<UJTL!7K3JXSA2G&>,IU72AE'UW \5X;$
MY;A,SJ8?,8X[!XK)LYPV68B6%S#&^!5X?\,:.#>-EX-\/5Z-.C4KXB>#C/$T
MZ<84,YG*-"4')XWZOB<FJT<77PD:F%>&Q%''X"IC*2K87#Q_\/!OC;G;]D\$
M9YX_L2\S\O7_ )B_;OZ4?\/!OC9@G[+X'P,9/]B7G&>F?^)OW[>O:N9N[N\_
MX1'2AX@O-&E^&C_ [P=;Z)9W5YH,LH^)20V(T]_#]G'*^MVVMVVK+,_B"X2*
M&$:0NI)JTC0R1H_>^+M;TKQ!K^LWWA>_L[KQ3HVJ?&CPYX4U#Q/>^%CJ6G^-
M7OM!NM TSP[<QP6>F+X;?PK#KLWP]GU'SY;'Q#)?6T=ZEVVG;\:7&/TB:V&G
M5_XFF\0J&*5++JM#*L34P=+-<?"O@L)C\96RW!QKREC,-6P^,I_ZNXCVV$CF
M]16Q=+!TIPJEU.'/"ZG6C3_XA#PS5HN6*A4QE&->>#PTJ>(KX:A#%UW32H5:
M=6A)YI2]G6>"@[T:E:49061_P\%^-O3[)X(SDKC^P[S[PZJ?^)OP?8\T'_@H
M+\;1D&T\$ C&1_8EYD9Z9_XF_?M573-3TR#3K^Q^)\^CWGBG6/AQI?A/XC7A
MGT>[U6PMO$7Q-%CX:U'4+NQ>2&X\6>&='GL=8O98I9=3@TNSLH-4D$D<BIJ>
M&1HOAY/"7@O2KG3[R_\  4_QG\/SZKX?U+0[35-?\877PNTZ_P!4U'1-8U1)
M;3'_  D=U+HGA2^NXI;4KI,+VRM)(RU>$XK^DABZV"?_ !-/QQAJ&+IJ$\+B
ML9AJ6?8+,ZN9932P^2XS*(>W4,?'*,=F6/S"I3K5L+E^99)B,AG&KC<5AH0B
MOD/A70AB%_Q"#A^K5H3O&K1HUI9=B,)#"XR=7,*&-E[/FPSQU#"X;#1E"%7$
MX7'TLQBX8>C5E*N/^"@?QO/2S\$_^".]_P#EO1_P\"^-_P#SY>"?_!'>?_+>
MODCQ\VJ/XQUU]9765U%[F%IE\0ZEIVL:VL9M+?[*NI:GI$4.FWEP+81#S+2&
M*,1^7&T:NC5R%?@.:_2>^DGEN:9EEW_$<O$R7]GX_&8)2Q&<4L/7DL+B:V'4
MJV'_ +#7L*LE24ITK+V<I<ME:R_1\'X0^%.*PF%Q/_$/N%%]8P]"O:E@IU::
M]M2A4:A4_M!^T@G.T9W?,E>[O=_<W_#P+XW_ //EX)_\$=Y_\MZ/^'@7QO\
M^?+P3_X([S_Y;U\,T5Y__$U?TD_^CX>(_P#X?J7_ ,XSH_X@UX4_]&^X7_\
M#?/_ .;S[F_X>!?&_P#Y\O!/_@CO/_EO75S?MI_'RP^&FL_&/Q#J'P0\%?##
MP_JSZ#JWC/Q[KVB^#-)MM82V@NUTU&U[Q/:3W=Y/;W$3VEM90W%Q=MYD=M%*
M\4@7\[J].O/V.O%?[2WPY^!GQ*\/^%?#/QDTK]GOXY_$C6/%/[./C;6;;0?#
M_P 4=-\7^#?!NG0:MH^J:DZ^'[/QQX3N;&.71_\ A)_)T2[T^ZO[>6^M90(K
MS^H?H?>(OC%X]>-V6>'7'?T@O&+*N'<7PSQ;G-?&</\ %.6X',UB\BR_ 8O
MT*6)S'A;,,'3IXFOB9T*KK89P2E3DZE.,)2?Y;XQ<(>'OA_P55XCR?P[X(J8
MRGF^48'ES'*,1B,-[''UL93K-TZ6<81JK_L].-*I.LJ5.4W*I&4;)?8GPD_;
M6^-_QYO-9TSX/>)_V>?'FL>';&/5->T'3/%>B67B+2-(F5)(-9OO#VM^(]+U
MJ'19TDC>'6/L)TR198BMT1+%O]HT'XE?MQ^*M/75_"_A?X.^)-*>62%-3T'Q
M5X3UC3WFBV^;$M[IWC*XMFECW+YD8E+)N7<!D9^5_#'_  3 \ WOQ*^"'[2W
MPN^'6M?L@>*O -E\?]+^(_PO\6^*=,\8:GXSTCXB>#-6\.^%- N_%'A3QCXT
MT2#P1H6K:G<ZC;V8U&\EM?"\R:!:Z?ID>FZ3!I\8_8H^)%AI^IZ%;?'KPI<Z
M)K7@W0-!O9[;X@:KX0MQ<:;X&\.>#I;S4M \+>$+&PU.VN=+T>#P#YFC/H-_
MK/A;1]*UCQ3<:EJ5]J-JO^JT_HU*T5'Z4OTF*53V</;4ZW'O#,E3K*=2%>$)
MT_#J2JPM&G5HS51MPFXU&Y)6_D=^)&5NW+X9^$Z?*G)2X5S=\LE*2G%2I\5S
MC)6490DI.ZE9W9]C?\)-_P %!/\ HG/PW_\ !MH/_P U='_"3?\ !03_ *)S
M\-__  ;:#_\ -77D'A?]G;Q/\,](UR'PC\0O#D3F_P#%?C;2TT+XD>.I;I+N
MTTJXOM%MK'2-2GM[:ZN;K6--TN#5TEU:+0=6T:*[L=<L;N2WTJZMN^M/AAXS
M>PT#5+GXNZ-J6OWGB>S\0_$#3+WXB^+-.@\5Z)>>'/"-YKW@ 36IU"UT;39?
M&ECXJGT\V-JT%CI-_9QJ\B7-W:K\;C/ G/L/C,3AL/X]_2CQE&A-JEC(>(W"
ME.EB:5Z,%5IQEX<.7,YU9OV2;E[+#U9IN;ITY^75\5:,*M2G3\'_  LJP@_=
MJKAG-HQG'W%S13XI;O>4GRWORPDUKRQ>W;^+_P!OR[@BN;3P!\,;JVG020W%
MOK?AZ:":-ONO%+'XM:.1&[,C%3V-3?\ "3?\%!/^B<_#?_P;:#_\U=><:5\!
MO'WA7P;;^%['XM^%M,\0KI-W;Z;J-K\1O&]K9^#%GU70]1T74=&LUM3#J$#^
M&+:_\*&U%OIBP6^K+J2-<M/=1UUVK_"'Q#.=.C\'_%W2K6*7Q,DNKZ4?B-XL
M8>(_#"Z)X#2U\)QW&JPZW;6IF\1:3XLU7S9+*>%1KBEQ(-0O88>2'@?Q0Z:G
M/QP^E(IJG3G."\3.$KJ<^52A!2\-TY.FVYSU35--+FK+V;R7BNN5-^#7A:GR
MQ;2X;S7=VNE?BC6V[UT6FLTT;/\ PDW_  4$_P"B<_#?_P &V@__ #5U\\>,
M_P!M']I'X?>)]5\'>+-%\"Z=XAT22VBU*SBTY[^.![NSM[^ +=V6N36TVZUN
MH)"8I&"ERC8=6 ]1O_#_ .T_IT7VJQ^/>AS>'/"^@F.;P_HWC&RU#Q#XKDL-
M/\.V>BZ99:IK?@2&;2M2N%M/%*:CK.HW]Q)J.J>(M$U*YCMUT"2"3\]_C6OB
MU?B)?CQ[,+CQO_PCO@$^+9A>6&H>9X@;P%X:?4BU_I<4&FWSK<,R27>GPPV=
MS(K36\21.JC^;_IE91XB?1]\,.%N->"?I%>.>/S;.^,\!P]C<#Q!QOD^94,)
MA,5PWF^<5+4L#P/EDEBJ6*P%+#NLJ]6BDJL%"4IQE#][\"Z_"_B7Q-F&3\0^
M&?AQAL+A>'ZF:T_[*R+,,-B8XJ&.R_#>RJU,3GV*IRIQIXJHIQA33]I&+52R
M<7](?\/ OC?_ ,^7@G_P1WG_ ,MZ/^'@7QO_ .?+P3_X([S_ .6]?#-%?YJ_
M\35_23_Z/AXC_P#A^I?_ #C/ZH_X@UX4_P#1ON%__#?/_P";S[F_X>!?&_\
MY\O!/_@CO/\ Y;T?\/ OC?\ \^7@G_P1WG_RWKX9HH_XFK^DG_T?#Q'_ /#]
M2_\ G&'_ !!KPI_Z-]PO_P"&^?\ \WGW-_P\"^-__/EX)_\ !'>?_+>C_AX%
M\;_^?+P3_P"".\_^6]?#-%'_ !-7])/_ */AXC_^'ZE_\XP_X@UX4_\ 1ON%
M_P#PWS_^;S[F_P"'@7QO_P"?+P3_ .".\_\ EO1_P\"^-_\ SY>"?_!'>?\
MRWKX9HH_XFK^DG_T?#Q'_P##]2_^<8?\0:\*?^C?<+_^&^?_ ,WGW-_P\"^-
M_P#SY>"?_!'>?_+>C_AX%\;_ /GR\$_^".\_^6]?#-%'_$U?TD_^CX>(_P#X
M?J7_ ,XP_P"(->%/_1ON%_\ PWS_ /F\^YO^'@7QO_Y\O!/_ (([S_Y;T?\
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MXP_X@UX4_P#1ON%__#?/_P";S[F_X>!?&_\ Y\O!/_@CO/\ Y;T?\/ OC?\
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M0E+VBI<OU5INJ\=#+%32E"#E*69U*>7Q45-2Q\X82,YXF2HO]+Q_P3P^#0!
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M75H?QX8; SQ$J/[VM1_>JE3J<C]MA\12:E+F52C5A*,90:?ZN_\ #O3X/?\
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M+_\ PH]8_P#DRC_A:'Q'_P"A\\7_ /A1ZQ_\F5M_Q,Y]$7_I#3#_ /B:4O\
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M /,U7WI11_Q*!]&+_HR/ O\ X1YM_P#1.'_$;O%O_HO^(?\ P?@__G2?!?\
MP[T^#W_0R>/O_ WPW_\ ,U1_P[T^#W_0R>/O_ WPW_\ ,U7WI11_Q*!]&+_H
MR/ O_A'FW_T3A_Q&[Q;_ .B_XA_\'X/_ .=)\%_\.]/@]_T,GC[_ ,#?#?\
M\S5'_#O3X/?]#)X^_P# WPW_ /,U7WI11_Q*!]&+_HR/ O\ X1YM_P#1.'_$
M;O%O_HO^(?\ P?@__G2?!?\ P[T^#W_0R>/O_ WPW_\ ,U1_P[T^#W_0R>/O
M_ WPW_\ ,U7WI11_Q*!]&+_HR/ O_A'FW_T3A_Q&[Q;_ .B_XA_\'X/_ .=)
M\%_\.]/@]_T,GC[_ ,#?#?\ \S5'_#O3X/?]#)X^_P# WPW_ /,U7WI11_Q*
M!]&+_HR/ O\ X1YM_P#1.'_$;O%O_HO^(?\ P?@__G2?!?\ P[T^#W_0R>/O
M_ WPW_\ ,U1_P[T^#W_0R>/O_ WPW_\ ,U7WI11_Q*!]&+_HR/ O_A'FW_T3
MA_Q&[Q;_ .B_XA_\'X/_ .=)\%_\.]/@]_T,GC[_ ,#?#?\ \S5'_#O3X/?]
M#)X^_P# WPW_ /,U7WI11_Q*!]&+_HR/ O\ X1YM_P#1.'_$;O%O_HO^(?\
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M6_P[_P"C7_A+_P""?2?_ )2U^&<7T/#;CC#X.CGWTE^#:M?!XROC?K]#P/\
M&>GCJU6OE^ RZ5*56KB\13PN"5'+L/6>7Y;2P. J8Z*Q\\''%4J50_1LEQ7%
MN05*T\N\)<^A3K484/JU3CW@:6'IQAB<1BE-0A1I2K8CGQ-6FL5BIXG$QP[>
M&C7=&4H'P]Y$_P#SQE_[]O\ X4>1/_SQE_[]O_A7W#_PUO\ #O\ Z-?^$O\
MX)])_P#E+1_PUO\ #O\ Z-?^$O\ X)])_P#E+7P?_$-/!;_I)KA__P 4UXQ_
MYGT'^M_'W_1H\T_\3C@D^'O(G_YXR_\ ?M_\*/(G_P">,O\ W[?_  K[A_X:
MW^'?_1K_ ,)?_!/I/_REH_X:W^'?_1K_ ,)?_!/I/_REH_XAIX+?])-</_\
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MMS8WUJQ:.1"2KHZL%D@N()%>"YMITCN+6XCD@GCCFC=%W*_Z(/";P_X$\,^
M.'N%/#?#X6GPIA\%2QV!QV&Q5',)9]4S&CA\57XCQF:4)3I9KC<[YJ..K9A3
MFZ%6G/#4L'"A@<+@\-0_S#XSXDXBXLXDS/.>*:M:><UL1.AB*%:E/#++XX:=
M2C3RRAA*BC+!T,!:="&'E'VD)1J3K2J5ZM:I,HHHK]'/EPHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^$:AX(.<C_BK^N:_P Y(>"?TGZ^ P^%SKP*X1SW$TL#G&65,3C?$G@CV5;
M\18N6/SR,Z%3B;,,1+$8C$X+((82I4S-TL/A,NQ]'$PQ^(S6GF.7?U3+Q%\)
M*>)JUL!X@9WEU*>(P.+C2P_"N?<]/$9706&R]QJ1RG#4HTJ=*OF4J\(X13JU
M\5AJE*6'IX.6%Q7E)TO4FUK2[S7[BVM=)L_B3)8^%]#CT/P,O@:]\,WFB>,Y
M=%OOA_K6FO)K%WI=GI%II3ZHMPHMKBZO[274))M2B1QRW@?PUJD/BSP9XGCT
M.].C7/P!AM=+U/2[71)9[KQ1%\-;MHH-(&JI/ITGB9;RWD-M]NMW?[;$V_,N
M,^_#_@GEX;'3XS::."/^19@Z$Y('_%7\ GGCOS0?^">/ALDD_&;323U/_"-0
M\\Y_Z&_UK>IX'?2,K9A@\?5\#\-.6 S7+,[H2GXQ^&]?$SQ^65\?5I0Q%?$X
MF5-X&G1S#ZIA\+@Z670HT<LRF4*&#E3Q5%1'Q(\+H8:OAH<>UE'$X/%8"I%<
M#<44Z,<-BJ6&A.5*G2I*7UB53"^WJUJ\\5*I4QF-4ZF(4J-1_(_A@"3XK^,3
M\0K?48?!K:)J#?$T>*X=+A\26WA P:=]EFMUT>W@M8?& U(:'_PC?]B6\;RZ
M@;9)5-F]^3YI\3O[0M?'_B1M2BTF)X;^WDL(] $*Z%_PCZVMLWAHZ,T VMIL
MGA\:<UM+(#=NK%[[-Z;BOT$'_!//PX  /C/IV%.0/^$:AP#SR/\ BK^O)_.E
M'_!/3PZ!@?&C3@.>/^$:AQSR>/\ A+^^:_-L^^BE])K.^&:O#DO"[!4Y5.+<
MXXJ>;5_$WPYQ&-JK-YXIRRG%*.<P]K@<&Z[QV$C''R5/.L5F^9>SE',8T,+]
M/E_C1X2X'-8YG_K9B91638+*/J5/A/B>EAX?4XTE]<HMX%\F(KJ'U:M)X>+G
M@*6"PEXO"NI6X>W_ ."<?@&]\#_"S3K:VU>Q\6>"+;QUXHN=9;0?$$O@_P"(
M7C?QUXK\/>++2/XE>%=/\?V]GXM^'+Z3I.L>%/&G@'53_9/B73_$::A92:-K
M6EZ5-:RG]CN23QAXD\)Z'X^^+E_K?Q$\&^)-2_:>U#5E34/">N:YXM\47?C?
MP!+X,T+4[V6T\')I7Q&BUJXTS3--EO&TGX96]UX8NC&+[1-3M_45_8?N54*O
M[26KJJ@*JJFIJJJH 555?'H"JH "J      !3O\ AB&[QC_AI/6,9S]W4QDD
M 9/_ !7O)P ,GG  Z 5_K'D/T@_I$Y#5P.+H_18Q57'99A\,LOKR\=O!_DPV
M882E@:>&Q[HU)U(UOJU3"3Q-##SM36)EAZE5U(894:O\/\2^$?A7Q+@,;E&*
M\8XT\KS:I6HYQAH>'''"J8[*,5]<^NY5'$4JE*>%CCJ>(IX;%8JE>LL''%4:
M'LJN+>(H^?>)/V4M;\*VGQ&^/^H_$'XB7_QJU'PU\7+KXR7VJVE]:?"7QOX1
M\:^!+/1[[P-X/\#S:_>'PG8^$;?P'\+3X+UG[1J4UG<>"))KN&=_%WB)S^;R
M]!]!_*OU=F_8:DN89+>Y_:-U*YMYHVBFM[B#4)X)HG!#Q30R^.WBEB<$AXY$
M9&!(92#BL7_AWKX>_P"BTZ?_ .$W#_\ -A7\'?2U\,?I)?2;XKX2XFPO@EA^
M#UPSP[F613P>(\5/"_-%BI9AQ#//(UJ$L#G. IX6AAXS>%IX:4:SC%0Y*JIP
M47_3/@GQ7X4^$.29ODU3Q Q.??VGF&!QL<2N$.+L+4IQP650RSEKRQ."Q$\3
M7K>S5>KB/W3J5)5)3I\]23C^7M%?J%_P[V\/?]%IT_\ \)N'_P";"C_AWMX>
M_P"BTZ?_ .$W#_\ -A7\G_\ $C?TF_\ H@,M_P#$_P##S_Z*#]I_XF&\)?\
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M0'_$PWA+_P!%'C/_ !&N)?\ YTGY>T5^H7_#O;P]_P!%IT__ ,)N'_YL*/\
MAWMX>_Z+3I__ (3</_S84?\ $C?TF_\ H@,M_P#$_P##S_Z* _XF&\)?^BCQ
MG_B-<2__ #I/R]HK]0O^'>WA[_HM.G_^$W#_ /-A6SX>_P""?/@^+6M.FU3X
MJ)K>GPW44MWI.GZ+!8W=_!$WF26T5X?$>H&V,J*4:9;.9XT+.BAU!&^&^@K]
M)O$XG#X?_47*:'UBO1H.O6X^X"=&@JU6G2=:LL-Q#BL0Z5%5'5JK#X7$UW3I
M5%1P]>JZ5&IG6^D5X34J56JN(,=4=*G4J*G#AOB)3J.$)35.#JY;1I*<W%0@
MZM6E34IQ=2I3@I3CB?\ !/\ T_XNI<ZK?12BW^$LAE2^AU9)FCO=92'9 WAH
M;E,=];L(%U.Z4FS-BOV2Z2>[7338_JA69HNBZ3X<TG3]"T+3[;2](TJUBL]/
MT^SC$5O:VT0PD<:#DD\O)(Y:261GEE=Y'=VTZ_W*^CYX15/ [PKX=\/*_$V:
M<58K+(U\5C<QQ]>M/!8?'9A.&)Q>7<.8.NYU,JX;P6(=6&5Y?*M5J>_BL=6^
MKXC,J^$PO^>?B7QK'Q!XPS3B>GE.#R:CC)4Z5#"X:G3C6J8?#J5*CB<SK4^6
M.,S2O34)8O$J$(Z4J$/:4\-"M5****_:SX(**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI6D$L=KJ$,4C)'>6\=Y;V]W'#<H!+''=00W"*P6:)) RCTN7QSIE]\2?$?Q
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MH\QO1/\ OW'_ /$T[R9/[H_[[3_XJCR9/[H_[[3_ .*HMY2^Z?\ D%H]H_\
MD@WS&]$_[]Q__$T>8WHG_?N/_P")IWDR?W1_WVG_ ,51Y,G]T?\ ?:?_ !5%
MO*7W3_R"T>T?_)!OF-Z)_P!^X_\ XFM+1]<U7P_JECK6C7LVFZIIMS%=V-]9
ML;>YMKB!UDBEBFAV21NCJ"K(RLI&58'!K/\ )D_NC_OM/_BJU-%\/ZQXBU6P
MT31;"XU+5=3N8;.QL;1#/<W-Q.ZQQQ10Q;I'9G90 JDY/2NG!QQKQF$671QC
MS!XO"K+U@(XSZ^\=]9H?4OJ/U-?7/KOUSZK]4^J?[5]:^K_5OW_L3'$?55AZ
M[Q?U9854*WUIXGV"P_U;V53ZQ]8]L_8^P]A[;VWMOW7LO:>T_=\Y^VO[+W[4
M6E_&;2X?#?B6:VTWXC:=;XG@)C@M_$T$$;-)J.F1C8BWR1(TVHZ=$JJ$62^L
M4%JMU;:;]A5\A_LP_LOZ1\&-)A\0>(8;75/B-J5N#=79$<]OX;AF0A],TJ3Y
MD:[9':+4=2B/S@R65D_V,W%QJ/UY7_3I]'!>,$?"#A->.+PCX\^J?ON3G_MA
M9/R4/[&7%KC_ +'+BU82RSMY?^Y]K[!8QO.5G,G_ )'^*+X(?&V=/P^5=<.>
MW?L^?E^I?7.:I]=>3I_OUDSK7^H+$^_R<_L+8)X)(HHHK]S/SX**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "N>\2_P#"5_88_P#A#_\ A'O[3^U)YW_"2G4A8_8O+F\S
MR_[+!N/M7G>1LW?NO+\[=\VRNAHH \1U/7OBSHOD_P!LZQ\$=)^T;_L_]IZE
MXEL//\O;YGD_:I8O-\O>F_9NV;EW8W#.5_PG?CW_ *'']GS_ ,*+6?\ Y*K\
M>?V[_@-X _:<_P""LO[+7P6^*T.LZAX"U_\ 9O\ $-]?Z=I.KSZ3/]KTB[^-
M.MVLUO<1I*('>^T;3OM31Q![F"WCAD<HB;?H?_AQK^P-_P!"M\1/_#@W_P#\
MA5^FRX4X*RW*^'<7Q%Q5Q!@L?Q!D=#/H83*^%,+F>&P^&Q.-S3!4J3Q=7B#
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MJSJY31A&I/!YEEV*IT^>52I0Q^"JTZ=2.*H*I_?)_9WQD/73_@R?^W;Q3_\
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MXPJPJ2BX5)0IR_>3A"?][?\ 9_QE_P"?#X-?^ _BK_XU1_9_QE_Y\/@U_P"
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M<-_\ZC_1B_L_XR_\^'P:_P# ?Q5_\:H_L_XR_P#/A\&O_ ?Q5_\ &J_SG?\
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MH5GXI\6V6CWESX<\.W>MWC+::/:ZUK$5GIMQJMTRV^GQ7+W<Q$<+5_/5X?\
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MU'\8536UM<7EQ#:6D,MS<W,J0V]O"C23332,$CCCC0%G=V(554$DG K^S?\
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M1^'5E8W>C6_C#[=9>">)_P#@HG^U%=?!SPC\2_A_X7^!45_\.?\ @FM\,/\
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MO]E_]J#Q(L?C)%M-#^%7Q5URZ"IXL V6NF^"O&FHW#C_ (J<YBM/#GB&Z?\
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MT5]/_P 04R'_ **OQ)_\3C-?\SX;_B8SBC_HB/"'_P 5QDO^1_5U_P -A_\
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M:(/#GA^TE\2:=H-GXFU&UTG0ECTNTM]3UB\A%K#;B1)'MK=XO[K/^%Z?!O\
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M_OD2_P!P_I_C1Y$O]P_I_C7^@%_PO3X-_P#1TGPH_P##9:-_\DT?\+T^#?\
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M_P#EU7X$?U">KT5Y1_PBGQ5_Z*W9?^&ZTK_Y=4?\(I\5?^BMV7_ANM*_^75
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M=?>M% [ON?!7_#MG]EC_ *%OQ/\ ^%AJ_P#\71_P[9_98_Z%OQ/_ .%AJ_\
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M9K2[\1W,$B3V6O:@4,<]OX>@E2.>QC4I)K\J1S*RZ$N[7 #]YZ*** "BBB@
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M=36LZ06G%Z=_P2 _9NMOB3XK\2ZMK?CCQ%\*_$_[0WBO]IZ+X W^H06/P_\
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M]W_9FCR1V>FZO<68![1_PK[_ ()G_P#1<OCI_P"$O9?_ # T?\*^_P""9_\
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M\, X(&.""#[@U_5-7XI_M/?M_>+OA#\=?B%\.M/^%OPHUZS\,:CIMK!JVO\
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M7I@T?Q%=^*K"S'B&2,W\VG1ZS?7<DEC(YAFM+B6QD#6[%2 >0WO[.&E76B?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^5_C*NB_"/PO_P )=J'B3XO:NEWK,6FPZ?8?$76[8"XN
M[;4-0SN5;AHK>.&PGCC2&VF(=H(]J1%Y8_#_ /A9?B(]/AA^U-_X5GQ$_P#F
M2KU[]M+_ ))1I7_8[:=_ZCWBBOKD=!]!7WV&CP]E7"V2YGC^'*6=XW-<RS^A
M4JU\XS;+XT:.5U,LA0A3I9?^[ES+&5'.4_>NHV=M%^88N7%.=\:\19/EG%M;
MAW+\DRCA;%4J.&R'(LTEB*^=4LZJ8FI5K9JO:PY7E]%4X4WR).5TGJ_SH_X6
M7XC_ .B8?M3?^%9\1/\ YDJ/^%E^(_\ HF'[4W_A6?$3_P"9*OT8HKE_M_A3
M_H@,%_XD_$W^1W?ZK\;?]'/S'_Q#>#C\Y_\ A9?B/_HF'[4W_A6?$3_YDJ/^
M%E^(_P#HF'[4W_A6?$3_ .9*OT8HH_M_A3_H@,%_XD_$W^0?ZK\;?]'/S'_Q
M#>#C\Y_^%E^(_P#HF'[4W_A6?$3_ .9*C_A9?B/_ *)A^U-_X5GQ$_\ F2K]
M&**/[?X4_P"B P7_ (D_$W^0?ZK\;?\ 1S\Q_P#$-X./SG_X67XC_P"B8?M3
M?^%9\1/_ )DJ/^%E^(_^B8?M3?\ A6?$3_YDJ_1BBC^W^%/^B P7_B3\3?Y!
M_JOQM_T<_,?_ !#>#C\Y_P#A9?B/_HF'[4W_ (5GQ$_^9*C_ (67XC_Z)A^U
M-_X5GQ$_^9*OT8HH_M_A3_H@,%_XD_$W^0?ZK\;?]'/S'_Q#>#C\W;[XLZKI
M=G=:CJ7P\_:<T_3[&"2ZO;Z]\9^/K6TM+:%2\T]S<W'A:*""&) 6>261(U4$
MLP'-?4/@;PEI/CGPEH?BRS\9?%RSM];L_M26L_Q$UMY8&6:6WEC,BNHD5987
M\N39&TD>QVBB9C&O3?'O_DBGQ4_[$3Q+^NEW&:J?L]?\D8\ _P#8)G_].=]6
M^:TLBQ_"4<[RW(:>28JCQ)#**D:.:9GF-.OAZF35,PYI+,?X<XUHI)TUK&]V
M[V7+DM;B7+..7PYF_$U7B/ XCA"KGM.6(R7)LIJX;%T>(J&5*,)92OWM.>'J
M2<E6;M.SBE:[T/\ A4UG_P!#W\5O_#A:[_\ ':/^%36?_0]_%;_PX6N__':]
M6HKX0_2SRG_A4UG_ -#W\5O_  X6N_\ QVO&OBKKGP[^#LVCP>,/'GQK#ZY%
M=RV7]G>.M1G799O"DWFF[U2QP=TZ;1'YG&2VW*[OKNOR_P#^"B'_ "$?AE_U
MX^)/_2C2:^W\.N'\OXIXNRW),T^L+!8NGCYU?JU;V%:^&P-;$T^2K[.IRKVE
M./-[CO&ZTO<_//%3B?-.#N!\VXAR;ZK_ &A@JN60H?7,/]:P_+B\QH86MST?
M:T>=^RJ2Y'[2/+.TM;6?4_\ #0_P'_Z'WX^_^%G+_P#-'1_PT/\  ?\ Z'WX
M^_\ A9R__-'7YM:)X6DU_P /^)M2TZ>6;6?#TWAZ1-$2 ,=1TO6]2.B37L,X
MD\P3:?K%UHMO) (71X-4\\R)Y!5_74^".D-J+6<7BG5-5\D>-(!8:'HVGW&O
MZYJ?@G4] T?4]-\*V-YK%I;:K<"ZU;4;T0M=)=S:9HLKV5K=7-P(H_Z"QGA#
MX8X&<Z>)Q.?PJ4Y3C.$<=7J2BX4J-:\N7 *,83IXBFZ=6<Z=&=JW[V"P^(G0
M_F/ ^-WC#F-.G5PF'X8J4JT83IU)97AZ<9J=7$4.6//FKE*I3J8:I&M1A3J5
MZ?-0O1J2Q6%IXC[(_P"&A_@/_P!#[\??_"SE_P#FCH_X:'^ _P#T/OQ]_P#"
MSE_^:.OS[OO!OA;1M+L+C6_$NNVNK>([75=3\-6$'AB*2*+2K/5K_1M*E\4F
M?5X+O2[_ %N\TR[4V.GP:E_8\:I+>33E_*3T2Y^!%M!XPU;PE')\1+B?1]%\
M1:P!#X/T>34/$JZ'J6DZ9%'X1L(_$C?;X[R74GF:2^FL7BBABV1R/*XBRK>$
M_A?AU>M7XCIQ=/$58SGC*T*=2EA*M*AB*E*I4PU*-6G2Q%:%"<X-QC553F<*
M-.>*-Z'C/XR8E\M"CPG5FJF%HSIPR^A.K2K8VC6Q.%I5J=+'5IT:E;#4)XB$
M*B4I4G2Y8SKU88,^P/\ AH?X#_\ 0^_'W_PLY?\ YHZ/^&A_@/\ ]#[\??\
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M_M*_'3]A?X"?LN^"OAW^T1X,_: \*W/@C4(/CE\>/A?\-_V=[/\ 9ZTSP#\
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MV_:T_P"BYZ%_X*-)_P#F$H_U4RO_ *+S@_\ \&9__P#. /\ 7?./^C:<??\
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M,.BV^HVZ1E;*1K>^BCLW2ZL+9+>,GWG_ (8+^,O_ #_^#O\ P<7?_P JZ/\
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M#VL_%[2;XZ&R\E;S6/!DMQ<A0!+;2Q27:@269QU'_#!?QE_Y_P#P=_X.+O\
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M-'/N*9\]LSH)4ZBI5)U,%1IPC/V<ZE1J4J'OTJ3C2A.O!.E>O3DFH*;7>?\
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MB?\ S24?\*HT/_H9/B=_X=?XB?\ S25Z=11=]PN^YYC_ ,*HT/\ Z&3XG?\
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M10 4444 %%%% !1110!\[_M2_P#)'M8_["WA[_T[VU>U>%?^18\.?]@'1_\
MTWV]<#\</!6M?$#X=ZIX:\/-:+JMQ>:3<V_VZ0Q6Y6SU&WGFRX4C>L*O(D;&
M-9F00F:'S/-3RRPC_:NT^QL["&T^'QAL;2WLX2\2ES%;0I#&7(UH L40%B
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M?_?NX_\ DBC_ (47\(_^A#T/_OW<?_)%>L45Y?\ JOPS_P!$YD'_ (9<J_\
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MP4445J4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &W G # 2(  A$! Q$!_\0
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M[\5V_AKQ]X1TZP\/:KKGPNC\0Z;IGAG3;&WU>ZL(XI)0#^CVBOY2?V<_VA?
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M:5I<LLFHZUJ5T;BZ?X\_9 _;T_:J\8_MJ?M7?'KX]ZMXGT']EOQ1_P $X/\
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M[4VFK_V-9W,TGAV]2/2^/O[>/[1/A3_@IYH_Q#\+>+[FV_X)R?LU?'/X&_\
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MOQ[_ &$_V<Y_V@OVP_VP/V/K/P=IOQ?\5^/I[;4/A?X'_:;\5_"V3Q5JU[\
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M^,_$_C'PGH^E&[T/PUH\/Q&B\7:BV@ZAJ%P^E>'+[0])L[S4[FSN;Q_V7HH
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M)R45=NQ_3;_Q%U?\%F/^BA_ K_PPWA7_ .2*/^(NK_@LQ_T4/X%?^&&\*_\
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MU?\ !9C_ **'\"O_  PWA7_Y(K^8RB@#^G/_ (BZO^"S'_10_@5_X8;PK_\
M)%'_ !%U?\%F/^BA_ K_ ,,-X5_^2*_F,HH _IS_ .(NK_@LQ_T4/X%?^&&\
M*_\ R11_Q%U?\%F/^BA_ K_PPWA7_P"2*_F,HH _IS_XBZO^"S'_ $4/X%?^
M&&\*_P#R11_Q%U?\%F/^BA_ K_PPWA7_ .2*_F/"9 .<9]JF:/<,@Y_#G\/7
MOQQ^==M+ 5ZT'.,=$KI7C=K?;F3V:Z,ER2=KG]-7_$75_P %F/\ HH?P*_\
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MCE>:XZ'#]:M94*N95Z=/#SFVDH2K5'2C2=Y))RNKOWN5:GX9&,=,$'\_\B@
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M %6!CMT]JKU(@/X'^?\ G^E=F#=ZJIJ%^>UWORI;M]EJKOS1,MF[M6VUL2
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MM6?\G1?M)?\ 9?/C%_ZL/Q%7@=>^?M6?\G1?M)?]E\^,7_JP_$5>!T %%%%
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MC.W(X'X^YKZ7^"O[#7QU3Q!:&Q\7?LY1E2 S:=^U]^S#>S') VK%I_Q8N)&
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M=#)\[HT?9K%8;%X?#U<TJ9-A*M?ZI1Q-'#U:D9/%*M6KP7*JDZE-RC+DY_\
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MRM9I+E43_I3PKC2>&P]*%J<::BVDE&*C3TCY:I)(Q:***_&#TPHHHH ****
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M/^3HOVDO^R^?&+_U8?B*O Z]\_:L_P"3HOVDO^R^?&+_ -6'XBKP.@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAXUM#IVHI'=+!IWC+PAKVGVEV5\C4K6VAU&T9K6ZA8@'/VG_  3H_;WO]/\
M#&K6G[&W[2TVE^--=TSPUX5U$?!GQXEEKFL:UHK>)-(@L+J30UADM]3T".XU
MFPU(NNF76FV>H7D-X\&GWSV_+^%?V'OVQ_'/C7XJ_#?P=^R[\>?$OC_X&O)#
M\8?!FC?"WQC?^)?AM=I/-;1:=XPT>#27O=%U:_GMKF+2-(NX8]4UIK:X_LBT
MO1!*4_5;]I7_ (**_![XBC_@J5!X,^*_Q NK/]IG]E#_ ()T_!#X(VTND>+M
M+M]9G_9ZF_9A/Q7\)7]O,T<7A?P[HT/@#XD)8KJ*0:9X@5[A+%)AXC<7/WAJ
M7B#PW_P4T\)?$/2_@QKW[3?AWP?X<_;!_80^).G_ !V^#_P&^(?Q@U#QM\1?
M"7[!OP<^ 6K?#/Q3X0\":C#\0/ WQ%\)>//AQXNU_P"!'Q&\;V-C\+_$EWK?
MCY;SQWX5OGM;G40#\3?V2_\ @F)\3/VC_&VJ_#SQWXCOOV=_%VG_ +27PM_9
M930?B#\/]?GUF+XH>/\ PW\5_&FOZ=K6C->:-JFA/\._"?PDUB_\1V=U:O>?
M;M;\.Z8T=I)?B4?)O@C]DC]J#XE:G\+]&\ _L_\ Q<\6ZK\:]#\2>*/A+8Z'
MX$\0WUQ\0O"G@^]N]-\5^+?"J16)_M;PEX;U"PU"RUOQ1;%M TRZT[48;S48
MI-/O%A_H\^/W[>?[,OP1_P""NO@/6KGXAW/B#X7_  Q_X*>?MN_M3?M*>(=+
MT+4_%.F2^)O%?C"X^$7@/P]##H\93QY::1\./AAI&JW6H>%+F]T>>;XI>)(-
M-U%G%V\?)> /CY\-?^"A]Y^T!JW@Q?BGX(^,/[4G_!-_1O@C^TSX1^!_PD\9
M_$#P[^Q]>_LT_&_X"ZAX<\5?!WX9^$+QO$^K?L<_'CP-X*\-^&_&_P (?@[I
MWB7Q-\"-5UKQAJESX2UWX9V2S, ?S<?%KX)?&+X">)X/!7QO^%OQ ^$7C"ZT
MF#7K;PO\2/"6N>#-?N-#NK[4--M-9@TGQ!8V%]+I5Y?:3J5O9ZC' UI=O97!
MMII5C+5YA7[0_P#!;K2;+P=\9?V-OA9'XQ\7>-M9^#W_  3<_9/^'GBC4_B%
MH-_X/^(%GK%M:>-/$EEI7C#P-K-[?^(O 5_;>%_$OAR;2?!GBF>/Q1X?\*W7
MA^R\06>GZHMS86WXO4 %%%% !1110 4444 >D_!_X3>,_CI\2O"7PG^'T&B3
M>+O&>HR:?I3>)O%/AKP1X;LTM;*ZU34M5\0^,/&.JZ'X7\-:%H^DV-]JVKZU
MKNK6&G:?IUE<W$\ZJ@!_1GQ/_P $L[SX>?M3_M*_ KXC?M'_  ZT;X1?L@_!
M?X<?'+XZ_M.>&O#7B?QGX+B\+?%#PG\'M1\'Z=\,/"MD;#7/B+KOB[QQ\;/!
MW@/P- U[X:L/$:27/C"]U#P_X>MKN2U_)VOWV^('[:/[*GQM_:#_ &^O FM_
M$_6/ /P-_;3_ &0/V._A'X7^.=]\//%>L6OP^^,/[+W@K]E+Q)9R>-O ^C6E
MWXXF^'VL>./@EXS^'FL:KX7T37];LH]6T3Q=I>@ZQIEO/;R 'Y6_M5_LNZY^
MS'\3O#/@J#Q;H_Q4\'?$_P"&_P /?C/\$OB;X5TW6-*TSXH?"CXJ:6-2\'>(
MK?PYKUO;>(/#FMI=1:GX6\4^%-6@:_\ #GC/P_K^A?:=1BL8=2O.^A_X)F?\
M%#Y]4\*Z(O[$?[4<>K>-M1\0Z1X7T^Y^"7Q M+G5M3\*C.OV44=UH4)@N-/0
MK(4O#;FXBDBFM/M$4L3OV_[<_P ??A!\2OC!^S+X9^#OB35/&WPF_9+_ &;?
M@/\ LV:7\3]3\-ZCX5G^)]U\.]3\0>,_'OC_ $SP?JW_ !/= \-ZIXY\=^*[
M;P=I6NQV_B)_">G:)=Z[I^EZQ>7FEV?VY^UQ_P %%_A3\78O^"KH\'_%WXC:
MM)^UC_P4O_9Y_:#^$9OM/\8::?%/P'^%+_M+B2\UMKJ1#X>E\,Q>+OA$NA>%
M-5,5[&NFZ8NGP)_PBD/V4 _*KX:_L2_MA?&./Q^_PJ_9>^/7Q"/PK\2+X,^(
MT'A'X5>--<O/!GC,W4UF_@W7[&QT>:]L/%UO/;W/VSPQ+ -=LH;2[N;NP@MK
M2XEB]_\ @'_P3H\5_&3X4?$KXB>)?B#9_";7? 1_:O6R\ ^*/"6JW.M:[-^Q
MK^SCJO[0/QHM;J5;^P?P]<:/)/X \ 8O+&Y2VU[QRMS?-!'HEQ:7?]'WPPU3
MPU_P4#_:=^!/QT^$7B7]I/P#\)OAM_P7$_:0_:$^'WQ-^'7P&\>>./!_QTTK
MXT_$G]GSQ[)=^+->\*ZO;VW[.?Q1^'7A3PI%:^)M<_:#M/"W@]_@]X@N/%>D
M>*-43P5XS\-3_GOH_P#P4B_9[^ _[6UKXE\/:SX1\?\ @?X6_LU_\%+;FQM/
M$WPTU/QS\+_'W[7?[7FM?'+7]&\->*_"4T-O%XR^&]Q;7WP+^&>OZG<X\,ZO
MH?@^XN;FZGT21G< _$OP=^Q+^U_\0?%5GX&\$_LS?&_Q/XQOOAGHWQFMO#.D
M?#?Q3=ZT?A/XD5'\,_$2;3TTW[1:^$/%"S6O_"+ZY=)#8^)&O],31);]]4T]
M;GQ/XA_#?XA?"/QAJ_P]^*G@?Q9\-_'OA\:<=>\%>.?#^J^%?%>B'5M*L=<T
MQ-8\/ZW:V6JZ9+>Z/J>GZG;PWMK!+)97MM.$\N5"?Z8Y-?\ A;_P44\#?M\R
M?!?Q%^TEHMO^U)XT_8G_ &N/C9XH\)?!_P"*O[0VL? ?XX^&[7XY^$_&'[)W
MCG0/!5S>_$SQO\#]0\8^)[KQO^S3\3?"N@ZSX/\ !\>B?#3X:_$C_A$]>;2]
M5L_S._X+F:C8:A_P5)_:=BL/$NK>,#H$'P+\%:KXB\0W%I<^*+_Q-X!_9O\
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M^\EFN[R[N)6:6>YN)9)II&9Y'9B2<ZBB@ HHHH **** "BBB@ HHHH ****
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MZ1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\
MP68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0
M_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1
M_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*_
M_--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P
M&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_
M'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_
MZ1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\
MP68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0
M_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3
M_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U
M%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0
M!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*_
M_--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P
M&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_
M'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_
MZ1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\
MP68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0
M_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1
M_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*_
M_--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P
M&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_
M'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_
MZ1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0_?\
MP68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3_P 0
M_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U%?L3
M_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0!^.U
M%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*__--0
M!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P&\*_
M_--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_'7_P
M&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_Z1\_
M'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\ P68_
MZ1\_'7_P&\*__--0!^.U%?L3_P 0_?\ P68_Z1\_'7_P&\*__--1_P 0_?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@#8HK'^UZS_T![?_ ,&J_P#R%5>ZU35;2%IY='AV*\,9":HI;=/-' F ;,#
M>12W.0N2 3@$ Z"BL?[7K/\ T![?_P &J_\ R%1]KUG_ * ]O_X-5_\ D*@#
M8HK'^UZS_P! >W_\&J__ "%1]KUG_H#V_P#X-5_^0J -BBL?[7K/_0'M_P#P
M:K_\A4?:]9_Z!%O_ .#5?_D*@#8HKG[75-5O+>.YAT>'RY-^T/JB!AL=HSD"
MS8=4)&">,=^*L?:]9_Z ]O\ ^#5?_D*@#8HK'^UZS_T![?\ \&J__(5'VO6?
M^@/;_P#@U7_Y"H V**Q_M>L_] >W_P#!JO\ \A4?:]9_Z ]O_P"#5?\ Y"H
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MD4L21A02,GBIS=ZSD_\ $HMS[_VJO/O_ ,>5 &Q16/\ :]9_Z ]O_P"#5?\
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MGT/Q)I(O89AI^N:1/))-INJ6OE7ME([/;S1LQ)\QMOV9_P!G:S\5?$SQQ;_
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M[_2;HGY;8$8/GY'/IUK5_L#2O^?9O_ F[_\ C] &Q16/_8&E?\^S?^!-W_\
M'Z/[ TK_ )]F_P# F[_^/T ;%%8_]@:5_P ^S?\ @3=__'Z/[ TK_GV;_P "
M;O\ ^/T +KG_ "#9/^OG3O\ TXVE:]<GK.B:7'I\C+;-G[18#FYNR"&U"U4@
M@SXZ$^XZC! -:G]@Z5_S[-_X%7?_ ,?H V**Q_[ TK_GV;_P)N__ (_1_8&E
M?\^S?^!-W_\ 'Z -BBL?^P-*_P"?9O\ P)N__C]']@:5_P ^S?\ @3=__'Z
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M[)^&'[5?P+^,WQ7^*GP7^&?C*3Q7XW^#%AH%_P"/A9^'O$EOX9LU\0ZYXO\
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M.F7WC3P1IGA?6?%OANWG#ZIX?TKQJ=='A.^U*WP#!;Z^?#.OC3G)/G_V3>8
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M+%;KXH?M/:]\)]2O_P!G;XK_  ]MM)^.NLW/P5L/#]ZOCK0?&/A2TT-?$OA
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M_0"O?_ O2O\ Y.K7HH R/[0U#_H!7O\ X%Z5_P#)U']H:A_T KW_ ,"]*_\
MDZM>B@#E+N^OCJ>D$Z+>!E-]M4W6F$OFV ."+TJ-HY.YESVR>*U/[0U#_H!7
MO_@7I7_R=1>_\A71OKJ'_I**UZ ,C^T-0_Z 5[_X%Z5_\G4?VAJ'_0"O?_ O
M2O\ Y.K7HH R/[0U#_H!7O\ X%Z5_P#)U']H:A_T KW_ ,"]*_\ DZM>B@#E
M-:OKYM/D#:+>(/M%@=QNM,(R+^U('RWK'+$!1QC)RQ4 D:GV_4/^@%>_^!>E
M?_)U&N_\@V3_ *^=._\ 3C:5KT 9']H:A_T KW_P+TK_ .3J/[0U#_H!7O\
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M]&T"XUSQRUGK6IV4GNESXR^.7P6_:#_9'^"?B;X[R?&;0?C%X\_:$L_%>O\
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MD\6R^-?'GA.*&R1-$\4^*)?'GC&76]8L1#>7\GB/5))Y&>X)%CQI^S-^S_\
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M!-QD9Z'!&1P<UJ_V-;_\_.J?^#;4?_DBDO?^0KHWUU#_ -)16O0!D_V-;_\
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M"WBSX@^'=+\ R:*JW&JP>"/BC>:@94TF(6@!!X4_X)C? O0&\/6>O_$#X_\
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MPM^S9.,#C&2,D#)'29'5T5D_VA>_] 34/^_^E?\ RPH_M"]_Z >H?]_]*_\
MEA0!K45D_P!H7O\ T ]0_P"_^E?_ "PH_M"]_P"@'J'_ '_TK_Y84 :U%9/]
MH7O_ $ ]0_[_ .E?_+"C^T+W_H!ZA_W_ -*_^6% #= _Y!-I_P!M_P#TIFK8
MKD]#O[Q=+M0NC7\@'GX=9M, /^DS9P'OU;@\<J.F<5K?VA>_] /4/^_^E?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU;0VUSPSJ+Z/XDT9=6L+BP.J^']6C2232];TX7!N]*U&..1[*_AM[E49H@I
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M.L^'?!T1-AX2U'Q'XC /L'Q1_P %"/@YX7^*>I?#.7P9\9]8TW2_BOI_[/\
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M^*'BS4+Z,V8U;Q:FB:386L&F322?=?Q$_P""2'[.7C/P7\>_AQX3U[QW\$O
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M>&]&UW7?@K<Z]X#_ .%S:I:3>*?C-J?@'4/#>I>-?%=Q::M+<6D7AWPI9:$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>avxl-20200331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D05%2D07T02:18:27Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:avxl="http://anavex.com/20200331">
    <link:schemaRef xlink:href="avxl-20200331.xsd" xlink:type="simple" />
    <xbrli:context id="From2019-10-01to2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_ClinicalStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:ClinicalStudyGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-29to2020-05-01_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-29</xbrli:startDate>
        <xbrli:endDate>2020-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-19</xbrli:startDate>
        <xbrli:endDate>2015-10-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-06</xbrli:startDate>
        <xbrli:endDate>2019-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-03-31_custom_NYCBiotechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:NYCBiotechMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-03-31_custom_NYCBiotechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:NYCBiotechMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2019-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2019-10-01to2020-03-31">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2019-10-01to2020-03-31">0001314052</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2019-10-01to2020-03-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2019-10-01to2020-03-31">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2019-10-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2019-10-01to2020-03-31">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="From2019-10-01to2020-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntitySmallBusiness contextRef="From2019-10-01to2020-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-10-01to2020-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityFilerCategory contextRef="From2019-10-01to2020-03-31">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2019-10-01to2020-03-31">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2019-10-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-09-30" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-09-30" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">149888</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">149055</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2016-10-01to2017-09-30_custom_ClinicalStudyGrantMember" unitRef="USD" decimals="0">597886</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">74944</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">74527</avxl:NonOperatingIncomeFromGrant>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">15365492</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">5068834</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-04-29to2020-05-01_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" unitRef="USD" decimals="0">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <dei:EntityFileNumber contextRef="From2019-10-01to2020-03-31">001-37606</dei:EntityFileNumber>
    <dei:EntityShellCompany contextRef="From2019-10-01to2020-03-31">false</dei:EntityShellCompany>
    <dei:EntityInteractiveDataCurrent contextRef="From2019-10-01to2020-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityIncorporationStateCountryCode contextRef="From2019-10-01to2020-03-31">NV</dei:EntityIncorporationStateCountryCode>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="From2019-10-01to2020-03-31" unitRef="Shares" decimals="INF">10486266</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="From2018-10-01to2019-09-30" unitRef="Shares" decimals="INF">8812933</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <avxl:ValueOfSharesObligatedToPurchase contextRef="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <avxl:ValueOfSharesObligatedToPurchase contextRef="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <avxl:AgreementTerm contextRef="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">P36M</avxl:AgreementTerm>
    <avxl:AgreementTerm contextRef="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">P36M</avxl:AgreementTerm>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationDescription contextRef="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase.  The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park&amp;#8217;s committed obligation under any single purchase shall not exceed $2,000,000.  The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2019 Purchase Agreement.</us-gaap:UnrecordedUnconditionalPurchaseObligationDescription>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic contextRef="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">162191</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3 contextRef="From2018-10-01to2019-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">9631</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3 contextRef="From2019-10-01to2020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">49841</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3 contextRef="From2018-10-01to2019-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" xsi:nil="true" />
    <avxl:PercentageOfGrossProceedsFromSales contextRef="From2019-10-01to2020-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" unitRef="Pure" decimals="INF">0.03</avxl:PercentageOfGrossProceedsFromSales>
    <avxl:PercentageOfGrossProceedsFromSales contextRef="From2019-10-01to2020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember" unitRef="Pure" decimals="INF">0.1999</avxl:PercentageOfGrossProceedsFromSales>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="From2018-10-01to2019-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">-8750</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">2965177</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">3960139</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-10-01to2020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">1291410</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-10-01to2020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">1673767</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-10-01to2019-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">2006587</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-10-01to2019-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">1953552</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1700753</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">1893152</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">810309</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">890444</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-01-01to2019-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">950999</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-01-01to2019-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">942153</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-10-01to2020-03-31" unitRef="Pure" decimals="INF">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-10-01to2019-03-31" unitRef="Pure" decimals="INF">0.0291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-10-01to2020-03-31">P5Y5M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-10-01to2019-03-31">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2019-10-01to2020-03-31" unitRef="Pure" decimals="INF">0.9761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-10-01to2019-03-31" unitRef="Pure" decimals="INF">1.0596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2019-10-01to2020-03-31" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-10-01to2019-03-31" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-03-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2019-10-01to2020-03-31_custom_StockOptionPlan2015Member">The exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2019-10-01to2020-03-31_custom_StockOptionPlan2019Member">The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2019-10-01to2020-03-31_custom_StockOptionPlan2015Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2019-10-01to2020-03-31_custom_StockOptionPlan2019Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4 contextRef="From2018-10-01to2019-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">2229592</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4 contextRef="From2019-10-01to2020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">5964584</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4 contextRef="From2018-10-01to2019-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" xsi:nil="true" />
    <avxl:StockIssuedDuringPeriodValueNewIssues3 contextRef="From2018-10-01to2019-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">5361534</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3 contextRef="From2019-10-01to2020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">15365492</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3 contextRef="From2018-10-01to2019-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-06-06to2019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">324383</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-10-01to2019-03-31_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">2239223</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-10-01to2020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">6014425</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-10-01to2020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">10076680</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-10-01to2019-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2019-10-01to2020-03-31_custom_StockOptionPlan2019Member" unitRef="Shares" decimals="INF">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <avxl:StockIssuedDuringPeriodValueNewIssues4 contextRef="From2019-10-01to2020-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">30000000</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <avxl:RemainingAllocatedShareBasedCompensationExpense contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">5708800</avxl:RemainingAllocatedShareBasedCompensationExpense>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">717328</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">1660543</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2020-01-01to2020-03-31_currency_AUD" unitRef="USD" decimals="0">1203000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2018-10-01to2019-03-31_currency_AUD" unitRef="USD" decimals="0">2548000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">510990</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">924672</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2019-10-01to2020-03-31_custom_NYCBiotechMember" unitRef="USD" decimals="0">250000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="From2018-10-01to2019-03-31_custom_NYCBiotechMember" unitRef="USD" decimals="0">250000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-05-07" unitRef="Shares" decimals="INF">58664946</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:LeaseAndRentalExpense contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">110915</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">78261</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">60861</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">40507</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2019-10-01to2020-03-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">1667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">309383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-10-01to2020-03-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">1525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">2265399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">6506917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-03-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">9986266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">8462933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-03-31_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">6925642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-03-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2019-10-01to2020-03-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-10-01to2020-03-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-03-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2019-10-01to2020-03-31_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-10-01to2019-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">2353088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-03-31_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">4517080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">4115032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2020-03-31_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">3815680</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-03-31_custom_PurchaseWarrants2Member" unitRef="Shares" decimals="INF">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-03-31_custom_PurchaseWarrants1Member" unitRef="Shares" decimals="INF">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-03-31_custom_PurchaseWarrants2Member" unitRef="USDPShares" decimals="INF">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-03-31_custom_PurchaseWarrants1Member" unitRef="USDPShares" decimals="INF">4.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-03-31_custom_PurchaseWarrants2Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-03-31_custom_PurchaseWarrants1Member">2021-06-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod contextRef="From2018-10-01to2019-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">-319629</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">678379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2020-03-31_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod contextRef="From2019-10-01to2020-03-31_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">150000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice contextRef="From2018-10-01to2019-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">1.46</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice contextRef="From2018-10-01to2019-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">1.13</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">2.87</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-03-31_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">3.88</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">4.19</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice contextRef="From2019-10-01to2020-03-31_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">3.17</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">58664946</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-09-30" unitRef="Shares" decimals="INF">52650251</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">58664946</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-09-30" unitRef="Shares" decimals="INF">52650251</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:Assets contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">31020577</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">25329373</us-gaap:Assets>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">305559</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">500998</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">4151947</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">2642745</us-gaap:IncomeTaxesReceivable>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">6228831</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">5039674</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">2579097</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">1516342</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">3649734</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">3523332</us-gaap:AccountsPayableCurrent>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2019-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">58666</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">52652</us-gaap:CommonStockValue>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">31020577</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">25329373</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">24791746</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">22321696</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">17184034</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">20289699</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">57082</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">58666</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">45935</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">48175</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">165891753</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">171958462</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">129377542</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">138696975</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" decimals="0">-292700</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-139988685</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-147225382</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-107101781</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-121268416</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">46888</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">133438276</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-114021512</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">19463652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">52652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">153633807</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-133396760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">25960150</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">-147225382</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">-133396760</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">171958462</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">153633807</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:NetIncomeLoss contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">-13828622</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">-14166635</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-7236697</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-7246904</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-10-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-10-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-10-01to2019-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-7236697</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-10-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-14166635</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-7246904</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-10-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-10-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-10-01to2020-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-10-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-13828622</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">2965177</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">3960139</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1700753</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">1893152</us-gaap:ShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">-10988051</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">-8491627</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">1062755</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">51345</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">126402</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">2434633</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">-195439</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">-439552</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">1509202</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">1210661</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">26563071</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">22185630</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">15365492</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">5018834</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2019-10-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">50000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">4377441</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">-3472793</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:Cash contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">26563071</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">22930638</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">19457845</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">22185630</us-gaap:Cash>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">-272848</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">49693</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-325960</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">54199</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">116900</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">130265</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">70180</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">51465</us-gaap:InterestIncomeExpenseNet>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">1660543</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">1174672</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">717328</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">760990</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:OperatingExpenses contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">15473891</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">15613555</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">7773189</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">8140037</us-gaap:OperatingExpenses>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">12401715</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">11790996</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">6053047</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">6078786</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">3072176</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">3822559</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1720142</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">2061251</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">9214</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">56765</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">48048</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">-13819408</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">-14109870</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">-7236697</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">-7198856</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">1654483</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">1503685</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">536492</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">941181</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-10-01to2020-03-31" unitRef="Shares" decimals="INF">56554037</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2018-10-01to2019-03-31" unitRef="Shares" decimals="INF">46726649</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF">58353954</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-01-01to2019-03-31" unitRef="Shares" decimals="INF">47134686</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-10-01to2020-03-31" unitRef="USDPShares" decimals="INF">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-10-01to2019-03-31" unitRef="USDPShares" decimals="INF">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-03-31" unitRef="USDPShares" decimals="INF">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-01-01to2019-03-31" unitRef="USDPShares" decimals="INF">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">57080356</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">58664946</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">45933472</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">48173241</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">46887056</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">52650521</us-gaap:SharesOutstanding>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">5068834</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">3074134</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2018-10-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2229</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2018-10-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5359305</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2018-10-01to2019-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" decimals="0">-292700</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2018-10-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1279</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3365555</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2019-01-01to2019-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" decimals="0">-292700</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2 contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:StockIssuedDuringPeriodSharesAcquisitions2 contextRef="From2018-10-01to2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2229592</avxl:StockIssuedDuringPeriodSharesAcquisitions2>
    <avxl:StockIssuedDuringPeriodSharesAcquisitions2 contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1279592</avxl:StockIssuedDuringPeriodSharesAcquisitions2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2018-10-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2019-01-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2018-10-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">10</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2018-10-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-10</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2018-10-01to2019-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2018-10-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-7</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2019-01-01to2019-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2 contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2 contextRef="From2018-10-01to2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">9631</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2 contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6047</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2018-10-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2019-01-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2018-10-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2018-10-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-1</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2018-10-01to2019-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2018-10-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-1</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2019-01-01to2019-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares contextRef="From2018-10-01to2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">546</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">546</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">2965177</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">3960139</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">1700753</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">1893152</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-10-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1700753</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-10-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3960139</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-10-01to2019-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-10-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1893152</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2965177</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2020-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-10-01to2020-03-31" unitRef="USD" decimals="0">15365492</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0">4367540</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1571</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4365969</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-10-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5965</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-10-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">15359527</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-10-01to2020-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2019-10-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1570424</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2019-10-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5964584</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2019-10-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">13</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-13</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2020-01-01to2020-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2019-10-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">49</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2019-10-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-49</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2019-10-01to2020-03-31_custom_CommonStockToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1 contextRef="From2019-10-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1 contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">14166</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1 contextRef="From2019-10-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">49841</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1>
    <avxl:ResearchAndDevelopmentsIncentiveIncome contextRef="From2018-10-01to2019-03-31" unitRef="USD" decimals="0">924672</avxl:ResearchAndDevelopmentsIncentiveIncome>
    <avxl:ResearchAndDevelopmentsIncentiveIncome contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="0">510990</avxl:ResearchAndDevelopmentsIncentiveIncome>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2019-10-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note 1&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Business&#13;                                         Description and Basis of Presentation&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Business&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Anavex&#13;Life Sciences Corp. (the &amp;#8220;Company&amp;#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated&#13;therapeutics by applying precision medicine to central nervous system (&amp;#8220;CNS&amp;#8221;) diseases with high unmet need. Anavex&#13;analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic&#13;benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&amp;#8217;s lead compound ANAVEX&amp;#174;2-73&#13;is being developed to treat Alzheimer&amp;#8217;s disease, Parkinson&amp;#8217;s disease and potentially other central nervous system&#13;diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in&#13;the X-linked gene, methyl-CpG-binding protein 2 (&amp;#8220;MECP2&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basis&#13;of Presentation&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the&#13;Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) and accounting principles generally accepted in the United States of America&#13;(&amp;#8220;U.S. GAAP&amp;#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the&#13;annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.&#13;In the opinion of management, the disclosures are adequate to make the information presented not misleading.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring&#13;adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated&#13;balance sheet as of September 30, 2019 was derived from the audited annual financial statements but does not include all disclosures&#13;required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction&#13;with the audited consolidated financial statements and notes thereto included in the Company&amp;#8217;s annual report on Form 10-K&#13;for the year ended September 30, 2019 filed with the SEC on December 16, 2019. The Company follows the same accounting policies&#13;in the preparation of interim reports.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating&#13;results for the six months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year&#13;ending September 30, 2020.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Liquidity&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;All&#13;of the Company&amp;#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its&#13;research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved&#13;for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.&#13;The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,&#13;if ever, our business might become profitable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will&#13;be sufficient to meet its cash commitments for at least the next two years after the date that these interim condensed consolidated&#13;financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials&#13;is uncertain.&amp;#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to&#13;change.&amp;#160;The actual amount of the Company&amp;#8217;s expenditures will vary depending upon a number of factors including but&#13;not limited to the design, timing and duration of future clinical trials, the progress of the Company&amp;#8217;s research and development&#13;programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels&#13;based on the timing of future clinical trials.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;than our rights related to the Sales Agreement and the 2019 Purchase Agreement (each as defined below), there can be no assurance&#13;that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable&#13;terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to&#13;delay or scale down some or all of our research and development activities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World&#13;Health Organization (&amp;#8220;WHO&amp;#8221;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus&#13;beyond its point of origin.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;global outbreak of COVID-19 continues to rapidly evolve as of the date these interim condensed consolidated financial statements&#13;are issued. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&amp;#8217;s financial condition&#13;and future results of operations. Management is actively monitoring the global situation on its business, including on its clinical&#13;trials and operations and financial condition. Given the daily evolution of the COVID-19 situation, and the global responses to&#13;curb its spread, the Company is not able to estimate the effects of COVID-19 on its results of operations or financial condition&#13;for the year ending September 30, 2020.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;March 27, 2020, the President of the United States signed into law the &amp;#8220;Coronavirus Aid, Relief, and Economic Security (CARES)&#13;Act.&amp;#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer&#13;side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to&#13;the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections&#13;to tax depreciation methods for qualified improvement property. The enactment of the CARES Act did not have any impact on the&#13;Company&amp;#8217;s interim condensed consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Use&#13;of Estimates&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect&#13;the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and&#13;expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research&#13;and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss&#13;contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors&#13;that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the&#13;carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.&#13;The actual results experienced by the Company may differ materially and adversely from the Company&amp;#8217;s estimates. To the extent&#13;there are material differences between the estimate s and the actual results, future results of operations will be affected.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Adjustment&#13;of Prior Period Financial Statements&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;previously disclosed in Note 1 to the Company&amp;#8217;s consolidated financial statements included in the Company&amp;#8217;s annual&#13;report on Form 10-K for the year ended September 30, 2019, the Company adjusted amounts to previously reported consolidated financial&#13;statements which were immaterial. These adjustments were identified in connection with the preparation of the consolidated financial&#13;statements for the year ended September 30, 2019 and related to the timing of recognition of research and development incentive&#13;income. Previously the Company accounted for research and development incentive income when received in cash. During the year&#13;ended September 30, 2019, based on a continuing assessment regarding the Company&amp;#8217;s eligibility for the incentive programs&#13;under which it was receiving such income, the Company determined that the income should have been accrued and recorded in the&#13;period in which the qualifying research and development expenditures were incurred.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;interim condensed consolidated financial statements for the three and six months ended March 31, 2019 have been similarly adjusted&#13;to reflect the adjusted research and development incentive income for the three and six months accordingly in the amount of $510,990&#13;and $924,672, respectively and should be read in conjunction with Note 1 to the Company&amp;#8217;s consolidated financial statements&#13;for the year ended September 30, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Principles&#13;of Consolidation&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex&#13;Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the&#13;laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company&#13;transactions and balances have been eliminated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Fair&#13;Value Measurements&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last&#13;unobservable, that may be used to measure fair value which are the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 0.75in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;    1 - &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;quoted&#13;    prices (unadjusted) in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;    2 - &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;observable&#13;    inputs other than Level 1, quoted prices for similar assets or liabilities in active &amp;#160;markets, quoted prices for identical&#13;    or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or&#13;    whose significant value drivers are observable; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;    3 - &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;assets&#13;    and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant&#13;    to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the&#13;short-term maturity of those instruments.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;March 31, 2020 and September 30, 2019, the Company did not have any Level 3 assets or liabilities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Basic&#13;and Diluted Loss per Share&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic&#13;loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common&#13;shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except&#13;that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into&#13;shares of common stock that were outstanding during the period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of March 31, 2020, loss per share excludes 10,486,266 (September 30, 2019 &amp;#8211; 8,812,933) potentially dilutive common shares&#13;related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2019-10-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of the Company&amp;#8217;s outstanding share purchase warrants is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White; width: 0.75in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Balance, September 30, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;678,379&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.87&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Exercised&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(8,750&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.13&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Expired&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(319,629&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.46&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Balance, September 30, 2019&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Granted&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Balance, March 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.88&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2019-10-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;March 31, 2020, the Company had share purchase warrants outstanding as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    Price&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry&#13;    Date&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 25%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 25%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 44%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 30,&#13;    2021&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May&#13;    6, 2024&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2019-10-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These amounts have been included in general and &amp;#9;administrative expenses and research&#13;and development expenses on the Company&amp;#8217;s interim condensed consolidated statements of &amp;#9;operations as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: White; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Three&#13;    months ended&lt;br /&gt;&#13;    March 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Six&#13;    months ended&lt;br /&gt;&#13;    March 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White; width: 0.75in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;810,309&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;950,999&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,291,410&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,006,587&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;890,444&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;942,153&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,673,767&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,953,552&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total share based compensation&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,700,753&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,893,152&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,965,177&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,960,139&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2019-10-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following&#13;weighted average assumptions:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest&#13;    rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.68&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.91&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options&#13;    (years)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.44&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.59&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Annualized volatility&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;97.61&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;105.96&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend rate&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2019-10-01to2020-03-31">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note 3&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Other&#13;                                         Income&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Grant&#13;Income&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant was being received&#13;in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for&#13;a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;grant income has been deferred when received and amortized to other income as the related research and development expenditures&#13;are incurred. During the three and six months ended March 31, 2020, the Company recognized $74,944 and $149,888, respectively&#13;(2019:$74,527 and $149,055, respectively) of this grant on its statement of operations within grant income.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development incentive income&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit&#13;(&amp;#8220;NYC Biotech credit&amp;#8221;), and the Australian research and development tax incentive credit (the &amp;#8220;Australia R&amp;#38;D&#13;credit&amp;#8221;) through a program administered through the Australian Tax Office (the &amp;#8220;ATO&amp;#8221;), which provides for a&#13;cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company&amp;#8217;s&#13;wholly owned subsidiary, Anavex Australia Pty Ltd. (&amp;#8220;Anavex Australia&amp;#8221;).&amp;#160;Research and development incentive income&#13;during the three and six months ended March 31, 2020 and 2019 represents the receipt by the Company&amp;#8217;s Australian subsidiary,&#13;of the Australian research and development incentive credit, (the &amp;#8220;ATO R&amp;#38;D Credit&amp;#8221;), as well as receipt by the&#13;Company of the New York City Biotechnology Credit (&amp;#8220;NYC Biotech credit&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;During the&#13;three and six months ended March 31, 2020, the Company recorded research and development incentive income of $717,328 (AUD 1,203,000)&#13;and $1,660,543 (AUD 2,548,000), respectively (2019: $510,990 and $924,672, respectively) in respect of the ATO R&amp;#38;D Credit for&#13;eligible research and development expenses incurred during the period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;During the&#13;three and six months ended March 31, 2019, the Company recorded research and development incentive income of $250,000 and $250,000&#13;respectively, in respect of the NYC Biotech credit.&lt;/p&gt;</avxl:OtherIncomeDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2019-10-01to2020-03-31">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note 2&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Recent&#13;                                         Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recently&#13;Adopted Accounting Pronouncements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference&#13;between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases&#13;classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make&#13;lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the&#13;lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class&#13;of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize&#13;lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is&#13;largely unchanged from that applied under previous U.S. GAAP. The Company elected to the package of practical expedients&#13;permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried&#13;forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases&#13;with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's&#13;results of operations, financial condition, cash flows, and financial statement disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based&#13;Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning&#13;it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the&#13;Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the&#13;date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results&#13;of operations, financial condition, cash flows, and financial statement disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent&#13;Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;December 2019, the FASB issued ASU 2019-12, &amp;#34;Simplifying the Accounting for Income Taxes (ASC 740)&amp;#34;, which is intended&#13;to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in&#13;Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company&#13;on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated&#13;financial statements but does not expect such guidance to have a material impact.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2019-10-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recently&#13;Adopted Accounting Pronouncements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference&#13;between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases&#13;classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make&#13;lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the&#13;lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class&#13;of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize&#13;lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is&#13;largely unchanged from that applied under previous U.S. GAAP. The Company elected to the package of practical expedients&#13;permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried&#13;forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases&#13;with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's&#13;results of operations, financial condition, cash flows, and financial statement disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based&#13;Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning&#13;it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the&#13;Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the&#13;date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results&#13;of operations, financial condition, cash flows, and financial statement disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent&#13;Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;December 2019, the FASB issued ASU 2019-12, &amp;#34;Simplifying the Accounting for Income Taxes (ASC 740)&amp;#34;, which is intended&#13;to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in&#13;Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company&#13;on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated&#13;financial statements but does not expect such guidance to have a material impact.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:EquityOfferingAgreementsTextBlock contextRef="From2019-10-01to2020-03-31">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note 4&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Equity&#13;                                         Offering Agreements&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Sales Agreement&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The Company has entered into a Sales&#13;Agreement dated July 6, 2018, as amended May 1, 2020 (the &amp;#8220;Sales Agreement&amp;#8221;) with Cantor Fitzgerald&amp;#160;&amp;#38; Co.,&#13;(&amp;#8220;Cantor Fitzgerald&amp;#8221;) and SVB Leerink LLC (&amp;#8220;Leerink&amp;#8221;), and together with Cantor Fitzgerald as Sales Agents,&#13;pursuant to which the Company may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $50,000,000&#13;from time to time through the Sales Agents (the &amp;#8220;Offering&amp;#8221;).&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Upon delivery of a placement notice&#13;based on the Company&amp;#8217;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may&#13;sell the Shares by methods deemed to be an &amp;#8220;at the market offering&amp;#8221; offering, in negotiated transactions at market&#13;prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by&#13;law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make&#13;any sales of Shares under the Sales Agreement. The Company or the Sales Agents may suspend or terminate the offering of Shares&#13;upon notice to the other party, subject to certain conditions.&amp;#160; The Sales Agents will act as sales agent on a commercially&#13;reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules&amp;#160;and&#13;regulations and the rules&amp;#160;of Nasdaq.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The Company has agreed to pay the&#13;Sales Agents commissions for their services of acting as agents of 3.0% of the gross proceeds from the sale of the Shares pursuant&#13;to the Sales Agreement.&amp;#160; The Company also agreed to provide the Sales Agents with customary indemnification and contribution&#13;rights. As of March 31, 2020, no shares had been sold pursuant to the Offering.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;2015 Purchase Agreement&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;On October 21, 2015, the Company&#13;entered into a $50,000,000 purchase agreement (the &amp;#8220;2015 Purchase Agreement&amp;#8221;) with Lincoln Park Capital Fund, LLC (&amp;#8220;Lincoln&#13;Park&amp;#8221;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up&#13;to $50,000,000 in value of its shares of common stock from time to time over a 36-month period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;During the six months ended March&#13;31, 2019, the Company issued an aggregate of 2,239,223 shares of common stock under the 2015 Purchase Agreement, including 2,229,592&#13;shares of common stock for an aggregate purchase price of $5,361,534 and 9,631 commitment shares. At March 31, 2020 and September&#13;30, 2019, all remaining purchase amounts available for issuance under the 2015 Purchase Agreement had been utilized and the 2015&#13;Purchase Agreement has expired pursuant to its terms. As such, no further shares will be sold under the 2015 Purchase Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&#13;Purchase Agreement&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;June 7, 2019, the Company entered into a $50,000,000 purchase agreement (the &amp;#8220;2019 Purchase Agreement&amp;#8221;) with Lincoln&#13;Park, pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $50,000,000&#13;in value of its shares of common stock from time to time from June 12, 2019, the date a prospectus supplement under which shares&#13;of common stock issuable under the 2019 Purchase Agreement was filed with the SEC, until July 1, 2022, which is the first day&#13;of the next month following the 36-month anniversary of June 12, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of&#13;common stock on any business day (a &amp;#8220;Regular Purchase&amp;#8221;). The amount of a Regular Purchase may be increased under certain&#13;circumstances up to 250,000 shares, provided that Lincoln Park&amp;#8217;s committed obligation for Regular Purchases on any business&#13;day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business&#13;day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase&#13;price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares&#13;at the time of sales as described in the 2019 Purchase Agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;2019 Purchase Agreement limits the Company&amp;#8217;s sale of shares of Common Stock to Lincoln Park to 10,076,680 shares of Common&#13;Stock, representing 19.99% of the shares of the Common Stock outstanding on the date of the 2019 Purchase Agreement unless (i)&#13;shareholder approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock&#13;to Lincoln Park under the 2019 Purchase Agreement equals or exceeds the lower of (A) the closing price of the Common Stock on&#13;the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average of the closing prices of the Common Stock&#13;on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date, and it also limits the Company&amp;#8217;s&#13;sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of the Company&amp;#8217;s&#13;outstanding shares of Common Stock at any given time.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock&#13;as a commitment fee and agreed to issue up to 162,191 shares pro rata, when and if, Lincoln Park purchases at the Company&amp;#8217;s&#13;discretion the $50,000,000 aggregate commitment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;During the six months ended March&#13;31, 2020, the Company issued to Lincoln Park an aggregate of 6,014,425 (2019: Nil) shares of common stock under the 2019 Purchase&#13;Agreement, including 5,964,584 (2019: Nil) shares of common stock for an aggregate purchase price of $15,365,492 (2019: $Nil) and&#13;49,841 (2019: Nil) commitment shares. At March 31, 2020, an amount of $30,000,000 remained available under the 2019 Purchase Agreement.&lt;/p&gt;</avxl:EquityOfferingAgreementsTextBlock>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2019-10-01to2020-03-31">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note 5&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Commitments&#13;                                         and Contingencies&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;a)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Leases&#13;                                         &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;During&#13;the three and six months ended March 31, 2020, the Company incurred office lease expense of $60,861 and $110,915, respectively&#13;(2019: $40,507 and $78,261, respectively).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;b)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Litigation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;The&#13;Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently&#13;uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that&#13;the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.&#13;The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its&#13;consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;c)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Share&#13;                                         Purchase Warrants&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of the Company&amp;#8217;s outstanding share purchase warrants is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White; width: 0.75in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Balance, September 30, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;678,379&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.87&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Exercised&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(8,750&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.13&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Expired&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(319,629&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.46&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Balance, September 30, 2019&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Granted&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Balance, March 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.88&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;March 31, 2020, the Company had share purchase warrants outstanding as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    Price&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry&#13;    Date&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 25%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 25%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 44%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 30,&#13;    2021&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May&#13;    6, 2024&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;d)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Stock&amp;#8211;based&#13;                                         Compensation Plan&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&#13;Stock Option Plan&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;September 18, 2015, the Company&amp;#8217;s board of directors (the &amp;#8220;Board&amp;#8221;) approved a 2015 Omnibus Incentive Plan (the&#13;&amp;#8220;2015 Plan&amp;#8221;), which provides for the grant of stock options and restricted stock awards to directors, officers, employees&#13;and consultants of the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;maximum number of our common shares reserved for issue under the plan is 6,050,553 shares, subject to adjustment in the event&#13;of a change of the Company&amp;#8217;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards were&#13;granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing&#13;stock option plans remain outstanding in accordance with their terms.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;2015 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The&#13;exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date.&#13;If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value&#13;of the Company&amp;#8217;s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise&#13;period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject&#13;to earlier termination in accordance with the terms of the 2015 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&#13;Stock Option Plan&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &amp;#8220;2019 Plan&amp;#8221;), which provides for the grant&#13;of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under&#13;the terms of the 2019 Plan, 6,000,000 additional shares of Common Stock are available for issuance under the 2019 Plan, in addition&#13;to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&amp;#8217;s 2007 Stock Option&#13;Plan (the &amp;#8220;2007 Plan&amp;#8221;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and&#13;any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards&#13;(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The&#13;exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value&#13;on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair&#13;market value of the Company&amp;#8217;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan&#13;for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by&#13;the Board, subject to earlier termination in accordance with the terms of the 2019 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of Company&amp;#8217;s outstanding stock purchase options is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Grant Date Fair Value ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    &lt;br /&gt; intrinsic value ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White; width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    September 30, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,506,917&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.83&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,353,088&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,265,399&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.79&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.27&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(309,383&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.25&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    September 30, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,462,933&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.58&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,115,032&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,525,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.86&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.17&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,667&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.64&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    March 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,986,266&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.47&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,517,080&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,&#13;    March 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,925,642&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.70&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,815,680&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market&#13;price of the Company&amp;#8217;s stock for the options that were in-the-money at March 31, 2020.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the three and six months ended March 31, 2020, the Company recognized stock-based compensation expense of $1,700,753 and $2,965,177,&#13;respectively (2019: $1,893,152 and $3,960,139, respectively) in connection with the issuance and vesting &amp;#9;of stock options&#13;and warrants in exchange for services. These amounts have been included in general and &amp;#9;administrative expenses and research&#13;and development expenses on the Company&amp;#8217;s interim condensed consolidated statements of &amp;#9;operations as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: White; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Three&#13;    months ended&lt;br /&gt;&#13;    March 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Six&#13;    months ended&lt;br /&gt;&#13;    March 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White; width: 0.75in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;810,309&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;950,999&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,291,410&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,006,587&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;890,444&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;942,153&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,673,767&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,953,552&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total share based compensation&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,700,753&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,893,152&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,965,177&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,960,139&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;An&#13;amount of approximately $5,708,800 in stock-based compensation is expected to be recorded over the remaining vesting period &amp;#9;of&#13;such options through fiscal 2022.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following&#13;weighted average assumptions:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest&#13;    rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.68&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.91&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options&#13;    (years)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.44&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.59&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Annualized volatility&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;97.61&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;105.96&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend rate&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2019-10-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of Company&amp;#8217;s outstanding stock purchase options is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Grant Date Fair Value ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#13;    &lt;br /&gt; intrinsic value ($)&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White; width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    September 30, 2018&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,506,917&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.83&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,353,088&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,265,399&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.79&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.27&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(309,383&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.25&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    September 30, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,462,933&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.58&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,115,032&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,525,000&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.86&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.17&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,667&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.64&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    March 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,986,266&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.47&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,517,080&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; background-color: White"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0; padding-left: 0; text-indent: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,&#13;    March 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,925,642&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.70&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,815,680&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>avxl-20200331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D05%2D07T02:18:27Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9KhZw7xRiXgen8uCa3dcOaGFKcPtw5Nx6Ykhv2dyfalKzyIlux3pGij7/oi2AdoI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:avxl="http://anavex.com/20200331" elementFormDefault="qualified" targetNamespace="http://anavex.com/20200331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" id="InterimCondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" id="InterimCondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" id="InterimCondensedConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" id="InterimCondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" id="InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity">
	  <link:definition>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" id="BusinessDescriptionAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Business Description and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
	  <link:definition>00000008 - Disclosure - Recent Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000009 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreements" id="EquityOfferingAgreements">
	  <link:definition>00000010 - Disclosure - Equity Offering Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000011 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" id="RecentAccountingPronouncementsPolicies">
	  <link:definition>00000012 - Disclosure - Recent Accounting Pronouncements (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000013 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" id="BusinessDescriptionAndBasisOfPresentationDetailsNarrative">
	  <link:definition>00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000015 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" id="EquityOfferingAgreementsDetailsNarrative">
	  <link:definition>00000016 - Disclosure - Equity Offering Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000017 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000018 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
	  <link:definition>00000019 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
	  <link:definition>00000020 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
	  <link:definition>00000021 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000022 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AgreementTerm" name="AgreementTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues4" name="StockIssuedDuringPeriodSharesNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues4" name="StockIssuedDuringPeriodValueNewIssues4" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_RemainingAllocatedShareBasedCompensationExpense" name="RemainingAllocatedShareBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueAcquisitions2" name="StockIssuedDuringPeriodValueAcquisitions2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesAcquisitions2" name="StockIssuedDuringPeriodSharesAcquisitions2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" name="SharesIssuedPursuantToCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" name="SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentsIncentiveIncome" name="ResearchAndDevelopmentsIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingAgreementsTextBlock" name="EquityOfferingAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ClinicalStudyGrantMember" name="ClinicalStudyGrantMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreementMember" name="PurchaseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommonStockToBeIssuedMember" name="CommonStockToBeIssuedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NYCBiotechMember" name="NYCBiotechMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>avxl-20200331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D05%2D07T02:18:27Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/DocumentAndEntityInformation" xlink:href="avxl-20200331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20200331.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20200331.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20200331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20200331.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20200331.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20200331.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20200331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20200331.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>avxl-20200331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D05%2D07T02:18:27Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/DocumentAndEntityInformation" xlink:href="avxl-20200331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20200331.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20200331.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20200331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20200331.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20200331.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20200331.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20200331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20200331.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommonStockToBeIssuedMember" xlink:label="loc_avxlCommonStockToBeIssuedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_avxlCommonStockToBeIssuedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodValueAcquisitions2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlStockIssuedDuringPeriodValueAcquisitions2_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ClinicalStudyGrantMember" xlink:label="loc_avxlClinicalStudyGrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlClinicalStudyGrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_NYCBiotechMember" xlink:label="loc_avxlNYCBiotechMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlNYCBiotechMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseAgreementMember" xlink:label="loc_avxlPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_AgreementTerm" xlink:label="loc_avxlAgreementTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlAgreementTerm_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_90" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_60" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:label="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_60" xlink:to="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_60" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_60" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="loc_avxlRemainingAllocatedShareBasedCompensationExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlRemainingAllocatedShareBasedCompensationExpense_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_80" xlink:type="arc" order="6" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>avxl-20200331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D05%2D07T02:18:27Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Products and Services [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ClinicalStudyGrantMember" xlink:label="avxl_ClinicalStudyGrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalStudyGrantMember" xlink:to="avxl_ClinicalStudyGrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ClinicalStudyGrantMember_lbl" xml:lang="en-US">Clinical Study Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald &amp; Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseAgreementMember" xlink:label="avxl_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreementMember" xlink:to="avxl_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreementMember_lbl" xml:lang="en-US">2015 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">2019 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">2019 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_2_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommonStockToBeIssuedMember" xlink:label="avxl_CommonStockToBeIssuedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonStockToBeIssuedMember" xlink:to="avxl_CommonStockToBeIssuedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommonStockToBeIssuedMember_lbl" xml:lang="en-US">Common Stock To Be Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_NYCBiotechMember" xlink:label="avxl_NYCBiotechMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NYCBiotechMember" xlink:to="avxl_NYCBiotechMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NYCBiotechMember_lbl" xml:lang="en-US">NYC Biotech</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_DocumentAndEntityInformationAbstract" xlink:label="avxl_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DocumentAndEntityInformationAbstract" xlink:to="avxl_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Reporting Status Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 5</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 58,664,946 common shares (September 30, 2019 - 52,650,251)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss), net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in non-cash working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Deferred financing charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance Beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="avxl_StockIssuedDuringPeriodValueAcquisitions2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodValueAcquisitions2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueAcquisitions2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="avxl_StockIssuedDuringPeriodSharesAcquisitions2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of warrants (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance Ending (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="us-gaap_OtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAbstract_lbl" xml:lang="en-US">Component of Operating Income [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="avxl_EquityOfferingAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingAgreementsTextBlock_lbl" xml:lang="en-US">Equity Offering Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of exercisable share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ResearchAndDevelopmentsIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentsIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentsIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentsIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ResearchAndDevelopmentsIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ProductOrServiceAxis_2_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_2_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Total number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_AgreementTerm" xlink:label="avxl_AgreementTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AgreementTerm" xlink:to="avxl_AgreementTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AgreementTerm_lbl" xml:lang="en-US">Agreement term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription_lbl" xml:lang="en-US">Description of purchases price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of share issued</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Gross sale proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:label="avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:to="avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate intrinsic value [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:to="avxl_RemainingAllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Description of grant option</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AgreementTerm" xlink:to="avxl_AgreementTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_AgreementTerm_doc" xml:lang="en-US">Terms of the agreement under agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalStudyGrantMember" xlink:to="avxl_ClinicalStudyGrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ClinicalStudyGrantMember_doc" xml:lang="en-US">Information by clinical study grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingAgreementsTextBlock_doc" xml:lang="en-US">Represents information related to equity offering agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NonOperatingIncomeFromGrant_doc" xml:lang="en-US">Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_OtherIncomeDisclosureTextBlock_doc" xml:lang="en-US">Disclosure of other income disclosure.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreement1Member_doc" xml:lang="en-US">Represents the information pertaining to purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreementMember" xlink:to="avxl_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreementMember_doc" xml:lang="en-US">Terms of the purchase agreement under purchase agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrantsMember_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:to="avxl_RemainingAllocatedShareBasedCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense_doc" xml:lang="en-US">It represents as a remaining stock based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_doc" xml:lang="en-US">It refers to amount of research and development incentive income during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_doc" xml:lang="en-US">The number of exercised in period made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_doc" xml:lang="en-US">Represents information related to share based compensation arrangement by share based payment award equity instruments other than options expired in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_doc" xml:lang="en-US">Represents information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average expired price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2019Member_doc" xml:lang="en-US">Represents the information pertaining to stock option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodValueAcquisitions2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueAcquisitions2_doc" xml:lang="en-US">Stock issued during period value acquisitions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodSharesAcquisitions2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesAcquisitions2_doc" xml:lang="en-US">Stock issued during period shares acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_doc" xml:lang="en-US">Commitment shares issued shares underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_doc" xml:lang="en-US">Commitment shares Issued value Underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_doc" xml:lang="en-US">Commitment shares issued shares underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_doc" xml:lang="en-US">Commitment shares issued value underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentsIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentsIncentiveIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentsIncentiveIncome_2_lbl" xml:lang="en-US">ResearchAndDevelopmentsIncentiveIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>avxl-20200331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by Electro Filings, LLC- http://www.electrofilings.com -->
    <!-- Field: Doc-Info; Name: Source; Value: avxl.xfr; Date: 2020%2D05%2D07T02:18:27Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/DocumentAndEntityInformation" xlink:href="avxl-20200331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20200331.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20200331.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20200331.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20200331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20200331.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20200331.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20200331.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20200331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20200331.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20200331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_DocumentAndEntityInformationAbstract" xlink:label="loc_avxlDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommonStockToBeIssuedMember" xlink:label="loc_avxlCommonStockToBeIssuedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_avxlCommonStockToBeIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodValueAcquisitions2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlStockIssuedDuringPeriodValueAcquisitions2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaapOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="loc_avxlEquityOfferingAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_avxlEquityOfferingAgreementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ResearchAndDevelopmentsIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentsIncentiveIncome" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_avxlResearchAndDevelopmentsIncentiveIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaapOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ClinicalStudyGrantMember" xlink:label="loc_avxlClinicalStudyGrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlClinicalStudyGrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_NYCBiotechMember" xlink:label="loc_avxlNYCBiotechMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlNYCBiotechMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseAgreementMember" xlink:label="loc_avxlPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_AgreementTerm" xlink:label="loc_avxlAgreementTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlAgreementTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:label="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200331.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="loc_avxlRemainingAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlRemainingAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001731122-20-000447-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-20-000447-xbrl.zip
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MI"F:\A?MG6+@7Z/OBO9:';_61O]?Q<%C.TZB='#E4>%_V.M_?9R$GOL:_Y8
M/7[T^C%R?WJ16]6#/@C"^2M-4=17__O+I]OI'5G85ZX?Q;8_)2_$6[#F/\K>
M4RW+>D6_%8^N/8F3BSGT5_CUQ(ZRD1' +<^O00+?.G'Z0OYAXQ7[LO"H6_JH
MR1YUQ:,.67DN(M/!/+A_!5_ \ZIUI:A7NBH>#\EL(\CF*_A6/.A&P5!31]O6
MQYX0+R31U=RVE^D+,SN:T(?Y%R7 P#=AX)&H]!WZ3<E+?N#[R:(<+B<.7\5/
M2_(*'KJ"ITCH3M/W=K]4? %@P(_+H:/?E$ W#1(_#I_*MX1_B:^-5EY+PA".
M_*;W^+<E\T5AO X??%CR*![?]%G;M^_)([*"5WB,%1V>$X<6"?UU1(_3-S*3
MZ!EY?4<I!\>X$B\,'B/G!?\:\?'3B\A=+#T@^%=B*':(IX$?D\=8<IV?7GP(
M@P6%354 O#C P:X4_2J;/WV-^+$;/Z6?II^[#GXS<TDH42A)85\%TFX^_L^+
MOP$[475UJ!C:7U^MOIQ-]ZIT/C[;$F@B<-:A@,,=QL@(_Y8M1XR4?;?V&O$=
M_I)8=S:]4WA%?%X 0'S(4;H9S]?1E]G9XI:QSK@$2>*;)I&DCJ\4ZTI7SA9)
M8@'M((F?V'%V8I&SG"%5%4[L>(\3*];=SHGE>#9S>!ZQ??W'-(GB8/&/&V"U
M[M3V;N/$>?HYA"W^A2PF)#S9/F2H)?,%R5%<^I4#P#PN/7?J<E@EQX4GF:8+
M<NKUUS!PDFG\);PEX;T[)=>/;O3B;RAG7F]:[E]?E8Z<A^I5.5@-T(VY#]V,
MBN>S#;I!1CF\TBPA40T 4M#-^W\EL-POLQF,[\]O;5"LKN<A(8@;AKN4P@#)
M0?C!C?^<D]#VG&O?N0G.F\BX^OGZ.V@H7V;7(=#1G*X\1VF[$;2;YJK  CKY
MZT]D;GOO*>[RM+X9\:<D=T%5M14;(W=&6F&3*^+H#.5W(^*H;;:B&@B82MD*
M^UE+V<K7))S>@4&\@9=\<OUIX/E?[?"/&WOIQK;W(?&=3Y]N+I^?;,!,VTQD
M!\9/*C<Y'=4C<$YPK1(X'"(3_B\8"?P\VDC@:D_AFRA<[4F<4U)M'HXD=TQ9
MB29,S\-['EZ;P#MK,Y=X$WL>WO/PBW#D[B;QWKSOS?MG1.X'<O1_<(KYQTVP
M6 3^;1Q,_[C\(W"VO+X. C"E@"Z.'7C8X&7@PZ\1 T@\MK;Q_1'<$A5;/7:_
MVTA@<7099^;ZP0X=/#@E9Z6XTF,3R;'">\5 <;_;I][MHT2\K?YL=V.W5WWX
MQPC=]SM_NIT_CZ!/!>V[)YA>5]RH*U+=^LLR!AQ_]6P?(SF702>X&DQ?SI')
MQK4^+X6QW_)GIS7V6W[YJN,63:#?_EX=J&]P]%1S:JHY*ZM#..M_)CX&3JY]
MY]I9N+X;Q:$=N_?D_>,2-H)<!@E]]*?!@J1>[$_!U$;:*7JO*V&B9TMU">P;
MB8@-!A_@]1VY)UZPI(&$9T=>%?#0$U?5)*N>>YT?]^ILDM,V NNYUWEPK\X2
M5RT[S[H,BJJDL5L=H)JNRCR<0UVG&G99_1_7O[X[5PK!BXDW?!V,.L2J7L.J
M3DD+ N4=HH7,'VQ<*:,SNX15]* :N4S\4V19:)?!6*M$T[13NT^/X3'?M=_J
M\]GOROF&Y[G?6V_:] +Q6:G46;3L#(MD%.-+QPHIGC62V@["E:G99X:PCJNP
MV55@]>IR2MQ8>^#Y&,Z&4K/Q8F]EG..EA X>T51>J%I/+AT@EX((I'MR%$.J
MW_?.[/O)#*J>!CHD*KIK?XF<Y)Y<.L,RCI&8W+.)#NY[JZZ$"E;%M>.X&-2S
MO:^VZWST^5WD9T4/6W'06QM5K(V>C#I&1B>V0GIZZ"P]G-PZZ6FC8[1QGE9+
M3T8=(Z,36S,]/727'DYEY8CJ;IG!]SUX2SY&44*<9T$8K,;:YN7WULTVZZ8G
MGXZ1SXFLFIX..DL')TQ>ZVFB4S1Q7E9,3SX=(Y\362\]'727#DX=F_E&8MOU
MB?/>#GWL3_LLZ"&[L%BV^-Y>J1*-Z0GGY(1SXOA+3P$=HH"31UQZ:C@Y-9R7
M==(33F<(Y\11E9X"ND0!1[!(RN[Z]!F#I\X8[/CUI51\]'=0.D$N!:'1HO51
M@67T8?F.A>7/DY7T9-0Q,NH B^E]YQWSG9\7:^G)IV/DTP&6TIN]G3%[SXN9
M](33&<(Y%ALI4L"9U4,Y.J_=7&"\]Q)TPZG4M5*J*[UU>G+ICE/I5 UV>F]
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MC:&EY<7#CFD;@;/N\3 4<SS6AT<&$U$XO-(L@4X#0!8GAJ40?9F!+$6=W_9
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MH:G]Q=5^*RUZ&[508-W2=M977YVV(4CK%]3?6;E\$Z1"]?T2SFW?_9/Z$V]
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M8/$\*:0]/ G%5 X/%)8)KQD^"T+V?4CL6.#1)TD8.&1.Z\FCMD*9+O\TQ3A
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M*=--85F?8378#E,(OEV(J+-YF=&Y"!SB78FB+'Q"L*1I'C9=++Z54R:#,(6
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M:/L1I6HU0I0:ZU#':(C_0L'(DY%<0D;KW#>WZ;SWR79'_^J=&T#S]72*3B!
MQ]<P\.''*6N-<>T[-]3M$GWT\\_ 0MRE1_9L9M('#_8)'E2\%-MN\. ;05JN
M%SW("$<J4E<?4#@CU0=>=C,*X(ZD:R=8HO-K^Q:[Y5M\.;CI# $<OI://H7S
M YF$"9@O*/!,>"Q8NE-I/ 0UYQ.Q40?!N( ;10ESC(*QY-E30@64QQX(R;\2
M-^0=ED",B2$4,02+,BS0,'7<V0Q,92 :.OF$Q _HE@4#[-X-DDCZ=7 [D'Z^
MOOY*Q64*#/HGN&V&#E!Z?1&D) 4 ;R.2F+628A^ V37!/$&T<L$6 ND5$6Y+
MQW=!) !G9K4'K[LS%YW D7!Q G'SM5$CN02\@73-QY6BNR#QG,PW*Z(M$]NS
M89WP/2%@>*=0/2$:%V!WT_D9Q$L6]H^8!5A<!:B8U#W-TB6N@ME5(A:=F:XT
MR@/OTV=P GP&QZ(+\)[P>_8*#X'D)H])N!A('^!SOFCT[F(<!3Y'+*N:T)'H
M(Q%0D2T6#_L"*%NX<<S( ]<%X$IVQB:6@>=.GR3BH:X#^P8[0I$NS.4U"/T@
M9I0F$+I[FP?2QUD&% (1,6^VF!7TJWAMIW(XX!HWQ4Z4@,+%4<%[F:'# [TM
M:-337?!<GY; <7D +-LVADTD^!P.[.720Q*#M3,H81J78<"# X\F!S!2JG\Y
MT@R4*AC0CM/7-E/A]YQ^2M?*MH':"< $N5MH&:+?!R-EN$['I?P:)\_VCDW!
M8F.V'[$C-D]<A](P@P;O!!-'QD@)K(F%2# .,(^8H@P(CX.0SL-P(0[7E(<-
M +()?&J'H<NCBX!O>ID922Y(D*!QFZ,(3P/09!+B)$4U/+=,I)0Z9$*W-W?X
M=Q$ZWT>'7Y@6(1+:3A"AAL^^3., (YC<8@ &YU"P:&L\ZED%J*?Q2ONZ_S<2
M%D#BL;9T67!%EF:N#UAW 8W8T<YE]$O]?S-L4L><H-E#69#&24V Z.3.F5[8
ME@A;VE@> ]V,I#]<W[X5LO7Z]E?I<S"@WUXI(UG*EUFXHKE@A8^DETPZCM3Q
MCZ^ECPMT&7,9#"?C<^ 37K]!HMEE5S2]C +!<\QRJIQP.T= K!X*0R9M<PR,
M\D4Z#O,]IP*+GL)T+G;"YD'@L!,8L=H15 Q3E(K4!N#&]/#5F":=0V:O"E\W
M>9P2EA#'CJL/VY R+E1>"*@<U,PNR#[!3K(DA9+3C&MXL%,5Q^$<3/#ED,1A
MD',;I4N:)HL$+RM@JTLZ>SYT"ZQ4 "'J-;BHTV";"1R8<<L6>8_$^8Z0P#WO
MN6C>LV+0,7-NDQD'G".6_@Y:&#?XNF/6]9M:(E#>P9;2#*K,7;DJ5)A_#NPY
M[I$>OKEE;/Y)>)2OBPR8N1,Q:@DPO+R^O9%&0^7']&TA+%S6>)>V6:1>U4#(
MCR?IW@ZIIFI3YABEJ3/PS JWYX[2F$XV02?K(KC'+]?9NU!L17_A9>J<A%$H
M"%PB#IFS%;3/D*^2Y?<0E@U''EV6+I:IMP&R2A2@M',PAG/]N,B,<YBDP?)5
MF9+&"2E/7>'-FCJ0WMN8.I?R\[SA5%3CX1OJ]$?7BT3N6>(WWRG!T$6NCE@
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M)@YXP<!XNX2/;</OTA-S\&U7S,'S><^V?2*MA"DH*!Y;NOZE(%:L4(#42E8
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M<3QP+; R!DI&3'9K'R0HL4SP4,F;:[?(0,DX>^U4/DA,XGC@02(W(2Y9^ P
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ME*UKT=E%AD+,.C0:1("P(9=, 0Y!C!@U(N1.X%&8,GJ.5]*N^L^VP" 3JL!
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M!EQ.O8RF9J'_T&2[CUZ$:4K>_-1+TQ?BWK/'/Q6--N2UFNNV3W-J%W)-&,'
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M%J \MJUG)\^NV.9O5DG%U=.^&Y;BQJ;W:J+<CAL5X1S>V\FM W8%P"BC96Y
MGO#2H>'Z\W(5)2^X..BJF+\B)@L[2R$.P?Z! WXHEN6L-]> T>MSHRL3=9M<
MJT:N#*#^3=-"G:8N<(Q3+V(!&R]8AG%(0S/L4<_:FXKT: _IG@?QP.(CCI(5
MNR!74$%3Z$W?B3<F9M2250T</;O..S3+UDO^7=]Y;)1*'$US(W:08A8<H0:
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MN5&(U^QBD9<]L&M$-%4%L;(9,?LTR_+]NCA72@9:G"9%96GTRT:)?K0.<':
M""/Y$L5)3NI8AKR4 WGQ9!YYQ'&0I!G;#IHG;(/?S6Z^43<;&X<&VPXB2F4:
M_D14+T1QY^V:=.')T?%[Q1$1)25 W&C$['E2G6Y- 1F8#\8#\V$W!N;#.$?B
MQ,;CRME1"V8?-">H6R/6Q0!KX RE-52LQ](TZ\Z$D\'-0WJ6"MPT._/)TC%C
MEY^SDUXS;8T3UA#W%5N:L*KA?(OU,A]OKU((I"$5U]V'C*F$=2<&52UWCU$5
MREL95C=WE9,E\;5H+_!6\=;RSU^I4\6.:E[-6R=\VZ,\O"A8H[YU.YHHV!18
MC+I A/AK71;*_"48Y]/EO<#LV2BX,"AI%V!AWHQN5/ 2A;W_NCN@,%"-X_&L
MQ?$NP*)'.[YK:V&*"X.2=@$6YLTP1@6W%M! 4;ZGE64XK]THK/]B.=%L35(Q
M7 J!6OF:V,^.NO$R].[I*PDASD[7:8KK=^S55("Z5R-<*V/XAO0 "6)7B92I
M \]O/&5\ZU;6\6VJWWX$T_$:X:3+%4'Z3X@3HUG.PZXL=4&>H&O/X7A4H#&+
M [/1Z>*!J21Z434JPR+BG-S1()4I-,1-,*G];Q$!&@:U;*TW@@M*5) ZZO,O
M29S4,Y=H'I=0$@,:@VX96[O9%0[$6=!KP:1](6S"8>%B7"89RSUPFL1$N#61
M3^ FB;-/>)ZDXH[=G?>,L\_/>>HE:1#&7OIRD>-E1AK&-K^2*.*O5[.7"64#
M.V%U@*!AHY7M6#S'$ZWU#<_TL*D8;6I&]ZSJ G^L\@-4KPP5M3D"I7"IRNX1
M.O()QW@>2G&EYP $#4-!6ZLKSE89M<*>H]>"UZ$%2>D+.F>8_WL15V!]@WT<
M/E+/3&$-3%@!#5]?B25:ROC0ZZ*$-_3,0E49T:88,"-Z37.#A8%FQN[B 3V&
M"E$-!T]P%PH)9M!FOD]ONV?7/*N;V:@UF$ /FTI6PW$KV)'@AS1PZ1H'E263
M\=@U^* /GTI<\Q&D):!*$:Y6-S@_];*':Y'S\-/+5W9 OEQ]S?P\?%0.I3DW
MH $=('1K081S1,M 12'TW-SKK_PT_ANT6;MNRG(TON*&1'8U/\/W>?$>VVF2
MR6/'&G) (V@B97/("AX:Q:=<J&!#C ^6^IV3U53L#U4_"3>@P1L@=$_U*XMR
MKWY42IJ%G_Q# X>/7D0QR ^[-"<6Z?*P!S^@,1XD=FOI2$>8AES9ATHY!XB7
MA"2SJ\-Q5HW?;^] C4LICJR_7;ZJ6;V&+MT+:A(!ZEBU;*V=($9Y@"JTSN:>
M)[&2H.?OTB0F'WU^0?$ZB4+_A?]7FFMX:!F ;-1@T=NST1/:E(3J11%;Q8I!
MW\2_M#S$"OP?.*GWLF&Y]YIL $9WB+3MT_TF[(ZT5BY<Y8(T#9ZGGI_?)=<\
MF]EYDK*KT%DME23+JB]3Z5$K ("(:=NEP@YS7"KUH$I%!ZBHBNWZ\\K8C2]>
M'?V]<G.<UPCJO>LQDLY\2>)'G.58//2FG/%M5 [-D[#:9JF'(E[XK@%Q5L_6
M4Z43@B FR4%QP*4B#(<V3V$@Y&&;=UPB\I')!#(]R'>89<[]&2M@'2'5$9>2
M@=24[SY]E?MI!&9_]%8?2P)^=UJT ^FH_M0A:7> 4J&-?'NF0>Q!.G#Z8RX5
M@/4VP,ZPJ#OFTNW:@K[MGTZP<%=5 F!6F+YM$RS$RZ5VI59'B^VQ^H]I6%8H
M&'N%;@H(2JH!8%QMM&Y*&/)ZV>%#5C/]AM2]HU \3](Y#O,UO84J>4MCPFKV
M"(JZUDT)Q4J]&SSN*!"%QTX/@TXW*;<JV2,0JMLV)00KM>[XI#P@U&VYZOWT
M((='WZ;P*PMID!"G #A&H%<\RM6>U%D:'=_C5;]+!GF"5@_!>3;<<]U1M)O/
MA+8MN6'5NX3RD5MLS1G93VQK;0K[\<S+\;D7IBR=T/1AA4X1]@CK0UMN-QS1
M CXC050T1&7C";=W%/\59^V"IOR.L]"?#.G*RO;3$U>TT9KO7=;O'J'WW1UZ
MWSTAUCOT6 G126J#9G>G;:0UMZ(;I-6O+LDG\G7Q%?D/K8I\\_\!4$L#!!0
M   (  *$IU":P,>)2!P  !#L 0 5    879X;"TR,#(P,#,S,5]P<F4N>&UL
M[5WM<^,V<__>F?X/[#W33CI3GRWY\N)+TF=D2;YH'L=R;5W2],L-34(2&XI4
M0<IGYZ\O )(6)1$@0 %:T-9]\,DR7G;WMP 6B\7BI[\_+4+G$>$DB*.?WW7>
MG[US4.3%?A#-?G[W^?ZD=]\?C=XY2>I&OAO&$?KY712_^_M__O,_.>3?3_]R
M<N+T,7)3Y#L/S\XP1%Z*8^<J"$D#R7\XU]?]$V>>ILN/IZ=?OWY]C[("T^SO
M[[UXX9R<E!N["E#H?W0&L7<RBJ;QC\Z-NT ?G?MXA3WTH_.;&Z[(K^[C4_C^
M:8I_= :DZX].]ZQ[]J_=P=FW],?WD[/NQ\X/'[O?_X]DXZF;KI*7QL^>SO)_
M6?6?"*U_?J0_'MP$.41@4?+Q*0E^?E=B[.OY^QC/3KMG9YW3__[U^MZ;HX5[
M$D14<!YZ5]2BK535ZUQ<7)RROQ9%=TH^/>"PZ./\M"#GI67RUT!0OD1)$GQ,
M&'G7L>>F#/?:;AQN"?K;25'LA'YUTNF>G'?>/R7^NT+X3((X#M$=FCKT_\]W
MHY=>W<A]1$]4%T[IGTX)/*L%BM)>Y ^C-$B?*59XP4@EY+.VYAA-?WY'U>"$
M8G]VGG7X-YFZZ?.2:'$2+)8A$<=I(QI'48IPL.C'D8^B!/GD0Q*'@4\'PJ4;
M4DG?SQ%*DSJ"E1LZ*/6W+B;"G*,T\-Q0&RN5K9KFBPYR1%4C&4_'2X292NP%
MC[C%0_+3=Y/Y51A_U<;.3H,'XX;T/7>C&4I&T7T:>W_.X] GJ]/P_U9D,&MA
M3ZH''?Q>KI(@0DDR0(F'@R75#C(M7;I)0"1\BU%"B)&:U)0;TD']'?+H/.IY
M\8I,I-'L%L<1^>AE*E)'LEQM'72.R42"1\1D6: ZHBJ*ZJ @TYSQ=$IT+YKU
M9AC)R:BNG@[:^O%B$:2L6:(R9#Q0,(B!%Z!:\B2JFM>S6S)\98A5:\6P9"?N
M0[B7?#<;..A<-$"I&X3)C8OI>O98.Z;V;ECS'*!*OT15DW.$*KFJ[1C6]+S;
M/51]JX7#T-O9G^#.82GN[D]Q][ 4G^]/\?EA*?ZP/\4?#DNQ]+31H"D1!\O2
MO'Y-OMBH@IY21.QOOVB(\K+77I]\35O(?3(=Y\0I:I4_NI'O9$TXY39RN@O*
MP]C;(#:D+I 8U\F/?O-%1&OO(4FQZZ5%0Z'[@$+6_!=:5Z[J:1-BJ6 3(EGF
ME4F0]WX6/Y[Z*#CMGG4NZ(<3^N'DK)/[9/Y&OOJ2$7&'9@'M.TJI'ZR"=%*T
MNN0VI66%Z&'/B3'94A'(BC9=[&VHP:X;*2]QNF2^@1-O'H0O&C3%\4)5EKG<
MXAI&RN(E)!P>@S[A!+OAB(R8IW^@9Q$(.T4E4>C8!P.':Q <"D8FI-UJ\6^6
MD)1ZUR:I5_$(*NQ;8K_&A 6?^N_%4M\J*BG^<QO%7\DU" X]0HY/2;H*W5FU
M_+>*2,K]@TURK^021-[]%:8\7@6)YX9_(!<+59]?6A*%;VU"H8YWP-7W*@C1
MS6KQ@+!HX2V7D@3@.YL X/$**'CJ<<'+.#LS8:[Y/O7<X>=^[ LMT9J*DO!\
M;Q\\4A*!-%2S47R'"(UT]Y@=F@OM54X-28Q^L \CL0Q AU.**.5D_TYF5C>G
M4SR.JFM(@G-A'SAB&0""<[]PP[#PDXLPV2HHO;VS#XM*E@$A&"X0GI$!^PG'
M7]-Y/UXLW4BXU^94D(7$PBVW4 3 )ACND^5N%F,A)%L%9:&P:A\N8!ER@IJC
M,)08%)OE9 &P:B?.9QC2M(H7BS@+1KF?$\Z3\2IE 9=DN H-+&$]67RLVK'+
M"P34?97M93-WSA7YCK.L"XK+HF/53KZ6?0M H0X&:4A*A64!L6IG7\-Z!1P_
MG>YP=TV^,'2\IQ[=NG'6UW5.G)>X/?)Y=#,9WHU^=?KCF\'PYGXXH)_NQ]>C
M06]"?KGL7?=N^D/G_I?A<'+O?/,Y<E=^0+KZ]T;'@#E/#-*IFSPP7%?)R<QU
MEYE"HC!-BF^V-3/_^DLI[O JB C' 1DY<1+4G!KFU>5J-QYK^[/72Q("7STC
MV^6@3A"5Y+HYWCB<Z)OY=*&1;WUE0=DI#G:N*)9P%0P<5NU @T91TW +\A^-
MVWIT0T0#,-*^B_$S,678?1,^.I+5P<XCI8"(F[!D$XA9;.#$?4()#3(E-#^$
M M XQ<%.+1N ).38#E!N,5JZ@3]\6E*S@N_NS,MSBH,=:38 1<BQ':!D[-2M
M-H!GF.K+2X6 ";531*3O7V<,<FEB!*5QZH:L)"@TUX'[$(3$ND$T_F_WVDN]
MJ2#? M@)Z?ZFG:J8[!AW):JE+3]1'; SU*8H<$&TVCK,+ZLDM^XS76!K%S%>
M>;#C5'EYQU*,6 8.7I$Y?H<W(3Z\*F"'JGM )&;?#I14X-D#%P,GK$V!D4*D
ME2:*Q'7#BBVRJ!+<8:V>A4SZ B;T,+PM](VQ6./5J"P,=YBK!RJ!!.R J'2B
M5N=UVBD)=]"K;QQ5\6X',CW?9UL3LDDA^_M1U'>7 9F02T0+3 Z)NG#'P'K0
MDY>/'7C>T?MT$?*'+HYHCB-B2JT6JY">> W0-/ "@8TB4Q?NX%@/GO+RL0-/
M?HZ0JM.ZW;)PY\IZ\*K+D=)>B[-.,,V=8?*HM\")(I2-5AVP-#:A.EW51J#"
MN:Y !>>;C=Z.@0L'VK00J8\QH]EG-N(MPBSR3'8?PZ_?WD '-0G9L5IOTIP%
M#_96Z3S&P5_K>:$.S=UZT"$1VF#DB<0.^$I6O?J(E*H,'2VQ!Y *PK$.3?F1
M**P$'4:A![W6C,&,T%&2K)00*RI QU?H1&M3")8B);XWP&.MR:T!8]X%G9C)
MW1JP9]=1DU!V8\?Q06W'<3\A__TZO"&[C?&5,[X=WO4F(U+ DB#I+.3LA9_Z
M[06W N!PS"&+9GF0ED14M* *\+ZA!I&MH5?+NAT3YB<4$3K#7N3W_$40L4Q0
M]+YP3C4?I]J*T/N#>@!B-89L@NV.R)+00".'!^@1A?&2JF0M:#75H'<"JI!)
M2<$.P'984Y@!X8U\56"XW*H[1R\R(R%",VH/3.SPD]_$45RPF"T+.:/UZYM$
M5>A-@MI")RV+?0<B)P<EZ7^\V?\58>@336A8@0*M(JP!;>W+BS.6Y,BH]*NG
M8$(#^4D6S\W4\ELX2-:%CIYNA(B27.Q8HM@^#"7I!H\W2+CEX-6 #IA6QJR6
M(YN0NHHQ"F91%N[H/4_(.$]HFI\X^N0&T76<))=H2LI,W"<^>$J-0$=4-\6S
M@:3L@)C+< /+ C[:NBE\M5)H>\!%QA350[I@9P&M*\+LVM>5Z6?I N+PB4B,
M !9$+GX>$1,M(5+R2$W"5\CDE$UA=9XB0YV"!Y WG_J-0]%V;<WCZU\DD OV
M$D5H*@KBJZL''I:NMN.1$\.^6UUXN(G=LQX4@G5GLQAXX+KB]K6*R;8/U"*2
MM#@$IX\/>70K$H0KHEKU7@KI!L CX=705A2,';9@#=&-4;0@$EX5#R4T6X4B
M>W5K$"1>&"<K+'-2UKA!\'AYK6.V3G!VH/\[V8;.J48_$FMREF<='T\90Z5#
M>>FAW;0]\-C[?=&,M8BA9:$/NX_/;D0^?+M/Y$._=_^+<W4]_MV6R(?RL[0%
MWTK1U16U8*UH2M MCA\#HA>7SY\)T*.UO[Y'\W-GUY<K]IP2!TJ:VK<G*IN+
M^J[IKE&R=JP39O=<QGPN>I%0VZ&!WE3]WU62W4>GGA\B N8%FL1WR"._T^=%
MRL1/8DDI2>0I--XS=#"(49TZ%'!VJ&EA:%$#8T%]56[Y,<F*M913'CH,Y6"H
MQ5+BL EBPC5&A,0!ROXO\9E?#Y>*()5N SI&Q>CLH"Y,6Y5 /56G7 /043(-
M$*J#6#;'9TN=^;L,;^;/5%&*[9K0$3H&M*%:.*]1#;9RSZGHP4Y5Z+ ? XK
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M>,T'3M- 5/Z-.3^X 7F5VVE#8T4G$>"/+;5FO.B'_@TX6.J$5K%E!QHTRI2
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MR;9*"3WGPH_(OXKQU8K>0Q^1+9(;B:Z2-F@*VCTGC61C,=F!<O4.6=7Q ._
MVO/"XMYAF^9N7]TA.K/3J->FY[6T&>56H-T_]8 V8LO^L2?AG1J@Q,/!LLE(
M56T=/!.I\8O(%<*T2#V:G.X090\P*RR5AEE/%]"[#35%T2E6B[2EB?YGF4;'
MT_4-T<R Z:W2>8R#OU"=_ICJ%'IK97[JD1>]TOE"_A?Z@RHQ^>;_ 5!+ 0(4
M Q0    (  *$IU 6\-^;*5T  (_2!  1              "  0    !A=GAL
M+3(P,C P,S,Q+GAM;%!+ 0(4 Q0    (  *$IU")YE[1B0H  %Q@   1
M          "  5A=  !A=GAL+3(P,C P,S,Q+GAS9%!+ 0(4 Q0    (  *$
MIU! &4_8\P@  ,9<   5              "  1!H  !A=GAL+3(P,C P,S,Q
M7V-A;"YX;6Q02P$"% ,4    "  "A*=0SXJB^T@2  # *0$ %0
M    @ $V<0  879X;"TR,#(P,#,S,5]D968N>&UL4$L! A0#%     @  H2G
M4*[F??F/+P  ?<," !4              ( !L8,  &%V>&PM,C R,# S,S%?
M;&%B+GAM;%!+ 0(4 Q0    (  *$IU":P,>)2!P  !#L 0 5
M  "  7.S  !A=GAL+3(P,C P,S,Q7W!R92YX;6Q02P4&      8 !@"* 0
&[L\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6773321696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Oct. 21, 2015</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross sale proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,365,492<span></span>
</td>
<td class="nump">$ 5,068,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember', window );">Lincoln Park Capital Fund, LLC [Member] | 2019 Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_AgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationDescription', window );">Description of purchases price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase.  The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park&#8217;s committed obligation under any single purchase shall not exceed $2,000,000.  The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2019 Purchase Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,014,425<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,964,584<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,365,492<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,841<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember', window );">Lincoln Park Capital Fund, LLC [Member] | 2015 Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_AgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,239,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,229,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,361,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember', window );">Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member] | 2019 Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,076,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember', window );">Cantor Fitzgerald &amp; Co [Member] | Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross sale proceeds</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Terms of the agreement under agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the nature of an unconditional purchase obligation that is not recognized as a liability on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763480240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recently
Adopted Accounting Pronouncements</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected to the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
results of operations, financial condition, cash flows, and financial statement disclosures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results
of operations, financial condition, cash flows, and financial statement disclosures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU 2019-12, &#34;Simplifying the Accounting for Income Taxes (ASC 740)&#34;, which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762425584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 1,700,753<span></span>
</td>
<td class="nump">$ 1,893,152<span></span>
</td>
<td class="nump">$ 2,965,177<span></span>
</td>
<td class="nump">$ 3,960,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">810,309<span></span>
</td>
<td class="nump">950,999<span></span>
</td>
<td class="nump">1,291,410<span></span>
</td>
<td class="nump">2,006,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 890,444<span></span>
</td>
<td class="nump">$ 942,153<span></span>
</td>
<td class="nump">$ 1,673,767<span></span>
</td>
<td class="nump">$ 1,953,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6773673040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,720,142<span></span>
</td>
<td class="nump">$ 2,061,251<span></span>
</td>
<td class="nump">$ 3,072,176<span></span>
</td>
<td class="nump">$ 3,822,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,053,047<span></span>
</td>
<td class="nump">6,078,786<span></span>
</td>
<td class="nump">12,401,715<span></span>
</td>
<td class="nump">11,790,996<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(7,773,189)<span></span>
</td>
<td class="num">(8,140,037)<span></span>
</td>
<td class="num">(15,473,891)<span></span>
</td>
<td class="num">(15,613,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">74,944<span></span>
</td>
<td class="nump">74,527<span></span>
</td>
<td class="nump">149,888<span></span>
</td>
<td class="nump">149,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">717,328<span></span>
</td>
<td class="nump">760,990<span></span>
</td>
<td class="nump">1,660,543<span></span>
</td>
<td class="nump">1,174,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">70,180<span></span>
</td>
<td class="nump">51,465<span></span>
</td>
<td class="nump">116,900<span></span>
</td>
<td class="nump">130,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss), net</a></td>
<td class="num">(325,960)<span></span>
</td>
<td class="nump">54,199<span></span>
</td>
<td class="num">(272,848)<span></span>
</td>
<td class="nump">49,693<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">536,492<span></span>
</td>
<td class="nump">941,181<span></span>
</td>
<td class="nump">1,654,483<span></span>
</td>
<td class="nump">1,503,685<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(7,236,697)<span></span>
</td>
<td class="num">(7,198,856)<span></span>
</td>
<td class="num">(13,819,408)<span></span>
</td>
<td class="num">(14,109,870)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(48,048)<span></span>
</td>
<td class="num">(9,214)<span></span>
</td>
<td class="num">(56,765)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (7,236,697)<span></span>
</td>
<td class="num">$ (7,246,904)<span></span>
</td>
<td class="num">$ (13,828,622)<span></span>
</td>
<td class="num">$ (14,166,635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">58,353,954<span></span>
</td>
<td class="nump">47,134,686<span></span>
</td>
<td class="nump">56,554,037<span></span>
</td>
<td class="nump">46,726,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to amount of research and development incentive income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6618724208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note 2</font></td><td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Recent
                                         Accounting Pronouncements</u></font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recently
Adopted Accounting Pronouncements</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected to the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
results of operations, financial condition, cash flows, and financial statement disclosures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results
of operations, financial condition, cash flows, and financial statement disclosures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU 2019-12, &#34;Simplifying the Accounting for Income Taxes (ASC 740)&#34;, which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6773439648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 5 months 9 days<span></span>
</td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">97.61%<span></span>
</td>
<td class="nump">105.96%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763531728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Component of Operating Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note 3</font></td><td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Other
                                         Income</u></font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Grant
Income</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant was being received
in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for
a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">The
grant income has been deferred when received and amortized to other income as the related research and development expenditures
are incurred. During the three and six months ended March 31, 2020, the Company recognized $74,944 and $149,888, respectively
(2019:$74,527 and $149,055, respectively) of this grant on its statement of operations within grant income.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">The
Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit
(&#8220;NYC Biotech credit&#8221;), and the Australian research and development tax incentive credit (the &#8220;Australia R&#38;D
credit&#8221;) through a program administered through the Australian Tax Office (the &#8220;ATO&#8221;), which provides for a
cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company&#8217;s
wholly owned subsidiary, Anavex Australia Pty Ltd. (&#8220;Anavex Australia&#8221;).&#160;Research and development incentive income
during the three and six months ended March 31, 2020 and 2019 represents the receipt by the Company&#8217;s Australian subsidiary,
of the Australian research and development incentive credit, (the &#8220;ATO R&#38;D Credit&#8221;), as well as receipt by the
Company of the New York City Biotechnology Credit (&#8220;NYC Biotech credit&#8221;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">During the
three and six months ended March 31, 2020, the Company recorded research and development incentive income of $717,328 (AUD 1,203,000)
and $1,660,543 (AUD 2,548,000), respectively (2019: $510,990 and $924,672, respectively) in respect of the ATO R&#38;D Credit for
eligible research and development expenses incurred during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">During the
three and six months ended March 31, 2019, the Company recorded research and development incentive income of $250,000 and $250,000
respectively, in respect of the NYC Biotech credit.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other income disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6765558064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,236,697)<span></span>
</td>
<td class="num">$ (7,246,904)<span></span>
</td>
<td class="num">$ (13,828,622)<span></span>
</td>
<td class="num">$ (14,166,635)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,700,753<span></span>
</td>
<td class="nump">1,893,152<span></span>
</td>
<td class="nump">2,965,177<span></span>
</td>
<td class="nump">3,960,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,509,202)<span></span>
</td>
<td class="num">(1,210,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,439<span></span>
</td>
<td class="nump">439,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,402<span></span>
</td>
<td class="nump">2,434,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,062,755<span></span>
</td>
<td class="nump">51,345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,988,051)<span></span>
</td>
<td class="num">(8,491,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,365,492<span></span>
</td>
<td class="nump">5,068,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred financing charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,365,492<span></span>
</td>
<td class="nump">5,018,834<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase (decrease) in cash and cash equivalents during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,377,441<span></span>
</td>
<td class="num">(3,472,793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,185,630<span></span>
</td>
<td class="nump">22,930,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 26,563,071<span></span>
</td>
<td class="nump">$ 19,457,845<span></span>
</td>
<td class="nump">$ 26,563,071<span></span>
</td>
<td class="nump">$ 19,457,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6765641728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,664,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>24
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W$W;>V(/]Q\970=G"K[N07U!+ P04    "  "A*=0F5R<(Q &  "<)P
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MI&'/#$4* A/YHR1J8GE!T(L&=FMNMH3G#1?-031I=$(#>UDSS!MCV@!,BX+
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M@L,S3/W<4C(U_QDNH$)Z5!)JE*A<^I*R=Q[UQ!*D:/$VGM*D<YCXK[!U )\
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MG\T\9K/A<%A^$%N_<?4;4$L#!!0    (  *$IU )DT 9M $  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;'U3VX[<( S]%<0'+#-,]J)1$FEG
MJZJ56FFT5=MG)G$2M%Q2()/MW]>0;)JV45\ &Y_C8V/RT;H7WP$$\JJ5\07M
M0NB/C/FJ RW\C>W!X$UCG18!3=<RWSL0=0)IQ?AN=\>TD(:6>?*=79G;(2AI
MX.R('[06[N<)E!T+NJ=OCF?9=B$Z6)GWHH4O$+[V9X<66UAJJ<%X:0UQT!3T
M<7\\93$^!7R3,/K5F<1*+M:^1.-C7=!=% 0*JA 9!&Y7> *E(A'*^#%STB5E
M!*[/;^SO4^U8RT5X>++JNZQ#5] '2FIHQ*#"LQT_P%S/+25S\9_@"@K#HQ+,
M45GETTJJP0>K9Q:4HL7KM$N3]G&ZX?<S;!O 9P!?  \I#YL2)>7O1!!E[NQ(
MW-3[7L0GWA\Y]J:*SM2*=(?B/7JOY?Z0Y>P:B>:8TQ3#US%+!$/V)07?2G'B
M_\#Y-ORPJ?"0X(<_%-YN$V2;!%DBR/Y;XE;,W5])V*JG&ER;ILF3R@XF3?+*
MNPSL(T]O\CM\FO;/PK72>'*Q 5\V];^Q-@!*V=W@"'7XP19#01/B\1[/;AJS
MR0BVGW\06[YQ^0M02P,$%     @  H2G4.(/GI*W 0  T@,  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL;5/;;IPP$/T5RQ\0LRQIMBM RJ:J6JF5
M5JF:/GMA "N^4-LLZ=]W; @E*2^V9SSGS)GQ.!^-?78=@"<O2FI7T,[[_LB8
MJSI0W-V8'C3>-,8J[M&T+7.]!5Y'D)(L39(/3'&A:9E'W]F6N1F\%!K.EKA!
M*6[_G$":L: [^NIX%&WG@X.5><];^ '^9W^V:+&%I18*M!-&$PM-0>]WQU,6
MXF/ DX#1K<XD5'(QYCD87^N")D$02*A\8."X7>$!I Q$*./WS$F7E &X/K^R
M?XZU8RT7[N#!R%^B]EU!#Y34T/!!^D<S?H&YGEM*YN*_P14DA@<EF*,RTL65
M5(/S1LTL*$7QEVD7.N[C='.;SK!M0#H#T@5PB'G8E"@J_\0]+W-K1F*GWO<\
M//'NF&)OJN",K8AW*-ZA]UKN]G<YNP:B.>8TQ:3KF"6"(?N2(MU*<4K_@Z?;
M\/VFPGV$[]\H/&P39)L$623(WA!\?%?B1DR6O$O"5CU58-LX38Y49M!QDE?>
M96#OXR.R?^'3M'_GMA7:D8OQ^+*Q_XTQ'E!*<H,CU.$'6PP)C0_'.SS;:<PF
MPYM^_D%L^<;E7U!+ P04    "  "A*=0((YGJ+8!  #2 P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6QM4V%OW" ,_2N('U N7+K>3DFD7JMIDS;I
MU&G=9RYQ$E0(&9!+]^]G2)IE7;X -G[/S\9DH[$OK@7PY%6KSN6T];X_,N;*
M%K1P-Z:'#F]J8[7P:-J&N=Z"J")(*\9WNP],"]G1(HN^LRTR,W@E.SA;X@:M
MA?U] F7&G";TS?$DF]8'!RNR7C3P'?R/_FS18@M+)35T3IJ.6*AS>I\<3VF(
MCP'/$D:W.I-0R<68EV!\J7*Z"X) 0>D#@\#M"@^@5"!"&;]F3KJD#,#U^8W]
M4ZP=:[D(!P]&_925;W-ZH*2"6@S*/YGQ,\SUW%(R%_\5KJ P/"C!'*51+JZD
M')PW>F9!*5J\3KOLXCY.-W>'&;8-X#. +X!#S,.F1%'YH_"BR*P9B9UZWXOP
MQ,F18V_*X(RMB'<HWJ'W6B1IDK%K()IC3E,,7\<L$0S9EQ1\*\6)_P?GV_#]
MIL)]A._7V?G';8)TDR"-!.D_!(=W)6[$I.]5LE5/-=@F3I,CI1FZ.,DK[S*P
M]SR^R=_P:=J_"=O(SI&+\?BRL?^U,1Y0RNX&1ZC%#[88"FH?CG=XMM.8388W
M_?R#V/*-BS]02P,$%     @  H2G4#WH\CKJ 0  9@4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL=53;CILP$/T5Q >L"9>$1H"TV:IJI5:*MNKV
MV8'AHK4QM9VP_?O:AE#*3E^P9WSFG!F;F6P4\E6U -I[XZQ7N=]J/1P)464+
MG*H',4!O3FHA.=7&E U1@P1:N2#.2!@$>\)IU_M%YGQG663BJEG7PUEZZLHY
ME;]/P,28^SO_[GCNFE9;!RFR@3;P'?2/X2R-11:6JN/0JT[TGH0Z]Q]WQU-J
M\0[PTL&H5GO/5G(1XM4:7ZK<#VQ"P*#4EH&:Y09/P)@E,FG\FCG]1=(&KO=W
M]D^N=E/+A2IX$NQG5^DV]U/?JZ"F5Z:?Q?@9YGH2WYN+_PHW8 9N,S$:I6#*
M?;WRJK3@,XM)A=.W:>UZMXXS_ST,#PCG@' 30"8AE_E'JFF123%Z<KK[@=HG
MWAU#<S>E=;JK<&<F>66\MV(71QFY6:(9<YHPX1JS((AA7R1"3.(4O@L/\? (
MS3!RX=%:/4IQ@A@EB!U!_$^)\:9$#)/@(@DJDB $^XT(ACG@(GM49(\0I!L1
M#/,!%SF@(H?W!$FP$<$P__DG4E0D10C"C0B&B38B9/6?<Y"-ZW#EE>+:N^FR
M\BY#Y#%T??(7/DV@;U0V7:^\B]"FVUQ/U$)H,*D$#^;I6C/T%H-!K>WV8/9R
M:OW)T&*8IQI91FOQ!U!+ P04    "  "A*=02)UAJ"0"  #H!0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6R-5-N.FS 0_17$!RQ@,+F((&TN52NU
M4K35ML\.F02T!E/;"=N_KVT<0H!N^X(]PSG'9WR9I&'\3>0 TGDO:256;BYE
MO?0\D>50$O'$:JC4GQ/C)9$JY&=/U!S(T9!*ZB'?C[V2%)6;)B:WYVG"+I(6
M%>RY(RYE2?CO-5#6K-S O25>BG,N=<)+DYJ<X3O(UWK/5>1U*L>BA$H4K'(X
MG%;N<[#<88TW@!\%-*(W=W0E!\;>=/#EN')];0@H9%(K$#5<80.4:B%EXY?5
M=+LE-;$_OZE_,K6K6@Y$P(;1G\51YBMW[CI'.)$+E2^L^0RV'NPZMOBO< 6J
MX-J)6B-C5)BODUV$9*55459*\MZ.167&QNK?:-,$9 FH(P3X0T)H">'_$B)+
MB.Z$Z$,"M@1\)\1F>]O:S69NB21IPEGC\/8ZU$3?NF")U7%E.FE.Q_Q3^RE4
M]IH&.$J\JQ:RF'6+03U,C!XAFS$D>$3L)A 8=QA/F>R<HBFG:S1V$0Y<C"$#
MG]M_B^S&D#">]AE.[FAH^&&_4/07@6A2(#("T<-.Q8-*6PPVF*K%^-$\1O$
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M=Z^I>6^&B\S0T&H_7M*B\TUQ]@]02P,$%     @  H2G4(@@T^N0 @  U@@
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M3<(9DF 1B>,G2X/);5A@'118.X'UFU-(O5,(8;9>(2',!T8V02.;@, 7ST@
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M!A7?:ON:F7?9=1/=0(NV[Y2BH5V;_P=02P,$%     @  H2G4&JJQ(=4+@
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MUC78]8L72Y4M$- ?LO2AN(=M+E=A4J,S#[^ $D#-(LUJ@R;3J8+G\'3&(]N
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M1=3K.7DK!(B<Q+_>JVBI,CN97BH >P]=D3Q-JH\(R!40+)YU'&^TF]U\A,*
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M@'#@/(19X%WGIB-_F$S>V&4XC,)8R4Q^"Y@45LX0\_$F ,+)"@SG1%[BEO@
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MO1&/*RD[H)>80E3X1AXN54EZP1;!ZLF%AI@EJ:6HL@ ")6K#A7!H^3H&+!C
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MIZVZHF!B^,! F/?-C/('X"%\\8?EW8^[)Q)F(OT:^QIZJC,PG6>A?%7,.H\
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M6)'&D'EE?74;PE#1JFC9JG]<WD;-Q:%]J*M*64'UL U1:?+V:!B3M'A],*]
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M5L:P9&6(BB;U!#JNQM.%[NJC)[A;EBQKS5=HF<0)-<$Q'0_E2V#4H*P!>9C
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M-[DY%*1E^LXNT043/-H?K?!H,<Q:#A0)'NU/D-.67[J"XYLS_0902P,$%
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M_$7R:>UB7Y_DG_#I-U!+ 0(4 Q0    (  *$IU ?(\\#P    !,"   +
M          "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  *$IU GZ(<.
M@@   +$    0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L!
M A0#%     @  H2G4(1&K7_N    *P(  !$              ( !F0$  &1O
M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @  H2G4)E<G",0!@  G"<  !,
M             ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  "A*=08FGPRZ,"  !R"@  &               @ 'W"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @  H2G4'0AM:[R @  ] H  !@
M             ( !T L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    (  *$IU"J\?.W&0(  *<&   8              "  ?@.  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  "A*=0=:4QU1$$
M$0  &               @ %'$0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @  H2G4-3E_^J( P  ZPT  !@              ( !CA4
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  *$IU!\5P['
MRP8  .LF   8              "  4P9  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    "  "A*=0)Y]TLK !  #2 P  &
M@ %-(   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @  H2G
M4+56:,BU 0  T@,  !@              ( !,R(  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    (  *$IU!WT#&/LP$  -(#   8
M      "  1XD  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  *$IU!(G6&H) (  .@%   9              "
M >XM  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @  H2G
M4$UW_^6D @  ]@@  !D              ( !23   'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    "  "A*=0**(7(3<#   U#@  &0
M        @ $D,P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   (  *$IU"((-/KD (  -8(   9              "  9(V  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @  H2G4 BWFJ[^ 0  " 8
M !D              ( !63D  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    "  "A*=0]PC) 1T#   A#   &0              @ &..P
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  *$IU!HZP7W
M= (  )L'   9              "  >(^  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @  H2G4(JG$3,+ @  _04  !D
M ( !C4$  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  "
MA*=0OPW&AKL"  "Z"0  &0              @ '/0P  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  *$IU!JJL2'5"X  'VX   4
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     ? !\ 2P@  (]]      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762667872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Purchase Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, at beginning</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">678,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(319,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod', window );">Granted</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, at ending</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, at beginning</a></td>
<td class="nump">$ 4.19<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice', window );">Granted</a></td>
<td class="nump">3.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, at ending</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of exercised in period made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to share based compensation arrangement by share based payment award equity instruments other than options expired in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average expired price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6754475472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of exercisable share purchase warrants outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price ($)</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White; width: 0.75in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Balance, September 30, 2018</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">678,379</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.87</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Exercised</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(8,750</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.13</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Expired</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(319,629</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.46</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Balance, September 30, 2019</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Granted</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.17</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Balance, March 31, 2020</font></td><td style="border-bottom: Black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.88</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020, the Company had share purchase warrants outstanding as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Expiry
    Date</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 25%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 25%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 44%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June 30,
    2021</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.17</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May
    6, 2024</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price ($)</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Grant Date Fair Value ($)</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate
    <br /> intrinsic value ($)</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White; width: 72px"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2018</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,506,917</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.83</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,353,088</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,265,399</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.79</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.27</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(309,383</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.25</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,462,933</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.58</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,115,032</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,525,000</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.86</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.17</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(1,667</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.64</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    March 31, 2020</font></td><td style="border-bottom: Black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,986,266</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.47</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,517,080</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable,
    March 31, 2020</font></td><td style="border-bottom: Black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,925,642</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.70</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,815,680</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These amounts have been included in general and &#9;administrative expenses and research
and development expenses on the Company&#8217;s interim condensed consolidated statements of &#9;operations as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="background-color: White; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Three
    months ended<br />
    March 31,</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Six
    months ended<br />
    March 31,</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White; width: 0.75in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">General and administrative</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">810,309</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">950,999</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,291,410</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,006,587</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Research and development</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">890,444</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">942,153</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,673,767</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,953,552</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Total share based compensation</font></td><td style="border-bottom: Black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,700,753</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,893,152</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,965,177</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,960,139</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest
    rate</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.68</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.91</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.44</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.59</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">97.61</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">105.96</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Dividend rate</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763480240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note 1</font></td><td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Business
                                         Description and Basis of Presentation</u></font></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Business</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated
therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex
analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic
benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound ANAVEX&#174;2-73
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system
diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in
the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Basis
of Presentation</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission (&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the
annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
In the opinion of management, the disclosures are adequate to make the information presented not misleading.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring
adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated
balance sheet as of September 30, 2019 was derived from the audited annual financial statements but does not include all disclosures
required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K
for the year ended September 30, 2019 filed with the SEC on December 16, 2019. The Company follows the same accounting policies
in the preparation of interim reports.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Operating
results for the six months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year
ending September 30, 2020.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Liquidity</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least the next two years after the date that these interim condensed consolidated
financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to
change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but
not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels
based on the timing of future clinical trials.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
than our rights related to the Sales Agreement and the 2019 Purchase Agreement (each as defined below), there can be no assurance
that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable
terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to
delay or scale down some or all of our research and development activities.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World
Health Organization (&#8220;WHO&#8221;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus
beyond its point of origin.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
global outbreak of COVID-19 continues to rapidly evolve as of the date these interim condensed consolidated financial statements
are issued. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s financial condition
and future results of operations. Management is actively monitoring the global situation on its business, including on its clinical
trials and operations and financial condition. Given the daily evolution of the COVID-19 situation, and the global responses to
curb its spread, the Company is not able to estimate the effects of COVID-19 on its results of operations or financial condition
for the year ending September 30, 2020.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">On
March 27, 2020, the President of the United States signed into law the &#8220;Coronavirus Aid, Relief, and Economic Security (CARES)
Act.&#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer
side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to
the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections
to tax depreciation methods for qualified improvement property. The enactment of the CARES Act did not have any impact on the
Company&#8217;s interim condensed consolidated financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">Use
of Estimates</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors
that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent
there are material differences between the estimate s and the actual results, future results of operations will be affected.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Adjustment
of Prior Period Financial Statements</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
previously disclosed in Note 1 to the Company&#8217;s consolidated financial statements included in the Company&#8217;s annual
report on Form 10-K for the year ended September 30, 2019, the Company adjusted amounts to previously reported consolidated financial
statements which were immaterial. These adjustments were identified in connection with the preparation of the consolidated financial
statements for the year ended September 30, 2019 and related to the timing of recognition of research and development incentive
income. Previously the Company accounted for research and development incentive income when received in cash. During the year
ended September 30, 2019, based on a continuing assessment regarding the Company&#8217;s eligibility for the incentive programs
under which it was receiving such income, the Company determined that the income should have been accrued and recorded in the
period in which the qualifying research and development expenditures were incurred.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These
interim condensed consolidated financial statements for the three and six months ended March 31, 2019 have been similarly adjusted
to reflect the adjusted research and development incentive income for the three and six months accordingly in the amount of $510,990
and $924,672, respectively and should be read in conjunction with Note 1 to the Company&#8217;s consolidated financial statements
for the year ended September 30, 2019.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">Principles
of Consolidation</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the
laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">Fair
Value Measurements</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 0.75in"><font style="font: 10pt Times New Roman, Times, Serif">Level
    1 - </font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">quoted
    prices (unadjusted) in active markets for identical assets or liabilities;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Level
    2 - </font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">observable
    inputs other than Level 1, quoted prices for similar assets or liabilities in active &#160;markets, quoted prices for identical
    or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or
    whose significant value drivers are observable; and</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Level
    3 - </font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">assets
    and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
    to the fair value of the assets or liabilities.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020 and September 30, 2019, the Company did not have any Level 3 assets or liabilities.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">Basic
and Diluted Loss per Share</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Basic
loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except
that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into
shares of common stock that were outstanding during the period.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, loss per share excludes 10,486,266 (September 30, 2019 &#8211; 8,812,933) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760513760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">58,664,946<span></span>
</td>
<td class="nump">52,650,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="nump">58,664,946<span></span>
</td>
<td class="nump">52,650,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760549104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">$ 74,944<span></span>
</td>
<td class="nump">$ 74,527<span></span>
</td>
<td class="nump">$ 149,888<span></span>
</td>
<td class="nump">$ 149,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">510,990<span></span>
</td>
<td class="nump">$ 924,672<span></span>
</td>
<td class="nump">717,328<span></span>
</td>
<td class="nump">1,660,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_NYCBiotechMember', window );">NYC Biotech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 1,203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember', window );">Clinical Study Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 597,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_NYCBiotechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_NYCBiotechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6763565904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note 5</font></td><td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Commitments
                                         and Contingencies</u></font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">a)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">Leases
                                         </font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">During
the three and six months ended March 31, 2020, the Company incurred office lease expense of $60,861 and $110,915, respectively
(2019: $40,507 and $78,261, respectively).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">b)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">Litigation</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">c)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">Share
                                         Purchase Warrants</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price ($)</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White; width: 0.75in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Balance, September 30, 2018</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">678,379</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.87</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Exercised</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(8,750</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.13</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Expired</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(319,629</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.46</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Balance, September 30, 2019</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Granted</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.17</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;Balance, March 31, 2020</font></td><td style="border-bottom: Black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.88</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020, the Company had share purchase warrants outstanding as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Expiry
    Date</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 25%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 25%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 44%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June 30,
    2021</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.17</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May
    6, 2024</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 0.5in; text-indent: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0; width: 18pt; text-indent: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">d)</font></td><td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">Stock&#8211;based
                                         Compensation Plan</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2015
Stock Option Plan</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
September 18, 2015, the Company&#8217;s board of directors (the &#8220;Board&#8221;) approved a 2015 Omnibus Incentive Plan (the
&#8220;2015 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors, officers, employees
and consultants of the Company.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
maximum number of our common shares reserved for issue under the plan is 6,050,553 shares, subject to adjustment in the event
of a change of the Company&#8217;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards were
granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing
stock option plans remain outstanding in accordance with their terms.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
2015 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date.
If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value
of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise
period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject
to earlier termination in accordance with the terms of the 2015 Plan.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2019
Stock Option Plan</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, 6,000,000 additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#8217;s 2007 Stock Option
Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the Board, subject to earlier termination in accordance with the terms of the 2019 Plan.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price ($)</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Grant Date Fair Value ($)</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate
    <br /> intrinsic value ($)</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White; width: 72px"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2018</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,506,917</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.83</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,353,088</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,265,399</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.79</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.27</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(309,383</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.25</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,462,933</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.58</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,115,032</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,525,000</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.86</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.17</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(1,667</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.64</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    March 31, 2020</font></td><td style="border-bottom: Black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,986,266</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.47</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,517,080</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-right: 0; padding-left: 0; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable,
    March 31, 2020</font></td><td style="border-bottom: Black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,925,642</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.70</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,815,680</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#8217;s stock for the options that were in-the-money at March 31, 2020.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the three and six months ended March 31, 2020, the Company recognized stock-based compensation expense of $1,700,753 and $2,965,177,
respectively (2019: $1,893,152 and $3,960,139, respectively) in connection with the issuance and vesting &#9;of stock options
and warrants in exchange for services. These amounts have been included in general and &#9;administrative expenses and research
and development expenses on the Company&#8217;s interim condensed consolidated statements of &#9;operations as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="background-color: White; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Three
    months ended<br />
    March 31,</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Six
    months ended<br />
    March 31,</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White; width: 0.75in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">General and administrative</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">810,309</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">950,999</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,291,410</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,006,587</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Research and development</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">890,444</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">942,153</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,673,767</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,953,552</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: White"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Total share based compensation</font></td><td style="border-bottom: Black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,700,753</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,893,152</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,965,177</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,960,139</font></td><td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">An
amount of approximately $5,708,800 in stock-based compensation is expected to be recorded over the remaining vesting period &#9;of
such options through fiscal 2022.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td><td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest
    rate</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.68</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 8%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.91</font></td><td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.44</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.59</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">97.61</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">105.96</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Dividend rate</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td><td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>86</ContextCount>
  <ElementCount>210</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>19</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business Description and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</Role>
      <ShortName>Business Description and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Equity Offering Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreements</Role>
      <ShortName>Equity Offering Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncementsPolicies</Role>
      <ShortName>Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Business Description and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Equity Offering Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative</Role>
      <ShortName>Equity Offering Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferingAgreements</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="avxl-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avxl-20200331.xml</File>
    <File>avxl-20200331.xsd</File>
    <File>avxl-20200331_cal.xml</File>
    <File>avxl-20200331_def.xml</File>
    <File>avxl-20200331_lab.xml</File>
    <File>avxl-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762497792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - 2015 Omnibus Incentive Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning</a></td>
<td class="nump">8,462,933<span></span>
</td>
<td class="nump">6,506,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">1,525,000<span></span>
</td>
<td class="nump">2,265,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(1,667)<span></span>
</td>
<td class="num">(309,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending</a></td>
<td class="nump">9,986,266<span></span>
</td>
<td class="nump">8,462,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at ending</a></td>
<td class="nump">6,925,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning</a></td>
<td class="nump">$ 3.58<span></span>
</td>
<td class="nump">$ 3.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">2.86<span></span>
</td>
<td class="nump">2.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">2.64<span></span>
</td>
<td class="nump">3.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending</a></td>
<td class="nump">3.47<span></span>
</td>
<td class="nump">3.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at ending</a></td>
<td class="nump">3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate intrinsic value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at beginning</a></td>
<td class="nump">$ 4,115,032<span></span>
</td>
<td class="nump">$ 2,353,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at ending</a></td>
<td class="nump">4,517,080<span></span>
</td>
<td class="nump">$ 4,115,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at ending</a></td>
<td class="nump">$ 3,815,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762382208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6754178544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,486,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,812,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentsIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">$ 510,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 924,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentsIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentsIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6606268336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EquityOfferingAgreementsTextBlock', window );">Equity Offering Agreements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note 4</font></td><td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Equity
                                         Offering Agreements</u></font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Sales Agreement</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company has entered into a Sales
Agreement dated July 6, 2018, as amended May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&#38; Co.,
(&#8220;Cantor Fitzgerald&#8221;) and SVB Leerink LLC (&#8220;Leerink&#8221;), and together with Cantor Fitzgerald as Sales Agents,
pursuant to which the Company may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $50,000,000
from time to time through the Sales Agents (the &#8220;Offering&#8221;).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Upon delivery of a placement notice
based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may
sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market
prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by
law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make
any sales of Shares under the Sales Agreement. The Company or the Sales Agents may suspend or terminate the offering of Shares
upon notice to the other party, subject to certain conditions.&#160; The Sales Agents will act as sales agent on a commercially
reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules&#160;and
regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company has agreed to pay the
Sales Agents commissions for their services of acting as agents of 3.0% of the gross proceeds from the sale of the Shares pursuant
to the Sales Agreement.&#160; The Company also agreed to provide the Sales Agents with customary indemnification and contribution
rights. As of March 31, 2020, no shares had been sold pursuant to the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">2015 Purchase Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On October 21, 2015, the Company
entered into a $50,000,000 purchase agreement (the &#8220;2015 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln
Park&#8221;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up
to $50,000,000 in value of its shares of common stock from time to time over a 36-month period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">During the six months ended March
31, 2019, the Company issued an aggregate of 2,239,223 shares of common stock under the 2015 Purchase Agreement, including 2,229,592
shares of common stock for an aggregate purchase price of $5,361,534 and 9,631 commitment shares. At March 31, 2020 and September
30, 2019, all remaining purchase amounts available for issuance under the 2015 Purchase Agreement had been utilized and the 2015
Purchase Agreement has expired pursuant to its terms. As such, no further shares will be sold under the 2015 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2019
Purchase Agreement</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, the Company entered into a $50,000,000 purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln
Park, pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $50,000,000
in value of its shares of common stock from time to time from June 12, 2019, the date a prospectus supplement under which shares
of common stock issuable under the 2019 Purchase Agreement was filed with the SEC, until July 1, 2022, which is the first day
of the next month following the 36-month anniversary of June 12, 2019.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#8220;Regular Purchase&#8221;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#8217;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase
price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares
at the time of sales as described in the 2019 Purchase Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
2019 Purchase Agreement limits the Company&#8217;s sale of shares of Common Stock to Lincoln Park to 10,076,680 shares of Common
Stock, representing 19.99% of the shares of the Common Stock outstanding on the date of the 2019 Purchase Agreement unless (i)
shareholder approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock
to Lincoln Park under the 2019 Purchase Agreement equals or exceeds the lower of (A) the closing price of the Common Stock on
the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average of the closing prices of the Common Stock
on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date, and it also limits the Company&#8217;s
sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of the Company&#8217;s
outstanding shares of Common Stock at any given time.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock
as a commitment fee and agreed to issue up to 162,191 shares pro rata, when and if, Lincoln Park purchases at the Company&#8217;s
discretion the $50,000,000 aggregate commitment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">During the six months ended March
31, 2020, the Company issued to Lincoln Park an aggregate of 6,014,425 (2019: Nil) shares of common stock under the 2019 Purchase
Agreement, including 5,964,584 (2019: Nil) shares of common stock for an aggregate purchase price of $15,365,492 (2019: $Nil) and
49,841 (2019: Nil) commitment shares. At March 31, 2020, an amount of $30,000,000 remained available under the 2019 Purchase Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to equity offering agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6774489392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Common Stock To Be Issued</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Beginning at Sep. 30, 2018</a></td>
<td class="nump">$ 45,935<span></span>
</td>
<td class="nump">$ 129,377,542<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (107,101,781)<span></span>
</td>
<td class="nump">$ 22,321,696<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in shares) at Sep. 30, 2018</a></td>
<td class="nump">45,933,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueAcquisitions2', window );">Shares issued under 2015 Purchase Agreement - Purchase shares</a></td>
<td class="nump">$ 2,229<span></span>
</td>
<td class="nump">5,359,305<span></span>
</td>
<td class="num">(292,700)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,068,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesAcquisitions2', window );">Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">2,229,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">Shares issued under 2015 Purchase Agreement - Commitment shares</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">9,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants', window );">Shares issued pursuant to cashless exercise of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares', window );">Shares issued pursuant to cashless exercise of warrants (in shares)</a></td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,960,139<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,960,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,166,635)<span></span>
</td>
<td class="num">(14,166,635)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending at Mar. 31, 2019</a></td>
<td class="nump">$ 48,175<span></span>
</td>
<td class="nump">138,696,975<span></span>
</td>
<td class="num">(292,700)<span></span>
</td>
<td class="num">(121,268,416)<span></span>
</td>
<td class="nump">17,184,034<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Mar. 31, 2019</a></td>
<td class="nump">48,173,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Beginning at Dec. 31, 2018</a></td>
<td class="nump">$ 46,888<span></span>
</td>
<td class="nump">133,438,276<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(114,021,512)<span></span>
</td>
<td class="nump">19,463,652<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in shares) at Dec. 31, 2018</a></td>
<td class="nump">46,887,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueAcquisitions2', window );">Shares issued under 2015 Purchase Agreement - Purchase shares</a></td>
<td class="nump">$ 1,279<span></span>
</td>
<td class="nump">3,365,555<span></span>
</td>
<td class="num">(292,700)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,074,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesAcquisitions2', window );">Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">1,279,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">Shares issued under 2015 Purchase Agreement - Commitment shares</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">6,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants', window );">Shares issued pursuant to cashless exercise of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares', window );">Shares issued pursuant to cashless exercise of warrants (in shares)</a></td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,893,152<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,893,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,246,904)<span></span>
</td>
<td class="num">(7,246,904)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending at Mar. 31, 2019</a></td>
<td class="nump">$ 48,175<span></span>
</td>
<td class="nump">138,696,975<span></span>
</td>
<td class="num">(292,700)<span></span>
</td>
<td class="num">(121,268,416)<span></span>
</td>
<td class="nump">17,184,034<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Mar. 31, 2019</a></td>
<td class="nump">48,173,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Beginning at Sep. 30, 2019</a></td>
<td class="nump">$ 52,652<span></span>
</td>
<td class="nump">153,633,807<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(133,396,760)<span></span>
</td>
<td class="nump">20,289,699<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in shares) at Sep. 30, 2019</a></td>
<td class="nump">52,650,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares</a></td>
<td class="nump">$ 5,965<span></span>
</td>
<td class="nump">15,359,527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,365,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">5,964,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">49,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,965,177<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,965,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,828,622)<span></span>
</td>
<td class="num">(13,828,622)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending at Mar. 31, 2020</a></td>
<td class="nump">$ 58,666<span></span>
</td>
<td class="nump">171,958,462<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(147,225,382)<span></span>
</td>
<td class="nump">24,791,746<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Mar. 31, 2020</a></td>
<td class="nump">58,664,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Beginning at Dec. 31, 2019</a></td>
<td class="nump">$ 57,082<span></span>
</td>
<td class="nump">165,891,753<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(139,988,685)<span></span>
</td>
<td class="nump">25,960,150<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in shares) at Dec. 31, 2019</a></td>
<td class="nump">57,080,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares</a></td>
<td class="nump">$ 1,571<span></span>
</td>
<td class="nump">4,365,969<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,367,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">1,570,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">14,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,700,753<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,700,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,236,697)<span></span>
</td>
<td class="num">(7,236,697)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending at Mar. 31, 2020</a></td>
<td class="nump">$ 58,666<span></span>
</td>
<td class="nump">$ 171,958,462<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (147,225,382)<span></span>
</td>
<td class="nump">$ 24,791,746<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Mar. 31, 2020</a></td>
<td class="nump">58,664,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issued shares underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issued shares underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issued value underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares Issued value Underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6773376896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,563,071<span></span>
</td>
<td class="nump">$ 22,185,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">4,151,947<span></span>
</td>
<td class="nump">2,642,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">305,559<span></span>
</td>
<td class="nump">500,998<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">31,020,577<span></span>
</td>
<td class="nump">25,329,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,649,734<span></span>
</td>
<td class="nump">3,523,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,579,097<span></span>
</td>
<td class="nump">1,516,342<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Liabilities</a></td>
<td class="nump">6,228,831<span></span>
</td>
<td class="nump">5,039,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 58,664,946 common shares (September 30, 2019 - 52,650,251)</a></td>
<td class="nump">58,666<span></span>
</td>
<td class="nump">52,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">171,958,462<span></span>
</td>
<td class="nump">153,633,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(147,225,382)<span></span>
</td>
<td class="num">(133,396,760)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">24,791,746<span></span>
</td>
<td class="nump">20,289,699<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 31,020,577<span></span>
</td>
<td class="nump">$ 25,329,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762711808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease expense</a></td>
<td class="nump">$ 60,861<span></span>
</td>
<td class="nump">$ 40,507<span></span>
</td>
<td class="nump">$ 110,915<span></span>
</td>
<td class="nump">$ 78,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,700,753<span></span>
</td>
<td class="nump">$ 1,893,152<span></span>
</td>
<td class="nump">2,965,177<span></span>
</td>
<td class="nump">$ 3,960,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_RemainingAllocatedShareBasedCompensationExpense', window );">Remaining stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,708,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of grant option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of grant option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_RemainingAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a remaining stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_RemainingAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
